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Abstract  
Cell therapy is an emerging treatment strategy for a wide range of 
diseases. Blood cells, pancreatic islets, hepatocytes and stem cells are 
only a few of the vast array of cell types explored for this purpose. 
Appropriate cell delivery and encapsulation systems are needed for 
immune-sequestration and protection of the cells and to enable them to 
function as an artificial organ. Current research is focused on developing 
an ideal strategy to provide a protected and vascularized environment for 
the subcutaneous transplantation of cells for their long-term function. 
Thus, the encapsulating material or device should permit the cells to 
function as an artificial organ. In this case, by compartmentalizing the 
therapeutic cells within a semi-permeable membrane, and protecting its 
viability and function from being impaired by the host immune system, 
complement proteins and antibodies and permit bi-directional transport of 
oxygen and the release of therapeutic agents such as hormones. Physical 
parameters such as porosity, rigidity and tortuosity, chemical composition 
and surface functionalization of the materials, and the ability to refill and or 
retrieve the device play an important role in engineering the encapsulating 
material and device ensuring the long-term functioning of the graft.  
To meet these needs, in this thesis is presented the design, fabrication 
and In Vivo validation of an adaptable, scalable and refillable cell 
encapsulation system (NICHE, Neovascularized Implantable Cell Homing 
and Encapsulation) for subcutaneous transplantation of autologous 
endocrine cells. 
The innovative aspects of this technology are multiple: 1) 3D printing 
technology permits adjustment of structure design in accordance to 
implantation site and cell volume in a time and costly manner; 2) Minimally 
invasive surgery to implant in the subcutaneous tissue; 3) Allows 
vascularization and tissue formation within the device prior to cell 
transplantation; 4) Allows for cell refilling via minimally invasive 
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transcutaneous injection; 5) Easy removal in case of an adverse body 
reaction. 
Over the course of the PhD, my contribution has been focused on NICHE 
structure design, and its validation in vitro and in vivo. 
First, NICHE was tested in murine, swine and in nonhuman primate animal 
models to evaluate the formation of a highly vascularized environment 
within the device. Next, to validate NICHE as a technological platform for 
cell encapsulation, human pancreatic islets and Leydig cells were 
transplanted using murine animal models. 
The results of the in vivo experiments confirm insulin and testosterone 
release for up to 22 and 11 weeks, respectively. Therefore, demonstrating 
the possibility within NICHE to become an optimal environment for 
transplanted cells.  
It is important to realize that the here presented NICHE does not include 
immune protection strategies to avoid graft rejection. Correspondingly, it is 
designed for autologous cell transplantation only. 
However, in order to perform heterologous cell transplantations, Grattoni’s 
Team is currently developing a second version of the NICHE with 
immunosuppressant properties. This device implements a nanochannel 
membrane for the sustained release of immunosuppressant drugs with the 
objective of achieving local immunosuppression while minimizing systemic 
drug exposure and associated adverse effects.  
In the light of the promising results, NICHE has the potential means to 
provide a valuable and universally applicable cell transplantation 
encapsulation system for a wide spectrum of endocrine diseases. The 
aforementioned approach could also be explored for cell therapy delivery 
in other pathologies, such as cardiovascular and neurodegenerative 
diseases. 
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Chapter 1 
Introduction About This Thesis  
  
  14 
Goal and Thesis Scope  
The objective of the thesis was to develop and assess in vitro and in vivo a 
3D printed implantable encapsulation system for cell transplantation. This 
thesis is divided in four main chapters. In Chapter 2 the history and impact 
of recent cell encapsulation technologies that are currently under clinical 
investigation is presented. Chapter 3 describes the development and 
mechanical properties of the 3D printed NICHE. Chapter 4 describes as 
approach for addressing the limitation in cell availability by differentiation 
of human mesenchymal stem cells into islet-like insulin-producing cells. 
Chapter 5 presents the in vivo validation of the 3D printed device in small 
and large animal models. An ore detail outline of each chapter is 
presented here below: 
 
Chapter 2 
Cell-based therapy is emerging as a promising strategy for treating a wide 
range of human diseases, such as diabetes, blood disorders, acute liver 
failure, spinal cord injury, and several types of cancer. Pancreatic islets, 
blood cells, hepatocytes, and stem cells are among the many cell types 
currently used for this strategy. The encapsulation of these “therapeutic” 
cells is under intense investigation to not only prevent immune rejection 
but also provide a controlled and supportive environment so that their 
function is preserved long-term. In this chapter, various encapsulation 
strategies developed in academic and industrial settings are reviewed, 
including the state-of-the-art technologies in advanced preclinical phase 
as well as those undergoing clinical trials. Advantages and challenges are 
indicated for each technology.  
 
This chapter contains reedited parts of the review manuscript submitted 
for consideration for publication in Advanced Drug Delivery titled “Cell 
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Encapsulation: Overcoming Barriers in Cell Transplantation in Diabetes 
and Beyond” and authored by Marco Farina, Jenolyn F. Alexander, Usha 
Thekkedath, Mauro Ferrari, Alessandro Grattoni. The manuscript is 
currently under peer-review. 
 
Chapter 3 
Cell transplantation in bioengineered scaffolds and encapsulation systems 
has shown great promise in regenerative medicine. Depending on the site 
of implantation, type of cells and their expected function, these systems 
are designed to provide cells with a physiological-like environment while 
providing mechanical support and promoting long-term viability and 
function of the graft. In this chapter, we describe the development of a 
minimally invasive 3D printed system termed neovascularized implantable 
cell homing and encapsulation (NICHE) for subcutaneous transplantation 
of endocrine cells, including pancreatic islets and Leydig cells. The 
suitability of the NICHE for long term in vivo deployment is investigated by 
assessing mechanical behavior of both fresh devices under simulated 
subcutaneous conditions and NICHE retrieved from subcutaneous 
implantation in pigs. Both experimental and numerical studies were 
performed with a focus on validating the constitutive material model used 
in the numerical analysis for accuracy and reliability. Notably, 
homogeneous isotropic constitutive material model calibrated by means of 
uniaxial testing well suited experimental results. The results highlight the 
long-term durability for in vivo applications and the potential applicability of 
the model to predict the mechanical behavior of similar devices in various 
physiological settings. 
Part of the results described in this chapter have been published in the 
manuscript titled “Mechanical characterization and numerical simulation of 
a subcutaneous implantable 3D printed cell encapsulation system”, 
authored by Federica Adamo*, Marco Farina*, Usha Thekkedath, 
Alessandro Grattoni and Raffaella Sesana, (*equal contribution, co-first 
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authorship) in Journal of the Mechanical Behavior of Biomedical Materials, 
https://doi.org/10.1016/j.jmbbm.2018.03.023. 
 
Chapter 4 
Diabetes is one of the most prevalent, costly, and debilitating diseases 
in the world. Pancreas and islet transplants have shown success in re-
establishing glucose control and reversing diabetic complications. 
However, both are limited by donor availability, need for continuous 
immunosuppression, loss of transplanted tissue due to dispersion, and 
lack of vascularization. To overcome the limitations of poor islet 
availability, in this chapter we investigate the potential of bone marrow–
derived mesenchymal stem cells differentiated into islet-like insulin-
producing aggregates (ILIPAs). Islet-like insulin-producing aggregates, 
characterized by gene expression, are shown to be similar to pancreatic 
islets and display positive immunostaining for insulin and glucagon. 
Moreover, in order to ensure the biocompatibility of the PLA (Polylactic 
acid) adopted for fabricating the NICHE, we encapsulated ILIPAs (Insulin 
like in the 3D device and tested in vitro showing that encapsulated islet-
like insulin-producing aggregates maintained viability and function, 
producing steady levels of insulin for at least 4 weeks. NICHE—islet-like 
insulin-producing aggregate technology investigated in this chapter as a 
proof of concept holds potential as an effective and innovative approach 
for diabetes cell therapy. 
 
Part of the results described in this chapter have been published in the 
manuscript titled “Three-dimensional printed polymeric system to 
encapsulate human mesenchymal stem cells differentiated into islet-like 
insulin-producing aggregates for diabetes treatment”, authored by 
Omaima M. Sabek*, Marco Farina*, Daniel W. Fraga, Solmaz Afshar, 
Andrea Ballerini, Carly S. Filgueira, Usha R. Thekkedath, Alessandro 
Grattoni and A. Osama Gaber, (*equal contribution, co-first authorship), 
Journal of Tissue Engineering, 2016, 7: 1–13, DOI: 
10.1177/2041731416638198 
 17 
Chapter 5 
In this chapter, we present the in vivo validation of the NICHE as 
technological platform for the transplantation of multiple cell types. 
Specifically, we transplanted human pancreatic islets or Leydig cells in in 
Nu/Nu female mice or Rag1-/- castrated mice, respectively. For both cell 
lines, we evaluated the vascularization and tissue formation within the 
NICHE prior to cell transplantation. The NICHEs protected the 
encapsulated cells from acute hypoxia and kept them functional over 22 
weeks (human pancreatic islets) and 14 weeks (Leydig cells). The 
adaptability of the encapsulation system was demonstrated by refilling 
some of the experimental groups transcutaneously with additional islets. 
The results described in this chapter have been published in the following 
paper Marco Farina, Andrea Ballerini, Daniel W. Fraga, Eugenia Nicolov, 
Matthew Hogan, Danilo Demarchi, Francesco Scaglione, Omaima M. 
Sabek, Philip Horner, Usha Thekkedath, Osama A. Gaber, Alessandro 
Grattoni, 3D Printed Vascularized Device for Subcutaneous 
Transplantation of Human Islets, Biotechnology Journal, 2017, 12, 
1700169, DOI: 10.1002/biot.201700169. Other results presented are 
included in the following manuscript currently under peer-review: Marco 
Farina, Corrine Ying Xuan Chua, Andrea Ballerini, Usha Thekkedath, 
Jenolyn F. Alexander, Jessica R. Rhudy, Gianluca Torchio, Daniel Fraga, 
Ravi R. Pathak, Mariana Villanueva, Crystal S. Shin, Jean A. Niles, 
Raffaella Sesana, Danilo Demarchi, Andrew G. Sikora, Ghanashyam S. 
Acharya, A. Osama Gaber, Joan E. Nichols and Alessandro Grattoni, 
Transcutaneously refillable, 3D-printed biopolymeric encapsulation system 
for the transplantation of endocrine cells, Biomaterials. 
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Chapter 2 
Cell encapsulation: overcoming 
barriers in cell transplantation 
in diabetes and beyond 
 
 
 
  
 19 
2.1 Cell-Based Therapy 
Cell-based therapy consists of implanting or delivering living cells or, 
sustaining their development in a patient for treating a certain disease or 
condition [1]. In contrast to small molecule drugs and biologics such as 
engineered proteins and antibodies, which are the predominant treatment 
modalities for most diseases, cell-based therapy delivers complex living 
entities that are capable of sensing, modulating their function and 
responding to the environment. The migratory and proliferative capacity, 
production and delivery of therapeutics and intercellular interactions are 
some of the characteristics of cells that can be manipulated to address 
unmet needs of various pathologies including diabetes, cancer, spinal cord 
injuries, autoimmune and neurodegenerative diseases [2]. For example, in 
the treatment of osteoarthritis, conventional treatment using opioids and 
non-steroidal anti-inflammatory drugs aids in pain relief but does not 
restore damaged tissue. In contrast, cell therapies utilizing induced 
pluripotent stem cells or autologous chondrocytes repair the damaged 
cartilage as well as renovate the injured tissue [3]. Transplantation of 
these cells may thus become a standard treatment option and in certain 
cases, as in the treatment of diabetes and liver failure, is predicted to 
replace whole organ transplant [4,5].  
 
The practice of adopting cells for therapeutic purposes has 
dramatically evolved over the years. Blood transfusions practiced in the 
1600s [6], renal transplantation in animal models by Dr. Emerich Ulmannn 
in 1902 [7,8], blood vessel and organ transplantation by Drs. Alexis Carrel 
and Charles Guthrie in the early 1900s [9], injections of ox parathyroid 
cells to human patients in 1931 and lyophilized cells in 1949 by Dr. Paul 
Niehans [10], and transplantation of islets encapsulated in semipermeable 
microcapsules by Dr. Thomas M.S. Chang in 1964 [11] represent early 
pioneering developments in the field of cell transplantation. Today, cell 
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types from different sources are being evaluated to treat a number of 
diseases, as a personalized approach.  
 
Currently, one of the most researched areas in cell transplantation is 
diabetes, which continues increasing in prevalence. Type 1 diabetes 
mellitus (T1DM) is elicited by severe inhibition of pancreatic β cell function 
which leads to complete lack of insulin production. As a result, exogenous 
insulin is required to be administered to the patients for survival. Despite 
significant advances in the treatment of T1DM, the management of the 
disease is still suboptimal and link to chronic complications, comorbidity 
and mortality even in individuals at a relatively young age. Whole-
pancreas transplantation has shown to prevent chronic complications and 
result in adequate glycemic control. However, the invasiveness of the 
intervention, post-surgical morbidity and high mortality are still of concern 
[12–14]. To address the continuous treatment need for “brittle T1DM” 
patients, a severe form of diabetes, intravascular cell infusion 
transplanting allogenic pancreatic islets was developed as a better 
alternative [15].  
 
Pancreatic islet transplantation was first attempted in 1893 [16]. It took 
eighty years to demonstrate acceptable rate of success, even in the 
absence of an immune barrier [17,18] (i.e. using autografts). In the 1980s, 
several autotransplant trials were performed extracting islets from patient’s 
own pancreas and infusing them into liver via the portal vein. 
Unfortunately, these early trials achieved insulin independence for only 
10% of patients [19,20]. Success of this approach was significantly 
improved with the development of the Edmonton protocol at the University 
of Alberta in 2000. In the NCT00706420 trial, all treated patients with 
T1DM (7) gained insulin independence and retained it for 12 months post-
transplant [21]. Since then, human pancreatic islet transplantation has 
transitioned from a rare, experimental protocol to a routine and safe 
clinical procedure with over 1,500 interventions performed worldwide 
(1,011 allogeneic transplants and 660 autologous transplants according to 
the Collaborative Islet Transplant Registry (CITR). Recently, a 12-year 
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follow-up of seven patients from the 2000 study reported continuous 
function of the transplanted islets over a decade since the procedure [22]. 
Since their first transplant procedure, one patient maintained insulin 
independence without supplemental diabetic medication or transplants, 
while another patient maintained insulin independence for 10.9 years and 
three patients received subsequent islet transplants. At the end of the 
study, five patients were being administered insulin while two patients 
were insulin independent. Long term safety of the islet transplantation was 
demonstrated since no adverse infections, hypoglycemia or lymphoma 
were observed in the patients. 
 
The establishment of the Edmonton protocol for islet 
autotransplantation represents an outstanding advance in the field. 
However, its success over the years has been challenged by islets 
dispersion post injection in the portal vein, and the limited number of viable 
islets that could be retrieved from the patient. While addressing the first 
issue is topic of research, the need for additional cell sources has 
prompted the use of allogenic or xenogenic cells from donors. This 
requires combating transplant immune rejection and the ensuing need for 
lifelong immunosuppressive treatments, which significantly reduce 
patient’s quality of life [23]. One of the first attempts to solve the problem 
of immune rejection was done by Drs. Prehn, Weaver and Algire in 1954. 
Using immunized mice, they demonstrated that transplanted homologous 
(allogeneic) cells did not trigger immune response when administered to 
the peritoneal cavity and encapsulated by a porous membrane [24]. 
Encouraged by this result, physical means to provide immunoisolation of 
the transplant graft and abrogate immune rejection via semipermeable 
membranes have been extensively investigated by several research 
groups. More recently, biological approaches involving genetic 
manipulation of transplant cells to avoid systemic immune suppression 
regimens are topic of research [25–30].  
 
The general objective of encapsulation materials or devices is to 
enable the transplanted cells to function as an artificial organ, by 
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compartmentalizing the therapeutic cells within a protected environment, 
and promoting viability and function long term. These systems need to 
allow for bi-directional transport of oxygen, metabolic products and real 
time and unobstructed release of therapeutic agents such as hormones or 
enzymes in response to external biological stimuli [31–33]. These 
functional requirements mean that physical parameters such as porosity, 
rigidity and tortuosity, chemical composition, and surface functionalization 
of membranes, device refillability and replaceability, all need to be 
considered when engineering an effective encapsulation technology 
[23,34]. The breadth of requirements has led to a surge in synthetic and 
bio-based materials being tested as means of encapsulating a wide variety 
of cells. Present day strategies comprise of implantable, personalized, and 
multifunctional living cell factories that are capable of providing immune 
protection and allow for controlled and continuous delivery of therapeutics. 
These structures are capable of housing a vast array of cell types such as 
patient’s own cells, animal derived and engineered cells, by synergistically 
leveraging genetic and bioengineering, material science, and 
nanotechnology [35–37].  
 
Cell-based therapy is making paradigm changes in the treatment of 
many diseases including some that were considered incurable, such as 
diabetes. It is already established as a standard-of-care treatment and 
reimbursable by insurance companies or covered by national health 
systems in several countries. Given the increasing rates of diabetes 
worldwide, the approval of islet-based therapy provides an opportunity for 
cell therapeutics to exit the investigative, niche arena and become a 
globally recognized standard-of-care [4]. Beyond diabetes, the strategy of 
transplanting cells is used or explored for the treatment of other 
pathologies (Fig. 2.1). A plethora of cells from autologous, allogeneic or 
xenogeneic sources – stem cells (neural, mesenchymal, induced 
pluripotent), pancreatic islets, fibroblasts and renal proximal tubule cells 
are being tested for treating different diseases such as neurodegenerative 
and chronic eye diseases, cancer, diabetes, cardiovascular diseases, 
wound regeneration and renal failure [38,38–42,36,43,3,4]. Ideally, these 
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cells upon encapsulation and implantation at a specific site in the body 
would function as the native organ. 
 
In this review, we describe various encapsulation strategies including 
the state-of-the-art technologies in advanced preclinical phase, as well as 
those undergoing clinical trials for diabetes and other diseases. First, we 
introduce the types of cells used in cell transplantation highlighting the 
various sources and applications. Second, we present current strategies of 
cell microencapsulation and macroencapsulation in diabetes. We describe 
each encapsulation approach, and assess their advantages and 
challenges. We also highlight the importance of “smart” - stimuli-
responsive and “live” - encapsulated cell systems in overcoming obstacles 
in cell transplantation and delivering them for patient use. Third, we 
describe the applications of encapsulated cell therapies in other 
pathologies, such as chronic eye diseases - age-related macular 
degeneration (ARMD) and diabetic retinopathy, neurodegenerative 
diseases - Alzheimer’s and Parkinson’s, several types of cancer, chronic 
wounds - venous leg ulcers (VLU) and diabetic foot ulcers (DFU), 
cardiovascular diseases - myocardial infarction (MI) as well as renal 
diseases - acute kidney injury (AKI) and end stage renal disease (ESRD).  
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Figure 2.1: Schematic diagram of various representative strategies and cell 
types under advanced pre-clinical and clinical development, where cells, upon 
encapsulation and implantation, are used to restore or mimic and replace the 
function of the diseased organs. 
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2.2 Cell Types 
The choice of cells for transplantation mainly depends on the 
pathology treated and target organ. Cells secreting therapeutic antibodies, 
hormones and aiding in regeneration of damaged or defective tissues are 
often selected for therapeutic transplantation. Cell viability and controlled 
release of therapeutic factors from cells are essential parameters in 
establishing long-term function and efficient therapy. The cell source could 
be autologous, allogeneic or xenogeneic. The therapeutic potential of cell 
transplantation for many chronic conditions has led to a greater demand 
for high quality cells, resulting in the development of innovative tissue 
engineering strategies for stem cell derived therapeutic cells and 
evaluation of animal derived cells. Even though non-human primates 
(NHP) are the most closely related species to humans and the NHP 
xenografts would be more physiologically and immunogenically 
compatible, apes being endangered, the use of NHP cells raises ethical 
concerns. Pigs have been the next alternative species of choice [42]. In 
addition to primary and genetically engineered cells, artificial cell-like 
structures such as polymersomes have also been investigated for 
therapeutic use [27,28]. Some of the most widely tested cell types for 
transplantation are summarized below (Fig. 2.2).  
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Cell sources for cell therapy applications 
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2.2.1 Cells for Allogeneic or Xenogeneic Transplantation 
A variety of human and animal cell types are evaluated for therapeutic 
transplantation into humans. While their detailed descriptions are beyond the 
scope of this review, various cell types that are being investigated in advanced 
preclinical or clinical studies are described below. 
 
Pancreatic Islets 
Pancreatic islets or islets of Langerhans are clusters of endocrine cells 
in the pancreas including beta cells, which sense blood glucose levels and 
release necessary amount of insulin to maintain normal blood sugar 
levels. Pancreatic islets harvested from human cadaveric donors and 
transplanted via portal vein injection have been shown to be a valuable 
alternative to frequent administration of insulin injections to treat type 1 
diabetes. However, due to the poor yield of harvesting protocols, islets 
from multiple (2 to 4) donors are required to achieve insulin independence. 
Further, challenges associated with immune suppression, and loss of 
viability and function over time remain significant hurdles to improve 
transplantation outcomes [44]. For this, immune segregation for islet 
transplants has been widely studied with materials such as alginate, 
chitosan, agarose, gelatin and other polymeric materials as wells macro 
scale devices [45]. Detailed descriptions of these encapsulation systems 
are provided in subsequent sections of this review. Several clinical trials 
for assessing the safety, metabolic and immune responses have been 
performed or are ongoing for alginate encapsulated human beta cells 
(NCT00790257, NCT00790257), and macroencapsulated human islets 
(NCT02064309). In an attempt to improve islet availability other sources 
have been explored. Porcine insulin differs from human insulin by just a 
single amino acid, and pigs are considered a suitable choice for harvesting 
islets from a xenogeneic source [42,46]. In light of this, porcine islets 
encapsulated in agarose are being investigated for clinical use [43].  
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Myoblasts 
Encapsulation of muscle cells (myoblasts) is being researched pre-
clinically for therapeutic protein delivery for skeletal muscle regeneration. 
Puicher et al. showed that genetically engineered murine myoblasts could 
be used in the treatment of Hurler’s syndrome – also known as 
mucopolysaccharidosis type I (MPS I). C2C12 cells, transfected to secrete 
high levels of lysosomal enzyme α-l-iduronidase (IDUA) [47], were 
encapsulated in alginate microcapsules and implanted intraperitoneally in 
mice. Increase in enzyme activity and drop in glycosaminoglycan activity 
were observed up to a period of 3 months. In another study by Lathuilière 
A. et al, C2C12 murine myoblast cells were infected with lentiviral vectors 
subcloned with firefly luciferase cDNA [48]. These genetically engineered 
cells expressing luciferase were then encapsulated in polymeric flat sheet 
macrodevices and implanted subcutaneously in the dorsum of mice. The 
density of injected cells, porosity of the permeable membrane and 
stiffness of the hydrogel used for encapsulation were tuned to achieve 
prolonged viability of cells and delivery of recombinant proteins in vivo 
[48]. The same research group showed that myoblasts genetically 
engineered to express anti-amyloid-β antibodies and encapsulated in the 
flat sheet device, could be used for treatment of Alzheimer’s disease [49]. 
3D-bioprinted constructs comprising of myoblast cells have shown to 
mimic skeletal muscle tissue in vitro and in vivo. The implantation of these 
bioartificial constructs in mice showed promise for muscle tissue 
regeneration and reconstruction [50]. These studies served as pioneering 
proof-of-concept for the allogenic implantation of myoblast cells for a 
prolonged therapeutic delivery and cost-effective alternative to 
recombinant protein therapy as well as tissue regeneration [48–51].  
 
Choroid Plexus 
The highly active and vascularized cluster of epithelial cells, situated in 
the blood - cerebrospinal fluid barrier - choroid plexus is responsible for a 
number of functions including maintenance of brain homeostasis, 
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production of cerebrospinal fluid, detection and transmission of immune 
signals [52,53] and clearance of toxic agents from the brain [54]. 
Encapsulation of the choroid plexus is under study for the treatment of 
conditions including aging disorders, cochlear [55,56] and neuro - 
degenerative diseases [57], chronic wounds [58] and Huntington’s disease 
[59]. Further, it is clinically tested for Parkinson ’s disease (NCT01734733) 
[60,61] owing to its abundance of trophic and regenerative components 
and ability to adapt and function in different microenvironments [58]. 
Borlongan et al. demonstrated that alginate encapsulated choroid plexus 
cells, when transplanted into a rodent model of Huntington’s disease, were 
able to release neurotrophic factors and protect the striatal neurons from 
damage [59]. Later the same group showed that alginate encapsulated 
porcine xenografts could provide structural and functional neuroprotection 
in a rodent model of stroke [62]. Luo et al. demonstrated the 
neuroprotective efficacy of alginate encapsulated porcine choroid plexus 
cells in a non-human primate model of Parkinson’s disease, without the 
need for immunosuppressant drugs [63]. These notable examples 
demonstrate the great clinical potential of encapsulated choroid plexus 
cells in delivering multiple neurotrophic agents to offer structural and 
functional protection for various neurodegenerative and traumatic 
conditions.  
 
2.2.2 Cells for Autologous Transplantation 
Patient derived cells for transplantation are either cells harvested from 
native organ as in the case trauma or surgical removal (eg. for 
pancreatectomy) or are differentiated from stem cells, using specific 
protocols. Below, various autologous cell types are presented, with 
particular emphasis given to stem cells, due to their largely untapped 
potential for the management of various diseases. 
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Pancreatic Islets 
Transplantation of autologous pancreatic islets is usually performed 
when a patient with chronic pancreatitis undergoes total pancreatectomy 
for intractable pain not controllable via medical treatment. Cells are 
isolated from patient’s own pancreas and transplanted back through portal 
vein. Since its first clinical application by the researchers at the University 
of Minnesota School of Medicine in 1977, advances in cell isolation and 
purification have improved islet autotransplant outcomes, and expanded 
its clinical use [64]. However, only a handful of clinical centers in the 
United States are performing this procedure and there is no available 
information on its worldwide use. While the clinical outcome depends on 
the yield of islets and about 70% of patients require insulin  therapy 
long term after surgery, most still benefit from functioning islets, and a 
simpler management of diabetes. 
Stem Cells 
Stem cell therapy has advanced as the treatment option for a number 
of diseases including cardiovascular, neurological, degenerative and 
autoimmune diseases, blood and bone marrow cancers, burns, corneal 
damage and organ failure. Stem cells have the potential to serve as an 
unlimited source for the development of various therapeutic cell types [65]. 
With the promise of islet transplantation in reversing diabetes and to 
address insufficient supply of islets from donors, increasing efforts have 
been focused on generating functional insulin-producing beta-like cells 
from stem cells. Several protocols have been developed to 
systematically guide the differentiation of human embryonic stem cells 
(hESCs), and more recently, induced pluripotent stem cells (iPSCs), into 
pancreatic endoderm (PE). PE cells have been shown to mature in vivo 
and function similarly to beta cells for prolonged periods following 
transplantation. In other cases, cells were transplanted after being fully 
differentiated into beta cells in vitro. While the results have been 
encouraging, recent efforts are directed towards improving differentiation 
conditions, cell expansion at specific progenitor stages, and purification 
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of target cell populations to obtain sufficient quantities of functional 
pancreatic beta-like cells. About 6000 clinical studies utilizing stem cells 
are currently registered and some of them utilize encapsulated stem cells. 
Some of the macroencapsulated stem cell derived beta cells (ViaCyte 
PEC-01) have reached the clinical trial stage now. However, challenges 
related to graft vascularization and viability and uncertainty about their 
long term fate in the host body, including teratoma formation, are to be 
addressed before their routine clinical use. Various strategies to address 
these challenges by many research groups are discussed in detail in the 
subsequent sections of this review. 
 
Human Embryonic Stem-Cell Derived Beta Cells: In a preclinical 
study, human embryonic stem cell – derived mature beta cells that are 
glucose responsive, when encapsulated in alginate derivatives and 
implanted in the mice intraperitoneal cavity, were shown to induce 
glycemic correction and survival even at 174 days post-delivery without 
being accompanied by immunosuppressive treatment [66]. In case of 
ViaCyte product, a rapidly developing one to treat type 1 and type 2 
diabetic patients, human embryonic stem cells are being differentiated into 
beta cell precursors (PEC-01TM) and encapsulated in the Encaptra® drug 
delivery system. After subcutaneous implantation, the beta cell precursors 
further differentiate into mature insulin secreting cells, controlling blood 
glucose levels.  
 
Pluripotent Stem Cells: Pluripotent stem cells (PSCs) have the ability 
to self-renew and differentiate into three germ layers including ectoderm, 
endoderm and mesoderm. Because of this ability they have the potential 
to play an important role in regenerative medicine and cell therapy. 
Through cellular reprogramming, it is possible to modify adult somatic cells 
using a cocktail of factors and reprogram them into embryonic state 
producing induced pluripotent stem cells, iPSC. Similar procedure can be 
used to reprogram somatic cells via factors present in the oocyte. 
Dr. Shinya Yamanaka shared the Nobel Prize for Medicine in 2012 for 
iPSC technology and several research groups are actively pursuing this 
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for diabetes treatment, regenerative medicine and drug delivery as well as 
for disease modeling purposes. Melton et al. at Harvard University have 
demonstrated the preclinical development of glucose responsive beta cells 
from human PSCs for the treatment of T1D [67].  
  
Mesenchymal Stem Cells: Mesenchymal stem cells (MSCs) are 
studied by many research groups for diabetes treatment, to generate 
insulin-producing cells [68], counteract autoimmunity [69,70], enhance islet 
engraftment and survival [71,72], and to treat diabetic ulcers and limb 
ischemia [73]. MSCs have also shown improved metabolic control in 
experimental models of type 2 diabetes (T2D) [74]. In a preclinical study, 
Gaber, Grattoni et al. have demonstrated that human bone marrow – 
derived mesenchymal stem cells, differentiated into islet like insulin 
producing cell aggregates (ILIPAs), encapsulated in a platelet lysate 
based gel matrix and housed in a 3D-printed polymeric device remained 
viable and secreted insulin for several weeks, proving potential as an 
autologous transplantable system for treating diabetes [36].  
In another preclinical study by Kauer et al. bone marrow - derived 
human mesenchymal stem cells were encapsulated in a synthetic 
extracellular matrix, along with murine neural stem cells, and administered 
into tumor cavity site of mouse models of human glioblastoma multiforme 
post tumor resection. This resulted in tumor size reduction, increase in 
survival rate, prolonged retention of encapsulated cells, tumor targeted 
migration and release of therapeutics. This study holds promise that 
patients’ own stem cells can be manipulated to deliver anticancer agents 
to improve survival [75].  
 
Adipose-Derived Cells: Adipose derived stem cells are easy to 
isolate, secrete several angiogenic factors and have great promise in the 
regeneration of ischemic tissue. However, they present limitations 
primarily due to poor survival, after transplantation. In a study, Cheng et al. 
encapsulated adipose derived stem cells in thermosensitive 
chitosan/gelatin hydrogel and demonstrated their sustained release, 
increasing the viability and promise for the treatment of ischemic diseases 
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[76]. In another study Xu et al. used a high density three-dimensional (3D) 
micromass model system to improve early chondrogenesis with adipose 
derived cells [77].  
 
Adipose derived regenerative cells (ADRC) are a blend of adult stem 
cells, endothelial progenitor cells, leucocytes and smooth muscle cells. 
They can differentiate into several tissue types, such as bone, cartilage, 
fat, skeletal muscle, smooth muscle and cardiac muscle and hence show 
great promise in regenerative medicine. Cytori Therapeutics Inc. is 
conducting a safety and feasibility clinical trial (NCT01556022) to evaluate 
ADRCs derived from patients’ own adipose tissue and specifically 
formulated for the treatment of chronic myocardial ischemia.  
 
Fibroblasts: are another cell type, widely being investigated for 
encapsulated transplantation. In an in vitro study, mouse NIH 3T3 
fibroblasts encapsulated in calcium alginate remained viable for up to 150 
days and released vascular endothelial growth factor for several weeks, 
suggesting that they may be able to induce angiogenesis and maintain 
cardiac function post myocardial infarction [41]. Microencapsulated 
fibroblasts, genetically engineered to secrete human basic fibroblast 
growth factor for treatment of retinal dystrophies, were shown to survive 
for 90 days in vitro and upon xenogeneic transplantation in rats [38,39]. 
Encapsulation of genetically engineered fibroblasts is also being evaluated 
for treatment of spinal cord injury [40].  
 
In majority of cases, encapsulation has shown to improve the in vivo 
viability of transplanted cells and enhance their functional ability for the 
intended therapeutic use, by providing a protected environment. Different 
strategies and a variety of natural and synthetic materials and their 
combinations have been investigated for this purpose, and are presented 
in the following sections of this review.  
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2.3 Strategies of Encapsulated Cell 
Transplantation in Diabetes 
Based on the geometry of the encapsulation system, the encapsulation 
strategies can be classified as microencapsulation, wherein individual cells 
are enveloped in a micron scale immunoisolating membrane, or 
macroencapsulation in which groups of cells are encased in a suitable 
membrane which could further be housed in a device. In this section, we 
describe the different types of microencapsulation materials, their clinical 
applications in diabetes treatment, the various macroencapsulation 
systems, their clinical status in diabetes followed by the clinical 
advancements of encapsulated cell transplantation for treating various 
disease conditions including chronic eye and neurodegenerative diseases, 
cancer, chronic wounds, cardiovascular diseases and kidney dysfunction.  
 
2.3.1 Encapsulation Materials 
Cell coating and microencapsulation are two strategies that are being 
extensively explored in order to address the challenges of immune 
rejection of transplanted cells. While cell coating refers to the deposition of 
a suitable polymeric membrane onto the cell surface, microencapsulation 
involves encasement of single cells or clusters in a polymeric matrix or 
membrane of micron range thickness. Both cell coating and 
microencapsulating materials allow for immunoisolation of the transplanted 
cells by preventing entry and interaction with the host immune cells, 
antibodies and complements several kDaltons in size. Thus, they provide 
permselective protection to the encapsulated cells while allowing diffusion 
of essential small molecules from the host into the graft and the 
simultaneous release of hormones, metabolites and waste produced by 
the encapsulated cells. The size of microcapsules is often reported to 
influence the determination of the transplant site and immunogenicity of 
  34 
the microcapsule system. Adverse effects have been associated with 
increase in volume of the encapsulated graft while, thickness of the 
capsule membrane influences the permeability for substance exchange 
and the diffusion rate of the therapeutic agents [34,78]. The diffusive 
properties and mechanical stability of the microcapsules were significantly 
enhanced in vitro, when capsule size was reduced from 1000 µm to 400 
µm. This resulted in the improved functioning of the encapsulated rat islets 
and murine hepatocytes [25,79,80]. The first microcapsules were designed 
to be 600-800 µm in diameter and now with conformal coating, it is 
possible to achieve close to 200 µm diameter capsules, rendering the 
system to be implanted in retrievable sites in the body [81–83]. 
Microencapsulation strategies utilizing different types of natural as well as 
synthetic materials are being evaluated based on the biochemical 
properties of the materials and the functional requirements of the 
transplanted cells. Here, we introduce the various microencapsulation 
techniques.  
 
Figure 2.3: Schematic of conformal coating and microencapsulation in 
pancreatic islet transplantation. (A) Over the years, significant efforts were spent 
in minimizing the ratio between encapsulation volume and surface area. (B) The 
semi-permeable membrane protects the encapsulated cells from the immune 
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system of the recipient while permitting the diffusion of molecules such as 
nutrients, oxygen, glucose, oxygen and insulin. 
 
Alginate Microcapsules: Alginate has been a widely explored encapsulating 
material due to the ease of generating microspheres, its rapid cross-linking 
potential to form gels, and the flexibility of incorporating other functional 
polymers [26]. Alginate does not present significant permselectivity against 
immune cells and factors that can destroy the encapsulated cells [84]. As 
such, polycations including poly-L-lysine (PLL) [85], poly(vinylamine) [86] 
and poly(allylamine) [87], poly-L-ornithine (PLO) [23], and chitosan [88] 
have been used as coating materials in alginate microcapsules to optimize 
the porosity, and enhance the efficacy and the biocompatibility of the 
microcapsule system. A typical alginate microcapsule comprises of an 
alginate core and an alginate outer shell, sandwiching a semi-permeable 
polycationic layer. Microencapsulation of islets using alginate has been 
promising in that it has proven to protect the encapsulated graft from host 
immune attack and prolong islet survival and is extensively evaluated in 
several preclinical and clinical trials. Graft xenosis and fibrosis were also 
shown to be prevented [89]. One of the main factors leading to necrosis of 
alginate microencapsulated cells is the host immune response [90]. 
Derived from seaweeds and algae via harsh chemical regimens, the 
polysaccharide alginate contains protein residues and toxins, including 
pathogen associated molecular patterns’ (PAMPs), which trigger 
inflammation, cell protrusion and complete fibrosis of the microcapsules 
[90,91]. A high concentration of mannuronic acid in the alginate copolymer 
is also known to elicit fibrosis. The stability of the outer alginate layer is 
important since it contributes to masking the inflammatory response 
stimulated by the PLL layer. Physical (surface roughness and charge) and 
mechanical (elasticity) properties of the alginate microcapsules play a role 
in determining the survival of the encapsulated cells [92–94]. However, the 
optimal values of these parameters, corresponding to the recipient and the 
site of transplantation are yet to be established from clinical studies.  
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PEG Coating: With the objective of overcoming the in vivo cytotoxicity 
and instability of PLL and other polycations, polyethylene glycol (PEG) and 
various polymers (e.g. chitosan, xanthan, agarose and cellulose) are used 
as coating materials [26]. The low immunogenic potential of PEG, its 
stability in physiological conditions, tunable biomechanical properties, and 
controllable protein adsorption, thickness, and porosity make it highly 
suitable for cell microencapsulation [95,96]. A variety of shapes of PEG-
based microencapsulation systems have been designed. When subject to 
glucose challenges, PEG encapsulated islets have shown to release 
insulin and also restored immunocompromised diabetic mice to 
normoglycemia for 110 days [97]. PEG encapsulated islets were also 
clinically assessed [98] and currently evaluated in advanced preclinical 
studies, as conformal coatings, in combination with matrigel. The main 
drawback of the PEG coating is that it creates an unfavorable cell 
microenvironment which can be overcome by incorporating collagen and 
laminin [99].  
 
Agarose Microcapsules: Agarose, another naturally occurring 
polysaccharide obtained from red algae, exhibits several properties of a 
suitable microencapsulating material. As a responsive polymer, the 
aqueous solutions of agarose go through a sol–gel transition with change 
in temperature [100,101]. While the conformation of a random coil is 
maintained over the sol-gel temperature, when cooled it is transformed to 
a double helix. By leveraging this sol–gel transformation at approximately 
37°C, agarose formulations can be employed for encapsulating cells. 
Agarose is a naturally occurring polysaccharide. It is less likely to trigger 
fibrosis and host inflammatory response and is also not biodegradable 
which makes it suitable for long term implants [102].  
 
Cellulose Microcapsules: Cell-in-a-Box® microencapsulation 
system, developed by PharmaCyte Biotech in partnership with 
Austrianova, utilizes cellulose sulfate and polymers such as 
polydiallydimethyl ammonium chloride to encapsulate genetically modified 
cells or beta cells by droplet formation. A combination of biocompatible 
 37 
natural and encapsulating polymers are passed through a microfluidic 
device to form microdroplets of a semipermeable membrane housing the 
therapeutic cells. The 0.7 to 0.8 mm sized microdroplets housing insulin 
producing cells referred to as the artificial pancreas is used for the 
treatment of type 1 and insulin-dependent type 2 diabetes. Preclinical 
studies in diabetic rats showed that transplantation of porcine insulin-
producing islet cells restored normal blood glucose levels and maintained 
for six months. Similar microdroplets encasing about 10,000 genetically 
modified liver cells, referred to as the artificial liver activates the 
chemodrug ifosfamide at the tumor site and kills the tumor. Clinical trial of 
the artificial liver is being initiated for the treatment of locally advanced 
inoperable pancreatic cancer (LAPC) [103–108]. 
 
Although the different encapsulating materials demonstrate different 
advantages in providing immunoisolation of the graft there are several 
hurdles left to overcome for their successful clinical deployment, starting 
from the choice of a suitable site for transplantation. Subcutaneous 
transplantation is potentially of interest to minimize the invasiveness of the 
procedure. Even though the subcutaneous tissue is known to deliver 
sufficient oxygen tension of 20 to 40 mmHg, transplantation of cells, as an 
example pancreatic islets, into an unaltered subcutaneous site has never 
been known to reverse diabetes in humans or in animal models [109–112]. 
This may be due to the inhospitable microenvironment owing to 
inadequate vascularization. Thus, angiogenesis stimulation is crucial for 
successful islet transplantation at the subcutaneous site. For this reason, 
oxygen generators [113], polymers [114,115], meshes [116], 
encapsulation devices [117,118], matrices [119], growth factors such as 
fibroblast growth factor, vascular endothelial growth factor and hepatocyte 
growth factor [119] as well as co-transplantation with mesenchymal stem 
cells have all been explored with some success [120,121]. Another critical 
issue is adverse tissue responses against the encapsulating capsules. 
Some of the reactions may be linked to the material or its components in 
the encapsulation. It has been shown that ‘pathogen associated molecular 
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patterns’ (PAMPs), which strongly trigger inflammatory responses are 
present in alginate. 
Cell protrusion, which has been associated with most encapsulation 
systems represents another challenge [91]. Over a certain limit, protrusion 
is known to generate high inflammatory responses which result in fibrosis 
of the transplanted microcapsules and necrosis of the transplanted cells. 
The different elasticities and mechanical robustness of the capsules [97], 
which determine the optimal conditions for cell survival and functioning are 
yet to be established. Along with these properties, factors such as 
roughness and charge of the microcapsule surface [85,122] and 
adsorption of protein [123,124], are vital to the success of the transplant. 
 
One of the main limitation of all microencapsulation approaches is that 
the transplanted cells cannot be retrieved in case of adverse reactions. 
This represents a safety concern, particularly in the case of stem cells, 
whose long term fate are unclear and that have the potential to 
differentiate into tumors [125,126]. An unmet need in cell encapsulation is 
the ability to monitor the delivered cells. Once microcapsules are 
transplanted, the only way to assess their functional state is through 
invasive recovery surgery. An unmet need in cell encapsulation is the 
possibility of monitoring the delivered cells. Invasive recovery surgery is 
the only mean to retrieve the transplanted microcapsules and examine the 
functional state of the encapsulated cells.  Barnett et al. have designed an 
interesting method to overcome this issue by using alginate-based 
radiopaque microcapsules, comprising of barium sulfate or bismuth 
sulfate, which could be observed by X-ray [127]. Although, the radiopaque 
agents did not affect cell viability and capsule permeability, the other 
materials employed in this work require more extensive examination. 
 
2.3.2 Microencapsulation in Diabetes 
In this section, we describe recent developments and deployment of 
microencapsulation systems in the field of diabetes treatment. Table 2.1 
shows the relevant microencapsulation materials, cell sources and sites of 
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implantation of these systems. Their applications in other disease 
treatments are discussed in a later section. 
Table 2.1: Clinical studies of microencapsulation systems for different 
application fields. 
 
 
Agarose encapsulated grafts were first shown to reverse diabetes in 
mice by Iwata in 1988, with the non-obese diabetic allografts surviving for 
80 days while isografts survived indefinitely [128]. In a more recent 
syngeneic islet transplant study without immunosuppression, mice 
implanted with the agarose microencapsulated islets were functional for 
more than 100 days. Encapsulated islets survived autoimmune destruction 
in contrast to the non-encapsulated islet grafts that lost their function in 2 
weeks and shown to be destroyed by complete infiltration by mononuclear 
cells and destroyed [129]. 
 
Alginate microencapsulation of human pancreatic islets demonstrated 
partial success clinically with limited survival period post-transplantation n 
1994 [130]. Interestingly, alginate microencapsulated neonatal porcine 
islets were functional and survived over 9.5 years when first implanted 
intraperitoneally (15,000 IEQs/kg) in a type 1 diabetic patient in 1996 
[131–133]. In addition to the 30% insulin reduction, there were no signs of 
xenosis or fibrosis of the graft. 
 
An interesting approach to avoid the use of immunosuppressive drugs 
and achieve immunoisolation of the transplanted pancreatic beta cells was 
designed by Encapsulife. Islet cells microencapsulated in a five-
component, triple layered polymeric system, were simply anchored without 
attachment to the peritoneal cavity by means of a 15-minute laparoscopic 
Company -
Institution Material Cell source Graft site Phase Ref.
DRI PEG-MG Xeno-allo pancreatic islets
Epididymal fat 
pad Preclinical [140]
LCT PLO-Alginate Porcine Insulin cell Peritoneal cavity I/IIa [144]
Encapsulife Organic polymers
Xeno-allo pancreatic 
islets Peritoneal cavity Preclinical
[134-135]
Vicapsys Alginate Porcine islet cell graft Intraperitoneal cavity Preclinical [145-146]
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procedure. This method of implantation enabled optimum nutrient and fluid 
exchange for the transplanted islets as well as stimulated insulin 
production. When canine pancreatic islets, encapsulated using this 
approach were transplanted to the pancreatectomized canines’ peritoneal 
cavity, the fasting blood glucose of all the nine experimental subjects, 
were normalized for 214 days without the use of any immunosuppressive 
or anti-inflammatory drugs [134,135]. 
 
Alginate encapsulated beta cell grafts with systemic 
immunosuppressive regimen such as basiliximab, anti-thymocyte globulin, 
tacrolimus and sirolimus were tested by Keymeulen group at AZ-VUB and 
University Hospital Brussels, Belgium demonstrated better outcome with 
encapsulated grafts than non-encapsulated controls in an immunodeficient 
mouse model [136,137]. An on-going phase II clinical trial, NCT01379729, 
involving non-uremic type 1 diabetic patients is currently assessing 
survival and function of the allografts of microencapsulated beta cells 
implanted in the peritoneal cavity. The microencapsulated grafts showed 
glucose secretory response in both mouse and human studies. Dr. 
Riccardo Calafiore and team at University of Perugia, Italy are developing 
microencapsules of human islets in a sodium alginate and PLO microbead 
based system [138,139]. Clinical evaluations have shown that the 
intraperitoneal transplantation of the microcapsules in non-
immunosuppressed type 1 diabetic patients elicited no immune response 
even with subsequent implants. However, the metabolic efficacy was 
limited due to poor oxygen and nutrient supply, affecting insulin secretion 
[83].  
 
Islets are non-uniform in size and range from 50 to 350 μm. Typical 
microcapsules are uniform in size and range from 500 to 1500 µm. 
Encapsulated grafts of such volume can suffer from islet aggregation and 
poor oxygen and nutrient distribution potentially leading to necrosis. 
Microencapsulation methods involving a thin coating to maintain volume 
comparable to the naked islet grafts, are being assessed to overcome this 
drawback [93]. Alice Tomei and team at the Diabetes Research Institute of 
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Miami are developing a system where islets are conformally coated (shrink 
wrapped) with a PEG hydrogel layer and matrigel (MG) extracellular matrix 
[140]. This system is characterized by enhanced immunoisolation and islet 
function owing to its permselectivity and minimal immunogenicity [140]. 
The aim of this process is to facilitate implantation in favorable sites and 
minimize core hypoxia and delayed insulin release [82]. This method did 
not negatively affect islet function in vitro and in vivo [141]. When the 
conformally coated PEG MG islets from Balb/c mice were transplanted 
into the epididymal fat sites of diabetic C57BL/6 mice, at a dose of 750-
1000 IEQ/mouse, the islets survived over 100 days without the 
administration of immunosuppressive drugs [140]. 
Another tri-layered encapsulation technology of significance is 
IMMUPELTM, developed by a New Zealand based company, Living Cell 
Technologies Limited (LCT Ltd). DiabecellTM and NTCELL®, both adopt 
the IMMUPELTM technology – intermediate PLO layer sandwiched by 
alginate layers - eliminating the need for immunosuppressive regimens 
post-transplantation [125,142]. Xenogeneic transplant of DIABECELL® has 
shown to lower the daily insulin requirement in diabetic rats as well as 
non-human primates [143]. It was also shown to have a favorable safety 
profile in mice, rabbits and dogs. In human trials, conducted in Argentina, 
New Zealand and Russia, DIABECELL® was safely implanted in the 
peritoneal cavity of type 1 diabetic patients. HbA1c, insulin dose and 
unaware hypoglycaemic events were significantly lowered with increased 
dosage [144]. With no signs of adverse reactions to up to 3 implants per 
patient, 6 patients demonstrating long term blood glucose control and the 
remaining 2 were completely insulin independent for up to 8 months, 
DIABECELL® was clinically approved in Russia in 2010. 
 
An advancing microencapsulation technology aimed at encapsulating 
and protecting the islet graft is VICAPSYS's VICAPSYN™eluting alginate 
system. This 200-600 µm system is designed to comprise 1-2 human or 
porcine islets microencapsulated by biocompatible polymers which 
gradually release VICAPSYN™ over time. VICAPSYN™ provides 
immunoisolation by repelling T-cells and prevents fibrosis and graft 
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rejection. The angiogenic properties of VICAPSYN™ is proposed to 
enhance perfusion of the islets and enhance vascularization at the 
transplant site. Transplants of the CXCL12 incorporating alginate 
microcapsules, in the intraperitoneal cavity of healthy NHPs demonstrated 
the absence of inflammatory cells when adjacent to the mesentery while 
capsules devoid of CXCL12 were marked with significant inflammation 
and fibrosis. Two autologous transplants of the encapsulated islets were 
found to be functional when retrieved 30 days post-transplant. Allogeneic 
islet transplant studies are ongoing [145,146]. 
 
2.3.3 Macroencapsulation Systems  
Microencapsulation and cell coating strategies have achieved 
important milestones in particular by limiting the access of host’s immune 
system to the transplanted cells [45]. However, achieving long term cell 
survival is still a major challenge for the many reasons previously 
described including dispersion, suboptimal oxygenation and engraftment 
[26,147,148]. 
Macroencapsulation systems have been developed to overcome these 
challenges using larger devices with a planar or cylindrical geometry, to 
provide a suitable hosting microenvironment for cells. The reservoir of 
these implantable devices often designed to avoid cell clustering while 
protecting cells from mechanical stress. Importantly, cells are isolated from 
direct contact with the host tissues via permeable flat sheet membranes or 
the lumen of semipermeable hollow fiber. This represents a significant 
advantage of macroencapsulation as it offers the option of full cell 
retrieval, in case of loss of function, adverse effects, or malignant 
transformation of the transplanted tissue [149,150].  
Macrocapsules are classified in two main categories: i) Intravascular 
systems, which connect the graft as a shunt to the systemic circulation. ii) 
Extravascular devices, which rely on the formation of new blood vessels at 
interface between the host tissue and the device interface [93,147,151].  
In some of the intravascular devices, cells are encapsulated within a 
semi-permeable membrane containing polymeric capillaries. After cells 
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transplantation within the membranes, these devices are directly 
connected to the host systemic circulation by vascular anastomoses 
creating an intravascular shunt. The close proximity with the recipient’s 
blood stream constitutes an important advantage in terms of ideal oxygen 
and nutrient supply, thereby enhancing graft survival [147].  This feature is 
also of paramount importance for cells whose therapeutic function is to 
secrete molecules in response to biological stimuli, in real time, as is the 
case for pancreatic islets. However, intravascular systems generate the 
risk of thromboembolic events, which require intense anticoagulation 
therapy and associated adverse effects (e.g bleeding and gangrene, 
among others). This has rendered intravascular devices are no longer 
suitable for routine clinical application. Extravascular devices are usually 
associated with lower risk to the recipient. These systems are designed in 
the form of either tubular or planar diffusion chambers. Common sites of 
implantation are the peritoneal cavity, an omental pocket, or subcutaneous 
tissues, which make their implantation simpler, less invasive, and mostly 
free of major surgical complications. Despite the advances in cell 
engineering, it is unlikely that transplanted cells would survive and function 
indefinitely. Pragmatically, strategies for the substitution, or replenishment 
of cells have to be considered in the context of clinical deployment these 
systems. In this context, extravascular macroencapsulation devices, 
especially those designed for subcutaneous implantation, offer a solution 
via device retrieval or transcutaneous cell loading and replacement.  
Diabetes is the medical field for which macroencapsulation strategies 
have been most widely explored for decades. In the following sections, we 
present early developments of macroencapsulation devices in diabetes, 
followed by current approaches in advanced preclinical clinical study as 
well as under clinical trials.  
2.3.4 Early Macroencapsulation in Diabetes 
One of the earliest pioneering studies attempting the implantation 
insulinoma tissues in a perm-selective membrane is the one by Dr. 
Bisceglie in 1933. The study focused on determining the effect of the 
absence of vasculature on the survival of implanted tissues. However, the 
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credit for originally developing an extravascular diffusion device based on 
a flat membrane system should go to Dr. Algire and his colleagues Drs. 
Prehn and Weaver. They studied both the cellular mechanisms of tissue 
rejection and tumor growth, the results of which were reported in a series 
of publications from 1948–1959 [147–155]. Notably, they found that while 
host cell exclusion achieved allograft survival, by itself it was not sufficient 
to protect xenograft transplants long term. This work led to the strategy of 
artificially creating an immune-privileged site for cell implantation and 
opened the door to pancreatic islet encapsulation studies that followed.  
In the 1970s, following Algire’s approach, Millipore Corporation 
produced an extravascular transplantation chamber for allotransplants. 
The device featured membranes with pore sizes in the order of 450 nm, 
with the objective of preventing direct cell–cell contact between the graft 
and the host [156]. In vivo assessments showed that cells remained viable 
only for a few weeks. Fibroblast overgrowth around the device was 
observed, which raised concerns about device biocompatibility. In an 
attempt to reduce the fibroblastic response, attempts were made to oat the 
outer surface of membranes with collagenase [157]. This approach helped 
eliminating the fibrous capsule directly in contact with the membrane. 
However, a fibrotic encapsulation formed at a short distance from the 
membrane, still limiting the inward and outward diffusion of molecules and 
nutrients [158].  
Additional factors challenging the success of these permselective 
systems were ascribed to the lack of mechanical robustness and chemical 
stability of membranes in vivo. The development of silicon nanofluidic 
systems based on microfabrication and sacrificial layer techniques 
[159]fostered new approaches to cell encapsulation systems. In fact, 
peculiar properties of transport in nanochannels [160,161] can be 
leveraged to achieve better control of molecule permeation and diffusion 
via physical and electrostatic confinement [162–164]. Starting in the early 
1990s, Ferrari, Desai et al. generated microfabricated capsules with 
regular patterns of slit-nanochannels in size smaller than 100 nm [165] for 
molecular sieving [166] and cell immune isolation [167,168]. They showed 
that islets and insulinoma cells encapsulated in these systems within a 
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supportive matrix, were viable and glucose responsive in vitro and in vivo 
in mice models [169]. These ceramic-based systems offered enhanced 
mechanical robustness and biocompatibility [170] showing minimal fibrotic 
encapsulation surrounding the device. However, long term graft survival 
was still elusive likely due to the lack of proper cell oxygenation.  
 
In the late 1990s, Baxter Healthcare that subsequently became 
Theracyte™, provided an important contribution in the field of 
macroencapsulation systems by designing a planar device employing a 
double membrane approach for immune protection and vascularization of 
the cells [171]. An outer Teflon membrane offered mechanical strength 
and promoted capillary ingrowth, while an inner hydrogel semipermeable 
membrane was used for allograft immune protection. High level of 
vascularization was achieved subcutaneously in rats and cell function was 
shown [115,172]. Despite these promising results, a fibrotic capsule 
overgrowth still challenged cell retrieval. Baxter’s technology is still used 
by various research groups and important players in the cell encapsulation 
field such as Living Cell Technologies (LCT), Betalogics of Janssen 
Pharmaceuticals, and Viacyte. 
Other macroencapsulation strategies based on alginate were 
developed, in late 1990s, to achieve immune protection and to support cell 
viability and function. Suzuki et al. implanted encapsulated islets into the 
epididymal fat pad(s) in streptozotocin-treated diabetic mice and 
demonstrated their in vivo viability and function for 12 weeks [173]. Islet 
Sheet Medical conceived alginate based islet sheets (250 μm) and tested 
them with allogenic islets sutured on to the omentum of dogs, 
demonstrating euglycemia for 84 days [174]. More recently, human islets 
were encapsulated within the islet sheets and tested both in vitro and in 
rats demonstrating islet survival [175].  
Recently, various other companies developed a number of 
approaches, without reaching clinical evaluation. Among 
them, Encelle transplanted intramuscularly porcine islets encapsulated in 
a hydrogel matrix and supported by a polyester net; BetaGene in 
partnership with Gore Hybrid Technologies designed a subcutaneously 
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implantable flexible tube containing islets. However, most of these 
technologies failed to reach clinical evaluation. 
 
 
3.3.5 Current Macroencapsulation in Diabetes 
More recently, external oxygen supplementation, vascularization of the 
devices prior to cell transplantation and the use of autologous cell sources 
have been adopted as strategies for achieving long term cell survival. 
Despite the difficulties in achieving suitable vascularization, subcutaneous 
implantation is now considered as one of the target implantation sites. 
Advantages include reduced invasiveness of surgical procedure and the 
potential for transcutaneous loading, replenishment and retrieval of cells. 
Table 2.2 lists recent macroencapsulation technologies are under 
advanced preclinical and clinical investigation and that are discussed in 
greater details below. 
 
Table 2.2. Current macroencapsulation systems under advanced stage of 
development for diabetes treatment.  
βAir. To improve cell oxygenation within the device, an implantable 
bioreactor was developed by the Israel based company Beta-O2 
Technologies Ltd. This device, named βAir (Fig. 2.4A) is a subcutaneous 
system that comprises a reservoir containing islets encapsulated in an 
alginate hydrogel slab, and a gas chamber that allows oxygen 
supplementation through a tubing system, to improve cell oxygenation 
within the device. A porous membrane protects islets from immune 
Company -
Institution Material Cell source Graft site Phase Ref.
TheraCyte PTFE membrane Islet ESC derived Subcutaneous I [171]
Beta-O2 
Technologies Teflon/Alginate
Human pancreatic 
islets Subcutaneous I/II [178]
Viacyte PTFE membrane Human embryonic stem cells Subcutaneous I/II [180-182]
Houston 
Methodist 
Hospital
Medical grade 
polymer/Silicon
Human pancreatic 
islets/beta cells Subcutaneous Preclinical [35,36]
Monolayer 
Cellular Device Alginate Pig islets Subcutaneous I [197]
Defymed Medical gradepolymers
Insulin secreting 
cell Subcutaneous Preclinical [192]
DRI Plasma-thrombin biologic scaffold Human islets Omentum I/II [202]
Sernova Medical grade polymers Human Islets Subcutaneous I/II [191]
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rejection and a silicon membrane allows the passage of oxygen contained 
in the gas reservoir. Preliminary studies in rats and pigs showed that daily 
oxygen supplementation via injection preserved islets function for up to 90 
days [176]. In 2012, ßAir was implanted in a 63-year-old patient in 
Germany. The case report indicated that islets retained function for the 10-
month study duration, achieving persistent graft function, regulated insulin 
secretion and preservation of islet morphology and function without any 
immunosuppressive therapy [177]. A phase I/II clinical trial 
(NCT02064309) [178] with 4 patients is ongoing (expected to end in 2018) 
with the primary objective to investigate the safety of implantation βAir 
containing human islets in type 1 diabetic subjects [179]. The secondary 
objective of the trial is to evaluate the efficacy of the βAir device in 
improving glycemic control, and the incidence of hypoglycemic episodes. 
Other key developments proposed by Beta-O2 are a market ready version-
2 device that holds enough beta cells to replace insulin altogether, instead 
of being an add-on to insulin therapy and to advance from cadaver cells to 
stem cells in the coming years.  
 
PEC-Encap and PEC-Direct. Over the past decade, ViaCyte, Inc. 
(San Diego, CA) has developed two subcutaneously implantable devices 
for the encapsulation of stem cell derived pancreatic progenitor cells 
(PEC-01™) for diabetes treatment. Both promote vascularization prior to 
cell transplantation in order to avoid graft hypoxia events [94]. PEC-
Encap™ device (Fig. 2.4B) consists of an immunoprotective membrane 
(Encaptra®) that allows oxygen and nutrients permeation from the 
vasculature generated on its outside, while limiting access to immune 
cells. PEC-Direct™, instead, consists of a polymeric membrane that 
allows direct vascularization of the encapsulated cells within the device. In 
this case immunosuppressive regimens are required to protect the graft 
from host’s immunerejection. PEC-Encap™ approach was shown to retain 
robust graft function for at least 6 months following transplantation. In late 
2014 Viacyte started a phase I/II clinical trial (NCT02239354) [180] with 
the purpose to test safety and efficacy of PEC-Encap™ implanted 
subcutaneously in type 1 diabetes patients, over two years. In 2016 a 3-
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year follow up safety study (NCT02939118) [181] was started in subjects 
previously implanted with PEC-Encap™. The expected recruitment is 200 
patients. An open-label clinical trial is ongoing to evaluate the safety and 
efficacy of PEC-Direct. In the first Cohort, T1D patients were implanted 
with the devices loaded with specific cells called sentinels. These cells, 
after the retrieval of the implant, will be examined histologically to evaluate 
the engraftment and maturation of the insulin-producing cells. On August 
1, 2017, ViaCyte announced that the PEC-Direct™ implantation in the first 
patient took place in collaboration between University of Alberta Hospital 
in Edmonton, Alberta, and the UC San Diego Altman Clinical Trials 
Research Institute (NCT03162926) [178]. In the second Cohort up to 40 
patients will be evaluate the ability of PEC-Direct™ to release a clinically 
relevant level of insulin [182]. On Jan. 5, 2018 in the first patient of the 
Cohort 2 was implanted a potentially efficacious dose of PEC-01™. In the 
coming months, the company proposes to expand the trial to additional 
centers in Canada and in the US, including the University of Minnesota. 
Efficacy results from this trial are expected by the first half of 2019. 
Figure 2.4: (A) Schematic view of the ßAir device showing the central gas 
module connected to the two access ports for exogenous oxygen refueling. The 
core of the device can be charged with oxygen to diffuse outwards to the two 
compartments surround the central gas cavity where alginate-immobilized 
pancreatic islets are housed. The central module is covered by hydrophylized 
PTFE porous membranes. (B) Schematic of the PEC-Encap™ device, which is 
composed by an immunoprotective membrane (Encaptra ®) that allows the 
transport of nutrients from the exterior of the device and hormones from the 
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encapsulated cells. 
 
Cell Pouch. A different approach developed by Sernova Corporation 
(Canada) [183] allows to pre-vascularize a subcutaneous site before the 
administration of the cells, through a port. The discoidal device named Cell 
Pouch™ (Figure 2.5A) is implanted and maintained subcutaneously for 4 
to 5 weeks. At the end of this period, islets are injected within the device. 
The Cell Pouch™ device does not protect transplanted cells from immune 
rejection and so immunosuppressant drug administration is required. To 
avoid immune rejection, immunesuppressant drug Transplanted cells in 
this vascularized space were proven to be functional, enabling diabetes 
reversal in a murine model [183,184]. Sernova's islet cell replacement 
therapy is currently in phase I/II development stage for Type-1 diabetes at 
University of Alberta [185]. In order to protect insulin producing islets from 
immune system attack locally within the Cell Pouch™, Sernova developed 
the Sertolin™ technology. Preclinical studies are ongoing. 
 
MAILPAN. With the purpose of developing an non-biodegradable, 
biocompatible material, Defymed [186], a spin-off of CeeD (European 
Center for Diabetes Studies) is developing an implantable device known 
as MAILPAN® (Macroencapsulation of pancreatic Islets) (Fig. 2.5B), with a 
first focus on type 1 diabetes and applicable to several other diseases. 
MAILPAN® is a semi-permeable device, designed to be implanted into a 
patient's abdomen that aims to work as a bio-artificial pancreas. Similarly, 
to other systems, MAILPAN encapsulates insulin-secreting cells within the 
cell chamber made of impermeable membranes to the immune system, 
but permeable to oxygen, nutrients, glucose and insulin. Thanks to the 
presence of input and output ports, cells within the MAILPAN® can be 
replaced without the need for surgery. In 2016 Defymed signed a strategic 
collaboration with Semma Therapeutics in order to use the MAILPAN 
technology to encapsulate Semma stem cell-derived insulin-secreting 
cells. Pre-clinical studies are ongoing. 
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Figure 2.5: (A) Cell Punch System where a polymeric scaffold is 
subcutaneously implanted and then removed leaving leaving a void vascularized 
space where the islets are transplanted. (B) Graphic representation of MAILPAN 
system composed by cell chamber and two ports for the external cell loading. 
 
 
In the macrodevices described above, the transplanted cells are 
housed between flat-sheet double membranes made with water-insoluble 
polymers [187] such as PTFE, PLA and Teflon. Other research groups 
adopt a “monolayer” configuration where cells are seeded as a monolayer 
within water-soluble polymers such as acellular collagen matrix and 
hyaluronic acid to provide a more natural and potentially less 
immunogenic environment to the encapsulated cells [188].  
 
 
 
 
 
 
Figure 2.6: (A) Scheme of Monolayer Cellular device planar consisting on a 
flat sheet made of acellular collagen matrix containing porcine islets 
encapsulated as alginate macrocapsules. (B) BioHub technology where the 
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donor islet cells are combined within a biodegradable scaffold made with patient's 
own plasma, thrombin and a clinical-grade enzyme. The area of the omentum is 
then folded over around the scaffold.  
 
Monolayer Cellular Device (MCM), developed by Dufrane et al. [189] 
at University Clinical Hospital Saint-Luc, Brussels, consists of a planar flat 
sheet made of acellular collagen matrix where porcine islets are seeded 
and encapsulated as alginate macrocapsules [190] (Figure 2.6A). 
Designated for subcutaneous implantation, it successfully controlled 
diabetes for 6 months in diabetic cynomolgus macaques, without the need 
of immunosuppression. Moreover, after transplantation of new monolayer 
cellular devices, diabetes was controlled for up to 1 year. [188]  
The implantation of a Monolayer Cellular Device in a 74-years old 
T1DM patient showed no inflammation and no immunization against donor 
cells for 361 days. Diabetes control and graft function was achieved during 
11 months post-transplantation. A 61% reduction of hypoglycaemic 
episodes was obtained. After 11 months, the device was easily removed 
showing the macroscopical integrity of the graft without sign of 
inflammation [191]. In 2016, a Phase I clinical trial involving 15 type 1 
diabetes patients was completed at the Université Catholique de Louvain 
(NCT00790257) [192]. As an additional effort to improve vascularization of 
the device, adult pig islets were co-transplanted with either bone marrow 
or adipose mesenchymal stem cells (BM-MSCs or AMSCs, respectively) 
[193]. However, despite the improved oxygenation and neoangiogenesis, 
MSCs only slightly improved the long term function of the device in an 
NHP model [193].  
 
BioHub. Another technology based on the encapsulation of pancreatic 
islets within a biological material has been developed at the Diabetes 
Research institute (DRI) of Miami [194]. This scaffold system, known as 
BioHub, is composed of a gel-like substance made with the patient's own 
plasma combined with thrombin. The scaffold containing pancreatic islets 
is then implanted onto patient’s omentum (Fig. 2.6B). Over time, the gel 
degrades leaving the islets intact, while new blood vessels are formed to 
support their survival and function. The omentum was chosen for relatively 
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easy access and its dense vasculature. Studies conducted in small animal 
model demonstrated an improved metabolic function and cytoarchitecture 
preservation of the encapsulated cells within the highly vascularized 
BioHub scaffold. Long-term nonfasting normoglycemia and adequate 
glucose levels were achieved [195]. BioHub is being evaluated in an 
ongoing clinical trial (NCT02213003) [196]. In May 2017, Baidal et al. 
published part of the results of the ongoing study (NCT02213003), where 
the patient, a 43-year-old woman with a 25-year history of type 1 diabetes, 
received a total of 602,395 islet equivalents from one deceased donor 
encapsulated within the autologous engineered-tissue and implanted onto 
the omentum [197]. BioHub restored euglycemia and insulin 
independence for 12 months. Although this strategy still requires the 
administration of immunosuppressive regimens, it demonstrates that the 
omentum could be considered as a good site for islet transplantation 
adopting the BioHub technique. The ongoing study aims to test the safety 
and long-term feasibility of the approach for islet transplantation. 
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2.4 Cell transplantation beyond 
Diabetes 
Many other medical conditions have been targeted with cell therapies 
and encapsulation strategies, especially those involving a protein 
deficiency (Table 2.3). Here we present the most successful micro or 
macro encapsulation approaches and applications that are currently under 
investigation or already approved for clinical use. 
 
Table 2.3: Clinical studies of macro encapsulation systems for different 
application fields. 
  
 
2.4.1 Chronic Eye Diseases 
Stem cell therapies are under development for several ophthalmic 
conditions including age-related macular degeneration (ARMD) and 
diabetic retinopathy as well as to provide trophic factors to protect 
compromised retinal neurons and to restore neural circuits.  
Utilizing its technological platform, Neurotech Pharmaceuticals, Inc. 
(Cumberland, RI) [198] has created intraocular implants for the treatment 
Application Company -Institution Material Cell source Graft site Phase Ref.
Chronic eye disease Neurotech Implantablepolymer
Human retiunal pigment 
epithelial cells Eye II/III [210]
Neurodegenerative 
diseases NsGene
Implantable
polymer GDNF secreting cells Intracranical II [230,231]
Neurodegenerative 
diseases NsGene
Implantable
polymer NGF secreting cells Intracranical I [237,238]
Cancer MaxiVax Implantablepolymer GM-CSF secreting cells Subcutaneous II [246]
Wound healing Organogenesis Extracellular matrix
Fibroblasts/epidermal 
keratinocytes Cutaneous
FDA 
approved [254]
Wound healing Organogenesis Polyglactinscaffold Fibroblasts Cutaneous
FDA 
approved [255,256]
Kidney failure CytoPherx
Polycarbonate/E
PDM/niobium 
coated carbon
Renal epithelial cells External IIb [265,265]
Kidney failure
Sentien
Biotechnologie
s
Biocompatible
polymers Mesenchymal stem cell External I/II [266,267]
Kidney failure UCSF Silicon Human kidney tubule cells Abdomen Preclinical [268-270]
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of a broad array of eye diseases that can deliver therapeutic proteins 
directly to the back of the eye for up to two years. These implants contain 
human retinal pigment epithelium cells (NTC-201) that have been 
engineered to produce and release a desired therapeutic agent and that 
are encapsulated in a semi-permeable hollow fiber membrane protected 
by a permeable exterior capsule (Fig. 2.7A). The implant is surgically 
inserted in the vitreous allowing oxygen and nutrients to freely diffuse 
inside the device, and therapeutic to freely diffuse outward. The implant 
termed Renexus® (NT-501) developed by Neurotech Pharmaceuticals 
[199] (Fig. 2.7A), is an implantable polymeric device containing NCT-201 
cells secreting ciliary neurotrophic factor (CNTF), and going through phase 
II and III clinical trials for the potential treatment of retinitis pigmentosa 
(RP), [200,201] age-related macular degeneration (AMD), [202] glaucoma 
neuroprotection [203], vision restoration [204] and macular telangiectasia 
(MacTel). In June 2017 Neurotech announced the results of the phase II 
trial on MacTel (NCT03071965) [205] showing achieving a significant 
reduction in the progressive loss of photoreceptors in the treated patients 
as compared to untreated individuals, at 24 months. Neurotech plans to 
initiate a phase III trial for the therapy by the end of 2017 and this therapy 
has the potential to become the first treatment available for macular 
telangiectasia. Neurotech is currently developing more advanced versions 
of this platform including NT-503 device secreting VEGF-antagonists to 
treat wet AMD [206] and NT-506 for the treatment of wet AMD by 
secreting a PDGF (platelet-derived growth factor) antagonist. With this 
system, the company expects to improve efficacy and reduce scarring of 
the retina.  
 
2.4.1 Neurodegenerative diseases: 
Chronic, degenerative central nervous system (CNS) diseases is 
currently the fourth leading cause of death affecting over 37 million people 
worldwide [207]. Despite extensive research efforts, most of these 
diseases lack of a cure. To date, the most promising approaches for their 
management consist on the delivering of neurotrophic or angiogenic 
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factors from engineered cells to slow, or even reverse the ongoing 
degeneration and its related neurological deficits [208,209]. Encapsulated 
cell therapy is developed as a means to overcome the challenges of 
sustained, controlled delivery of these factors across the blood brain 
barrier (BBB) [210]. Macro devices encapsulating cells in semipermeable 
hollow fiber membranes have been investigated for CNS pathologies such 
as Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's 
disease (HD) [152,211–213]. Early studies in guinea pigs or NHP brains 
using xenografts showed that un-encapsulated cells were rapidly rejected, 
while cells in intact capsules remained viable, confirming the promise of 
encapsulation [214,215]. 
Parkinson's disease (PD) is a degenerative disorder of the CNS 
characterized by the development of progressive and debilitating motor 
impairments due to the dysfunction of dopamine-secreting neurons in the 
substantia nigra.  
Initial validation of the possibility to use encapsulated PC12 cells 
implanted into the striatum for the treatment of PD came from studies in 
both rodents and NHPs [40,215,216].  
Several studies have demonstrated the benefits of glial cell line-
derived neurotrophic factor (GDNF) in preventing the loss of nigral 
neurons and abnormal motor function and enhancing dopaminergic 
function [217,218]. Unfortunately, the main limitation is that GDNF cannot 
be effectively delivered to the brain via systemic administration. To 
overcome this, encapsulated cells were implanted, in a small animal 
model, immediately rostral to the substantia nigra achieving a release 
approximately to 5 ng of GDNF/day. The results of these studies shown an 
attenuation of lost neurons but without having a significant effect on 
dopamine within the striatum [219–221]. Despite the potential role that 
encapsulated cells may have in the treatment of PD, the levels of GDNF 
and neurturin delivered were clinically not sufficient to register any 
beneficial effects. New technologies able to release with levels of GDNF 
are under investigation.  
NsGene A/S (Ballerup, Denmark) has developed a tubular device (Fig. 
2.7B) composed by polysulfone hollow fiber membrane for the 
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encapsulation of genetically engineered human cell line secreting GDNF 
[222–224], which, when implanted bilaterally into the putamen of the brain, 
have shown long-term stability (>1 year) in animal models and clinical 
trials [225,226]. Beyond GDNF, this product has potential for delivering 
various cell-derived substance, alone or in combination, to the CNS. In the 
first half of 2015, an IND has been filed to support a Phase Ib trial in 
approximately 12 patients with PD to demonstrate its safety and feasibility. 
Alzheimer's disease (AD) is an irreversible and progressive brain 
disorder that mostly affects older population. AD is the most prevalent 
form of adult onset dementia and is expected to affect 115 million patients 
by 2050 [227].  
AD is characterized by a progressive deterioration of cognitive and 
mnemonic ability, which is at least partially related to the degeneration of 
basal forebrain cholinergic neurons. Current therapies cannot prevent the 
loss of cholinergic neurons or the associated memory deficits. 
Encapsulated nerve growth factor (NGF) secreting BHK implants were 
shown to be efficacious in rats and NHPs in inducing a robust 
development of cholinergic fibers close to the implant site [226,228,229]. 
More recently, understanding the role of Aβ aggregates and neurofibrillary 
tangles in AD pathology, anti-Aβ therapies have been tested to prevent or 
delay development of AD [230,231]. Macroencapsulation devices 
composed by hollow fibers were used to transplant myoblasts genetically 
engineered able to release a single-chain variable antibody fragment 
(scFv) directed against the N-terminus of the Aβ peptide. 
This treatment reduced Aβ production and deposition and improved 
behavioral deficits associated with the amyloid pathology. However, the 
invasiveness of the procedure is a major obstacle to clinical development 
in presymptomatic AD patients [211].  
In order to increase the volume of the transplanted cells and reducing 
the invasiveness of the implant, novel flat sheet devices were developed 
for subcutaneous implantation [211]. These devices are composed of two 
porous polymer membranes enclosed in two mesh sheets, for mechanical 
stability and neovascularization. The inner chamber can contain up to 
several millions of myoblast cells, loaded into the device via a dedicated 
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port. Studies in mice have demonstrated that subcutaneously implanted 
Encapsulated Cell Therapy (ECT) devices achieved a release of 50 μg/ml 
of anti-Aβ IgG antibody for 19 weeks [49]. Ongoing investigations shown 
that similar levels of mAb can be achieved for more than 10 [211]. These 
results seem to validate the ECT technology combined with myogenic 
cells for the long-term delivery of anti-Aβ mAbs leading to a significant 
reduction of the amyloid brain pathology in Alzheimer’s mouse models. 
Another encapsulation device for Alzheimer treatment developed by 
NsGene (NsG0202), showed, in clinical studies (NCT01163825) [232], 
that a sustained delivery of NGF at low doses to the basal forebrain 
cholinergic neurons could have clinical benefits on the progression and 
even prevention of AD [233,234].  
 
2.4.3 Cancer  
Immunotherapy refers to the modulation of the natural immune 
response in order to treat or prevent diseases including cancer. Studies 
have reported that endostatin-expressing cells in an immunoisolation 
device are effective in inhibiting the growth of melanoma and Ehrlich 
tumors [235]. As an example, mice fibroblasts engineered for the secretion 
of endostatin were encapsulated in Theracyte™ devices and 
subcutaneously implanted in mice at a site distant from the tumors [235]. A 
42.4% reduction in melanoma growth was obtained [236,237]. These 
reports in the literature prove that macroencapsulation could provide a 
promising platform for innovative therapeutic strategies in cancer 
treatment [235].  
Recently, MaxiVax SA (Switzerland) [238], a Swiss biotechnology 
company, conceived a flat macroencapsulation device specifically 
designed for subcutaneous implantation of cells capable of localized 
release of granulocyte-macrophage colony-stimulating factor (GM-CSF) 
for the treatment of solid tumors [211]. The assembled device is 
composed of two permeable membranes presenting a length, width, and 
thickness of 27, 12 and 1.2 mm, respectively (Fig. 2.7C). A loading port is 
integrated into the device to allow the injection of cells into the device. 
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Clinical trials were performed in patients with various types of cancer, such 
as renal cell carcinoma , melanoma, prostate, lung and pancreas cancer 
[238]. The clinical results highlighted the ability of GM-CSF to induce an 
effective anti-tumor immune response when secreted locally at the site of 
cancer cell injection [239]. A new system from MaxiVax named MVX-
ONCO-1 is designed to allow for the local delivery of GM-CSF combined 
with irradiated tumor cells from the patient [240]. The objective is to deliver 
tumor antigens and cytokines at the same site as tumor cell injection, to 
produce a local adjuvant vaccine effect [241]. The first phase I clinical 
study (NCT02193503)[242] targeted patients with a variety of solid tumors, 
including pancreas, colon, head and neck, chordoma, prostate and 
ovarian, with failed standard therapies. The 8- week study, with 6 vaccine 
injections and 6 subcutaneous implantations of the immune booster 
demonstrated that MVX-ONCO-1 was safe and well tolerated, with no 
occurrence of any serious adverse events [242]. No clinically significant 
local or systemic reactions were reported. The company is initiating a 
Phase II clinical trial for head and neck cancer and other solid tumors. 
MVX-ONCO-1 the first in men cell encapsulation system developed for 
cancer immunotherapy. Numerous preclinical studies following similar 
immunotherapy approaches are ongoing. These are beyond the scope of 
this work, but are extensively reviewed in the literature (refs).  
Figure 2.7: (A) NTC-501 technology for chronic eye diseases, consisting of a 
semi-permeable exterior capsule and internal scaffolding, which allows for 
controlled cell growth and continuous protein release. (B) NsGene straw-like 
device implanted in the brain of patients, contains living cells which are 
genetically modified to produce a therapeutic factor. (C) MVX-ONCO-1 
encapsulation device containing allogenic cells for the release of GM-CSF. 
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2.4.4 Wound Healing and Regeneration 
Chronic wounds affect about 2% of the world population corresponding 
to 6.5 million patients, with a cost of $ 25 billion annually in the United 
States alone [243]. Venous leg ulcers (VLU), diabetic foot ulcers (DFU) 
and pressure ulcers are the most prevalent of chronic and non-healing 
wounds. Among several new treatment modalities for tissue regeneration, 
stem cell-based therapies have gained interest as a promising approach 
and demonstrated to enhance wound healing, and increase blood vessel 
and granular tissue formation [244].  
Various delivery systems have been developed to protect and improve 
the regenerative potential of stem cells within a wound environment. Of 
these, bioscaffolds, composed of collagen, hyaluronic acid, or other 
naturally derived or synthetic materials, have become popular to 
encapsulate stem cells [245–247]. Rustard et al showed that seeding stem 
cells onto a pullulan-collagen preserves cell expression of stemness-
related genes and significantly accelerates wound healing [248].  
By the geometrical and chemical alteration of porous scaffolds, a wide 
range of progenitor cell therapeutics has been valuated. Moreover, in 
order to modulate stem cell activity and wound healing capability, scaffolds 
have been supplemented with growth factors, small molecules, anti-
inflammatory and/or antioxidant substances [249]. These advanced 
materials play an important role in enhancing survival and functionality of 
the encapsulated cells, beyond their normal physiological capacity.  
Apligraf® (Organogenesis Inc.) is an FDA approved product for 
treatment of venous and diabetic leg ulcers, consisting of an extracellular 
matrix, allogenic dermal fibroblasts and epidermal keratinocytes to provide 
growth factores and wound closure, and a stratum corneum for 
mechanical strength and as a barrier to infections [250].  
In 2012, the same company received FDA approval for GINTUIT™ 
(allogeneic cultured keratinocytes and fibroblasts in bovine collagen) an 
allogeneic cellularized scaffold (Fig. 2.8A). This was shown to predictably 
generate new and aesthetically appealing oral soft tissue for the treatment 
of mucogingival conditions in adults. Shire Pharmaceuticals (United 
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Kingdom) developed Dermagraft®, a technology acquired by 
Organogenesis in 2014. Dermagraft® is another tissue engineered and 
FDA approved product, consisting of fibroblast–derived dermal substitute 
generated by the culture of neonatal dermal fibroblasts onto a 
bioabsorbable polyglactin mesh scaffold [251]. Dermagraft was validated 
in an extensive Phase 3 clinical study (NCT01181440) [252] where it was 
demonstrated to have faster and complete wound closure as compared to 
the control group.  
 
2.4.5 Kidney Failure 
Every year more than 200,000 people in the United States are affected 
by  acute kidney injury (AKI) and end stage renal disease (ESRD) with a 
mortality rate of about 50% [253]. Despite decades of efforts for the 
development of novel renal replacement therapies, the morbidity and 
mortality associated with these disease states have remained unaltered 
[254]. While conventional treatment is mainly focused on organ removal, 
newer strategies such as cell therapy and cell processing aim to reduce 
the need for dialysis and transplantation. 
Some of the current applications involve the seeding of cells within 
implantable or external devices such as hollow-fiber bioreactors or 
encapsulating membranes [255,256].  
The strategy adopted by Humes and colleagues at the University of 
Michigan, is to administer cell therapy from an extracorporeal circuit, 
allowing for immunoisolation and enabling the use of allogeneic cells 
[257].  
The developed device, called renal tubule assist device (RAD), is an 
external encapsulation system, composed of polysulfone hollow fibers 
coated with collagen IV containing living renal proximal tubule cells. RAD 
in canine and porcine models reached an improved regulation of plasma 
cytokine levels, cardiovascular performances, leading to an increase of 
survival times [258–260]. Phase I/II clinical trial on 10 patients showed that 
RAD therapy was safe over 24 hours and cells viability and functionality 
throughout therapy was demonstrated. Results also indicated a 50% 
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reduction in the mortality rates. In a Phase II randomized, open-label trial, 
involving 58 patients with AKI at 12 clinical sites, RAD treatment increased 
survival rate by day 28 from 61% (patients treated with conventional 
CVVH) to 33% of those patients treated with RAD [253,261,261]. Despite 
the achieved results, a follow-up Phase IIb study was suspended due to 
an expected higher survival rate in patients treated with RAD without cells.  
These unexpected findings, led CytoPherx, Inc. (Ann Arbor, Michigan) 
to develop a new therapeutic device called selective cytopheretic device 
(SCD) [262,263]. SCD is comprised of a synthetic membrane cartridge 
made with polysulfone fibers and a tubing system that allows its 
connection in series to a standard Continuous Renal Replacement 
Therapy (CRRT) device. The SCD cartridge works as an 
immunomodulatory device due to its capability to sequester and inhibit 
activated leukocytes, modutating the inflammation [262,264]. Safety of 
SCD device was proved in a phase IIa, single center study, where 12 
patients were enrolled. The reported mortality of control-group was 78%, 
compared to 22% of the SCD treatment group [253].  
A Phase-IIb multicenter US pilot study on 35 patients was performed to 
evaluate the safety and efficacy of the SCD treatment on patients requiring 
CRRT [264]. The results shown an improvement in patient outcomes 
treated with SCD + CRRT over standard of care therapy (CRRT alone) 
and a reduced mortality rate on day 60 (31.4% compared to 50%) [264]. 
In light of these results, an additional randomized trial on 134 patients 
where 65 received SCD therapy (NCT01400893) [265] was performed. 
Unfortunately, no significant difference in 60-day mortality was observed 
between the SCD group and control [266].  
Another encapsulation system for external dialysis able to control and 
sustain delivery of secreted factors is under development by Sentien 
Biotechnologies (Fig. 2.8B). Sentien device, named SBI-101 (Sentinel™), 
now going through a phase I/II clinical trial (NCT03015623) [267], contains 
mesenchymal stem cell (MSC) seeded in an approved blood-filtration 
device [268].  
Efficacy and pharmacodynamics responses to SBI-101 therapy will 
also be evaluated on 24 patients that will be enrolled by the end of 2018. 
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In Sentien devices, blood flows through the hollow fibers and therapeutic 
factors can be delivered into patient’s blood, without any leakage of MSCs. 
SBI-101 offers two major advantages over traditional cell therapy 
administration: a) significantly extended duration of therapeutic activity by 
housing the MSCs in an extracorporeal device compared to traditional 
routes of administration of MSCs – injection or intravenous infusion where 
less than 1% of systemically administered MSCs persist for longer than a 
week following injection; b) overcomes MSC dosage limitations seen 
during injection or intravenous infusion. 
A surgically implantable, artificial kidney is under investigation by Drs. 
Shuvo Roy and William Fissell at UC San Francisco for people with end-
stage kidney disease [269]. This artificial kidney is composed by a silicon 
nanofilter to filter the blood and human kidney tubule cells embedded 
within microscopic scaffolding with the purpose of performing metabolic 
functions and reabsorbing water from the filtrate to control blood volume 
[270,271]. The artificial kidney is designed to be implanted near the 
patient’s own kidneys and connected to the patient’s blood supply and 
bladder. Clinical trials for the implantable artificial kidney are expected to 
start in 2018. 
 
Figure 2.8: (A) Schematic of GINTUIT™ bioscaffold for wound regeneration 
consisting of allogeneic cultured keratinocytes and fibroblasts in bovine collagen) 
an allogeneic cellularized scaffold. (B) Sentien SBI-101 technology where MSCs 
are seeded into an extracorporeal device that delivers the factors secreted by the 
MSCs to the patient’s bloodstream. 
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2.4.6 Cardiovascular Diseases 
Cardiovascular diseases like myocardial infarction (MI), stroke and 
heart failure (HF) are leading causes of death worldwide [272]. As the 
damaged myocardium as well as the noncontractile scar tissue can 
significantly affect proper functioning of heart after MI and the regenerative 
capacity of endogenous cardiac tissue is limited, stem cell transplantation 
is explored as a potential treatment. Pluripotent stem cells (PSCs), 
including embryonic stem cells (ESCs) and induced pluripotent stem 
cells (iPSCs), have demonstrated the capability to differentiate into 
functional cardiomyocytes [273–275]. While PSCs may raise the concern 
of teratoma formation, administration of fully differentiated cardiomyocytes 
may not be useful as they do not integrate well with host cardiomyocytes 
and function in a coordinated fashion. Mesenchymal stem cells (MSCs) 
have shown to promote angiogenesis [276], prevent apoptosis 
[276], modulate immune response [277], recruit progenitor cells, and 
facilitate tissue remodeling [278] in such conditions. However, major 
challenges are the poor retention and survival of transplanted cells as well 
as adverse effects of inflammation and immunoreaction. Contractile nature 
of myocardium can mechanically disperse transplanted cells and the 
avascular, hostile and strong pro-inflammatory micro environment after MI 
can damage transplanted cells [279]. To address these challenges, 
various cell delivery and encapsulation strategies using natural or 
synthetic matrices, porous scaffolds, or cell sheets/patches are being 
investigated to improve cell retention and survival, as described below.  
In a preclinical study by Levitt R.D. et al. encapsulated human MSC‐
treated hearts retained stem cells longer, showed improved 
revascularization, reduced scar formation, and resulted in improvement in 
left ventricular function as measured by transthoracic echocardiography 
(TTE) and cardiac magnetic resonance imaging (CMR) [280]. Tang et al. 
demonstrated that human cardiac stem cells (hCSCs) encapsulated in 
thermosensitive poly(N-isopropylacrylamineco-acrylic acid) or P(NIPAM-
AA) nanogel transplanted in mouse and pig models of myocardial 
infarction (MI) preserved cardiac function and reduced scar size [281]. In 
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another in vivo study, Chi and others have demonstrated the potential for 
cardiac repair using bone marrow mesenchymal stem cells encapsulated 
in silk fibroin/hyaluronic acid patches in a rat model of myocardial 
infarction [282]. In 2002 Strauer et al. demonstrated the potential of cell 
therapy in myocardial regeneration and neovascularization in a clinical 
study using intracoronary administration of autologous mononuclear bone 
marrow cells in patients with MI. Since then numerous clinical studies 
[283] have investigated the safety and efficacy of different types of stem 
cells for cardiovascular applications demonstrating their great promise 
[283–287]; however issues related to long-term engraftment, optimal cell 
type, dose, route, and administration strategies are to be resolved and the 
promise of encapsulation is to be validated clinically to realize the full 
potential of stem cell therapy for cardiovascular diseases. 
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2.5 Key Challenges 
In addition to the availability of good quality donor cells and 
appropriate delivery strategies, determination of the optimal site for cell 
delivery is a matter of intense research.  
 
As described by Pepper et all., the optimal site should have an 
adequate tissue volume capacity and, in order to prevent hypoxia events, 
has to be in close proximity to vascular networks ensuring a sufficient 
oxygen supply to the graft. Moreover, has to be a site that is easily 
accessible via minimally invasive methods in order to allow for cell 
transplantation, biopsy and retrieve the graft [288]. Several other factors 
also have to be taken into consideration such as biocompatibility, safety, 
mechanical resistance and possibility of re-transplantation.  
 
Some groups attribute graft failure to the lack of direct vascularization, 
with consequent gradual tissue necrosis and death. Consequently, a site 
in which encapsulated islets are in close contact with the blood-stream is 
obligatory for clinical application. Although the peritoneal cavity has been 
investigated in several studies with encapsulated cells because of 
accessibility and capacity to accommodate a large transplant volume, the 
optimal site for transplantation is yet to be determined. The subcutaneous 
tissue was shown to provide sufficient oxygen tension (20-40 mmHg) for 
the transplantation of cells such as pancreatic islets [149]. However, thus 
far, islet deployment into an unmodified subcutaneous site has not been 
successful in reversing diabetes in either animal models or in humans 
[147]. 
 
Various strategies are emerging, which allow to prevascularize the 
chosen site before transplantation [288,289]. In light of these, less 
vascular sites, such as the subcutaneous environment, become potentially 
suitable for cell transplantation. Further, successful deployment of cell 
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transplantation as a clinically viable approach to treating diseases entails 
the ability of, monitoring, retrieving, replacing, and supplementing cells 
with simple and minimally invasive procedures. Based on this requirement, 
numerous new cell delivery technologies and approaches are designed for 
subcutaneous transplantation.  
 
Another critical limitation to the success of micro- and 
macroencapsulations is adverse tissue responses to the material of the 
system [173,290,291]. As an example, it has been shown that 
commercially available alginates can cause inflammatory responses due 
to ‘pathogen associated molecular patterns’ (PAMPs) contained within the 
alginate [148]. Further, many systems have been associated with 
protrusion of cells. Above a certain threshold, protrusion leads to strong 
inflammatory responses resulting in complete fibrosis of the capsules and 
necrosis of the transplanted cells. Mechanical properties might also be 
limiting factors. Different encapsulation systems are characterized by 
different elasticity and mechanical resistance. The optimal properties of 
encapsulation systems are also recipient and site dependent. The optimal 
mechanical parameters for cell survival are still unknown and difficult to 
determine.  
 
While cell therapy offers a great promise for the treatment of many 
medical conditions, with different types of cells of various sources being 
tested concerns regarding ethical use and regulatory challenges are to be 
addressed as well. 
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2.6 Conclusions 
Cell therapy and transplantation represent a vast research area. In this 
review, we presented only a subset of the current approaches by giving 
emphasis to the technologies at an advanced stage of development, under 
clinical evaluation, or already FDA approved. Despite several decades of 
intense research, drawing conclusions about which material, or if micro- or 
macroencapsulation is most appropriate for clinical use, is still difficult. 
Recent research indicates that cell encapsulation systems are possible 
solutions for many endocrine disorders for which the minute-to-minute 
regulation of metabolites is mandatory, and a structure similar to native 
organ is important. More generally, it is likely that these technologies may 
play a significant role in the next generation of therapeutics. Drug delivery 
may ultimately be achieved and finely controlled by cells as opposed to 
current modes of administration. This implies that drugs could be dosed 
exclusively when needed and at a precise amount in response to 
biological stimuli. It is clear that scalability and clinical translation of this 
biotechnologies will depend on cost-effectiveness together with 
establishing and satisfying a series of strict regulatory aspects. Indeed, 
one of the major challenges consists in moving from laboratory-based 
techniques to clinically acceptable large-scale practices operating under 
reproducibility, safety, and high-output requirements. 
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Chapter 3 
NICHE fabrication and 
mechanical characterization 
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 3.1. Introduction 
Cell transplantation offers an attractive therapeutic approach for many 
endocrine deficiencies. Transplanted endocrine cells or engineered cells 
can act as biological sensors detecting changes in hormonal levels and 
secrete molecules in response to maintain homeostasis. Over decades of 
research efforts, transplantation of primary or genetically engineered cells 
of auto, allo- or xenogeneic origin has been shown to achieve localized 
and regulated ‘de novo’ delivery of a variety of therapeutic agents with the 
potential to cure diseases related to the endocrine system. However, 
widespread clinical application of cell transplantation remains limited by 
poor cell engraftment, dispersion, and graft immune rejection.  
 
As reported in Chapter 2, several encapsulation strategies based on 
the encapsulation of cells within polymeric membranes, scaffolds or 
devices have been developed to offer isolation and protection of cells as 
well as to prevent their dispersion. However, due to the small dimension of 
the pores of their membranes (in the nanoscale), the majority of these 
systems do not allow for the vascularization and innervation of the graft, 
which are key for the long-term viability and function of the transplant. In 
fact, endocrine cells such as pancreatic islets in the body are irrigated by a 
dense network of capillaries that provide the highly needed oxygenation 
and delivery of nutrients. Tight engraftment with the vascular network 
allows cells to rapidly sense hormone fluctuations and respond 
accordingly. 
 
To address all the aforementioned needs and challenges, here is 
presented the development of a 3D printed encapsulation platform 
technology (NICHE) for the transplantation of endocrine cells. Our NICHE 
is designed to allow vasculature and tissue ingrowth within the device in 
order to provide a highly vascularized and three-dimensional housing 
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environment required for long-term cell survival and function. The system 
is designed for subcutaneous implantation, and has ports for 
transcutaneous loading and refilling of cells. The subcutaneous 
environment is an ideal site for minimally invasive surgical insertion, cell 
supplementation, monitoring and rapid retrieval in case of need. Our 
system is fabricated in biocompatible polymer (polylactic acid, PLA), which 
offers a robust, yet flexible design to mechanically protect the graft from 
impacts. Further, a micro-chamber cell reservoir design promotes a 
homogeneous distribution of cells in close proximity to each other, while 
avoiding clustering.  
 
In this chapter is presented the development, characterization and 
mechanical characterization in vitro and In Vivo evaluation of NICHE.  
 
First, it’s described the 3D printing and characterization of the 
polymeric structure, including the analysis of biocompatibility and 
degradation of the PLA. Second, is presented the mechanical properties of 
the encapsulation system in order to prove the safety for long term 
applications, both in vitro and in vivo. Third, using the experimental data 
previously obtained, we developed a finite element model (FEM) of the 
NICHE with the objective of optimizing device design by estimating the 
mechanical response of materials and tissues which is extremely 
challenging to be assessed in vivo. 
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3.2 Fabrication of the 3D printed 
NICHE:  
Materials and Methods 
 
NICHE and Dogbone fabrication 
A 3D printer (Bioplotter, EnvisionTec, Gladbeck, Germany) with custom 
nozzle designed to improve the resolution of the printed filament was 
used. By adopting the Fused Filament Fabrication (FFF) method, parts 
were built layer-by-layer with a bottom-up approach by heating and 
extruding thermoplastic filament. A solid modeling software (SolidWorks®, 
Dassault Systèmes, Vélizy- Villacoublay, France) was used to create a 3D 
dataset for the fabrication process. Medical grade polylactic acid (PLA; 
Foster Corporation, Putnam, CT, USA) was used to fabricate the discoidal 
NICHE device, with a diameter of 10 mm, a thickness of 2.5 mm, and a 
cell reservoir volume of 200 μl. The cell reservoir consists of an array of 
square micro-chambers (300 μm × 300 μm) that promote a homogeneous 
distribution of transplanted cells in small aggregates across the structure. 
The micro- chambers are connected to the outside (subcutaneous tissue) 
via an array of square micro-channels presenting a nominal cross section 
of 100 μm × 100 μm and a length of ~50 μm. The device features a 
loading port (3 mm diameter) for transcutaneous cell loading and 
supplementation, as needed. Channel size and distribution were assessed 
via scanning electron microscopy (SEM, Nova NanoSEM, FEI, Oregon, 
USA). Twenty (20) micrographs were captured for each individual device 
(n=6 replicate devices) at random locations of the structure for size 
analysis. Images were processed using a Matlab (Mathworks, Natick, MA, 
USA) algorithm, the dimension and aspect ratio of each channel 
measured, and the channel size distribution computed.  A set of 6 
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dogbone specimens with dimensions reported in Figure 1 were printed all 
with the same set up.  
 
PLA material degradation 
To assess the PLA material degradation, 3D printed NICHEs (n=10) were 
sterilized with 70% ethanol and ultra violet (UV) radiation, weighed, and 
completely immersed in glass tubes filled with 10 ml of 1X phosphate 
buffered saline (PBS; pH 7.0) and incubated at 37°C. Devices were 
recovered at 1, 2, 4, 6, 8, 12, and 16 weeks, dried, and then weighed 
(Mettler Toledo XPE56 Microbalance, Greifensee, Switzerland). Weight 
loss percentage (Wl%) was calculated using the following equation: 
Wl (%) = 𝑊𝑂−𝑊𝑟
𝑊0
 𝑥 100 
 
Where w0 and wr are the original and final device weight for the dry 
samples, respectively. To generate long term data, accelerated 
degradation conditions were used. 3D printed NICHE and rectangular 
samples (n= 20 each) were immersed in 10 ml of PBS and incubated at 
70°C, with samples incubated at 37°C serving as controls. Degradation 
was assessed in terms of weight change every 2 days. Degradation test at 
37°C was performed over a period of 365 days while that at 70°C was 
terminated when samples could no longer be weighed due to degradation. 
At each time point, SEM images and atomic force microscopy (AFM, 
BioScope Catalyst, Bruker Instruments, TX, USA) analyses (scanning 
region size) were used to evaluate microscopic structure changes. 
 
Cell proliferation assay 
To gain insight on the biocompatibility of the 3D printed PLA devices, MTT 
assays were performed with human umbilical vein endothelial cells 
(HUVEC) or mouse Leydig cells (TM3). HUVEC cells (ATTC, Manassas, 
VA, USA) were cultured in MEM medium (Sigma-Aldrich, St. Louis, MO, 
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USA) supplemented with 10% fetal bovine serum (FBS; Sigma-Aldrich, St. 
Louis, MO, US), 100 U penicillin, 1000 U streptomycin, and 2 mM L-
glutamine at 37°C in a humidified atmosphere of 5% CO2. Leydig cells 
were cultured in a 1:1 mixture of Ham's F12 medium and Dulbecco's 
modified Eagle's medium with 2.5mM L-glutamine, 0.5mM sodium 
pyruvate, 1.2 g/l sodium carbonate and 15 mM HEPES, 92.5%, 5% horse 
serum, 2.5% fetal bovine serum. Media was replenished every 48 h and 
the cells passaged when 70-85% confluence was reached. For cell 
viability and growth analyses, cells were seeded at a density of 2 × 104 
cells in 1 ml of media on the upper face of the polymers in wells of 24- well 
plate and incubated overnight to allow for cell adherence. Cells were 
seeded in triplicate for each time point. Proliferation was measured using 
WST-1 assay (Sigma Aldrich, St. Louis, MO, USA) on days 1, 4, 6, and 8 
then normalized with respect to day 0. Absorbance was measured at OD 
570/690 nm with SynergyTM HT Microplate Reader (Bio-Tech Instruments, 
Inc., USA). 
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3.3 Mechanical characterization 
Materials and Methods 
 
Uniaxial monotonic material testing 
Tensile monotonic tests were performed according to ISO 527-2 and 
527-3 Standard on a universal testing machine MTS Q Test/10 to 
determine stress-strain curve, and Young's modulus of 3D printed base 
material. Specimens were placed in the grips and pulled until failure. The 
machine was equipped with a 500 N load cell, and operated at a rate of 3 
mm/min. A MTS clip-on extensometer (25 mm gage length, 50 mm 
extension) was adopted to monitor axial strain during testing. Tests were 
performed at 23±2°C both with dry samples or samples previously 
immersed in a sodium chloride solution 0.9% w/v NaCl for 24 h. Stress 
was calculated as the ratio between the load and the nominal cross-
section area for each specimen. The elastic modulus E [MPa] was 
determined by considering the initial region of the stress V /strain H  curve 
(strain H up to 10%), where the material showed a proportional behavior. 
Three dry specimens and three wet ones were tested.  
 
Mechanical characterization of subcutaneous tissue 
While, the characteristics of human subcutaneous tissue may be 
different, for this pilot ex vivo evaluation, dermal chicken tissue was 
adopted. Triplicates of tissue-only samples (30x30x2 mm) were tested 
applying axial compressions to characterize the mechanical properties of 
the tissue. From experimental curves processing, calibration parameters 
for the tissue constitutive model were obtained for calibrating the 
constitutive material model for the numerical simulations. 
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Cell encapsulation system testing 
3D printed PLA encapsulation systems were tested at 23±2°C in both 
dry and wet conditions for monotonic compression, creep and cyclic 
stress-strain behaviors. The testing load was applied at the center of the 
mesh, perpendicular to the mesh. Uniaxial central compression tests were 
run with a MTS QTest 10, 500 N load cell testing machine. For performing 
the creep and fatigue tests, an electromechanical testing machine (Bose 
Electroforce 5500 Framingham, US) equipped with a 200 N load cell was 
adopted. Samples were positioned horizontally on a circular metallic ring 
with an internal diameter of 8.5 mm and force was applied on the center of 
the devices with a 7 mm diameter spherical puncher (Figure 3A). 
Monotonic axial central compression tests were performed at a 
compression velocity of 2 mm/min until device failure. Monotonic central 
compression of 3D printed devices (in dry and wet conditions) with 
subcutaneous tissue interposed between puncher and device were also 
performed in a similar way with the same set up.  
Creep central compression tests were performed by applying a 
constant load (2 and 3 N) in both dry and wet conditions for 2 hours. 
Fatigue testing was performed by applying two loads (2, 4 N in dry and 
wet condition) with a frequency of 1 Hz for a total of 100,000 cycles. Load 
and displacement data were acquired to evaluate the stiffness and 
hysteresis cycles. Four-point monotonic bending tests were performed 
utilizing the MTS Q/TEST 10 mechanical testing system equipped with a 
500 N load cell and the samples were placed in a custom-made metallic 
holder (Figure 3.1B). Crosshead displacement speed was 2 mm/min. 
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 Figure 3.1: Experimental setup adopted for the compression testing (A) 
and four-point bending test (B) of the NICHE 
 
 
In vivo implantation of NICHE in Yucatan minipigs 
3D printed NICHEs were sterilized with 70% ethanol and ultra violet 
(UV) radiation in a sterile environment (clean room of the Houston 
Methodist Research Institute). Thereafter, NICHEs were filled with 300 µl 
platelet-rich plasma (PRP) alginate hydrogel (PRP, ZenBio, Inc., Durham, 
NC, USA) and were implanted in the dorsum of Yucatan minipigs (n=3). 
Four weeks after implantation, all NICHEs were retrieved to evaluate 
tissue infiltration within the device (n=1) and mechanical properties (n=2). 
Samples were fixed in 10% formalin overnight and stored in 10% sucrose 
solution at room temperature. Monotonic axial central compression tests of 
NICHEs were performed as previously described using chicken dermal 
tissue both above and below the NICHE. For histological analysis, the 
NICHE was embedded in OCT before cryosectioning (thickness of 7 µm) 
and stained via H&E and Picrosirius staining. 
 
Finite Element Model simulations 
All numerical simulations were carried out with ABAQUS Software 
(Dassault Systems).  
At first, a set of FEM simulations was run for the tensile testing on 
dogbone specimens to validate the constitutive material model. Material 
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constitutive models, in dry and wet conditions, were calibrated with 
experimental stress-strain curves after the material testing under both 
conditions was completed. The dogbone specimen was modeled by 
means of three-dimensional solid elements (bricks). According to 
literature, the AM material was assumed to be homogeneous and isotropic 
as for metals [292] and for polymeric materials  [293]. A load ramp was 
simulated, corresponding to loading experimental history on each 
specimen. A second set of numerical simulations of subcutaneous tissue 
compressions was carried out in order to calibrate the correct constitutive 
model of the tissue. The tissue specimen was modeled with three-
dimensional hybrid solid elements (bricks). The Ogden model of hyper 
elasticity was used to simulate the behavior of the tissue [294,295]. In 
particular, the Ogden constitutive equation describes the nonlinear 
isotropic behavior of rubber like materials using the following 
incompressible strain energy function. The constitutive equation follows: 
 
𝜙 =
2𝜇
𝛼2
(𝜆1
𝛼 + 𝜆2
𝛼 + 𝜆3
𝛼 − 3) 
 
where 𝜙 is the strain energy density per undeformed unit volume, 𝜆1, 
𝜆2, 𝜆3 are the principal stretch ratios (in a Cartesian reference frame), 𝛼 is 
a strain hardening exponent and µ has the interpretation of the shear 
modulus under infinitesimal straining. A third set of simulations was run for 
the central compression testing on cell encapsulation systems, to estimate 
the stress distribution under central compression condition of the cell 
encapsulation system alone and wrapped in the tissue layer in for dry and 
wet conditions. The compression plates were modeled as rigid bodies. In 
particular the subcutaneous environment tests were modeled as shown in 
Figure 3.2B: the grey semilunar element represents the puncher; the 
purple lower element represents the device and the intermediate element 
represents the subcutaneous tissue. 
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Figure 3.2: Simulation of central compression tests on encapsulation 
systems: model without skin layer (A) and with skin layer (B). 
 
The cell encapsulation system was modeled by means of tetrahedral 
solid elements both in the annular strut and in the mesh parts (Figure 2A); 
displacements were fixed for circumferential nodes on the base of the 
annular ring. Constitutive material model of cell encapsulation system was 
adopted the average σ-ε curve obtained by means of experimental testing 
on dogbone specimen, validated by simulation of dogbone specimen 
monotonic testing. The spherical puncher was modeled as a rigid body. 
Contact zones were defined by creating contact surfaces characterized by 
a friction coefficient of 0.2 and using “contact pairs” interaction. 
Displacement boundary was applied on the puncher in order to simulate 
compression of the cell encapsulation system.  
Numerical simulations were carried out with different displacements 
values: 1.23 mm and 1.12 mm, in dry and wet conditions respectively 
(without tissue layer), and 2.50 mm and 2.37 mm, in dry and wet 
conditions respectively for specimens with tissue layer. These values 
correspond to mean experimental displacements registered at failure 
loads of static capsule central compression (see Table 2). Stress and 
displacement distribution on the cell encapsulation systems were pointed 
out. In particular, Von Mises maximum stresses corresponding to failure 
experimental loads were used to compare uniaxial experimental testing 
failure stresses. According to literature [296] on FEM simulation of 
polymeric components and lattices, equivalent stresses based on 
energetic hypotheses well suit for large deformation applications and 
simple loading cases [297]. Experimental failure locations and maximum 
stress and stress nodes were then compared. 
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3.4. Results 
NICHE structure characterization 
We developed the NICHE as a cell encapsulation device for promoting in 
situ vascularization and supporting the viability and function of 
transplanted autologous cells in the subcutaneous environment. The 
device was 3D printed using biocompatible PLA in a discoidal shape 
presenting two loading ports incorporated on the upper face for 
transcutaneous cell loading (Fig. 2A). Primary design considerations for 
the device were to provide a robust yet flexible structure suitable for 
subcutaneous deployment, to hold enough cell volume in close proximity 
to vasculature while preventing cell dispersion. PLA filaments with 
diameter of 50 μm were deposited layer by layer forming 0° and 90° angle 
squares. Temperature of the 3D printer build plate was kept at 120°C to 
allow fibers to melt onto each other, which is fundamental to avoid free-
space within layers that could decrease the mechanical properties of the 
NICHE. In order to facilitate the cell loading process, we developed a 3D 
printed external guide system that can be precisely superimposed on the 
skin above the implant. The guide features ports that coincide with the 
implant’s ports, allowing drug, gel or cells to be loaded using a syringe. 
Excess injected components are vented out through the venting port. The 
internal structure of the NICHE is comprised of an array of micro-
chambers (~300 x 300 μm2, 200 μm deep) designed to promote a 
homogeneous distribution of cells at loading to avoid clustering. Micro-
chambers are connected to the external surface through square 
microchannels (Fig. 3.3A,B). The microchannels present a nominal cross 
section of 100 x 100 μm2 to allow for the penetration of subcutaneous 
microvessels, while avoiding cell leakage and dispersion (Fig. 3.3C). In 
this context, to characterize the microchannel size in preventing cell loss, 
we accounted for the size distribution of Leydig cell clusters measured in 
this study (peak ~200 μm) as well as pancreatic islets (peak ~150 μm) 
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(Fig. 2D). The microchannel size measurement showed a positive-skewed 
and sufficiently narrow Gaussian distribution (c = 1.4) with a population 
peak at ~125 μm (Fig. 3.3D). In the extreme scenario of unobstructed 
microchannels, such channel population would be sufficient to prevent the 
dispersion of a large percentage of cell clusters. However, as shown later 
in this paper, at the time of cell loading, the NICHE is vascularized with 
capillaries penetrating into the device through the microchannels. In this 
case, cell leakage is further impeded. 
 
 Figure 3.3 NICHE structure characterization. (A) 3D rendering of NICHE 
showing loading and venting ports and (B) SEM image of cell micro chambers 
and (C) microchannels. (D) Gaussian distribution of dimension of NICHE 
microchannels compared to pancreatic islets and Leydig cell clusters 
 
 
Figure 3.4: Dogbone specimen, dimensions in mm. 
 
 
PLA degradation, mechanical characterization and 
biocompatibility 
As the NICHE devices are intended for long term deployment, degradation 
of material is an important parameter to be evaluated. To assess the 
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compatibility of NICHE for long-term deployment, we first performed in 
vitro degradation test at 37°C as well as in accelerated conditions (70°C) 
in PBS, by assessing changes in specimen’s weight. In vitro degradation 
at 70°C was shown in the literature to represent a viable test mimicking 
the mechanism of degradation at 37°C in vivo, in an accelerated 
timeframe]. On day 5, we observed 10% and 15% weight increases at 
37°C and 70°C, respectively, attributable to initial water absorption in PLA 
bulk. This finding is consistent with previous reports [298,299]. At 37°C, 
the weight of the NICHE remained stable over 365 days with a slight 
decrease of ~1% per month (Fig. 3.5A). Samples incubated at 70°C 
became increasingly brittle and fractured by day 18. Based on PLA study 
by Weir et al.[298], 18-day degradation at 70°C corresponds to several 
years in vivo degradation condition. We analyzed the mechanical 
properties of PLA samples retrieved from 37°C degradation testing at day 
365, as compared to fresh specimens (Fig. 3B). The destructive 3-point 
bending test showed that aged specimens were more brittle and withstood 
lower bending stresses (52.0 ± 15.6 MPa) as compared to the non-
degraded controls (68.0 ± 25.6 MPa). Further, for aged specimens, cracks 
nucleated at the extrados rapidly propagated to the intrados leading to 
failure. In the fresh samples, fractures nucleated at the extrados did not 
propagate and samples continued to bend. In general, lower stiffness was 
observed in non-degraded samples, which is typical of plastic materials. 
Aiming at evaluating the NICHE for endocrine cell transplantation, we 
used murine Leydig cells as a representative cell line. To ensure material 
biocompatibility with Leydig cells, we performed a cell viability assay on 
PLA over a period of 8 days. No significant differences were observed 
between cells cultured on PLA or in regular media (Fig. 3.5C), confirming 
that PLA does not impact negatively cell viability. Further, as endothelial 
cells are essential for vasculature network formation, we have previously 
demonstrated the cytocompatibility of PLA with human umbilical vein 
endothelial cells (HUVECs) with PLA via cell viability assay [36]. Our 
results are in accordance with the literature that the adopted PLA can be 
used for cell encapsulation applications. 
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Simultaneous to the degradation test, we assessed the changes in surface 
morphology under 37°C incubation condition for 365 days. SEM images 
showed clear surface degradation as indicated by a significant increase in 
the root mean square roughness RRMS (25.1 ± 6.2 nm) as compared to 
day 0 (RRMS=3.2 ± 0.4 nm) (Fig. 3.5D-G). 
Overall while these tests highlighted the modes of PLA degradation, all 
samples retrieved on day 365 maintained integrity and sufficient 
mechanical properties in support of potential long-term applicability of the 
NICHE. 
 
Figure 3.5: PLA characterization. (A) PLA degradation test under 37°C 
and 70°C showing weight change over time; (B) Three point bending monotonic 
tests of degraded and not degraded NICHEs; (C) viability of Leydig cell cultured 
on PLA and control media. (D) Baseline SEM image of PLA with (E) AFM 
analysis. (F) SEM image of PLA under 1 year degradation with corresponding (E) 
AFM analysis. 
 
Dogbone base material monotonic tensile tests 
The tensile stress-strain curves of base 3D-printed material are 
reported in Figure 3.6 and the mechanical properties are listed in Table 
3.1. The material shows an elastic brittle behavior: linear elasticity is 
observed for part of deformation with a non-linear trend occurring shortly 
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prior to failure. The average and standard deviation of failure stress and 
strain are reported in Table 3.1. Mechanical properties quantified in terms 
of tensile strength (Rm) and Young's modulus (E) seem not to be affected 
by wet conditions. The small standard deviation indicates that the 
processing technique for dogbone specimens are affected by low density 
and small dimension of defects in the material. 
 
  
 
 
 
 
 
 
 
Figure 3.6: base material monotonic testing curves on dry (blue) and wet 
(red) specimens.  
 
Table 3.1: base material monotonic testing results in dry and wet conditions 
 
 
 
NICHE Dry conditions Rm (MPa) E (MPa)
1 123 11,210
2 124 10,845
3 107 11,530
Average 118 11,195
Standard deviation 9 343
NICHE Wet conditions Rm (MPa) E (MPa)
1 128 9,706
2 123 11,388
3 129 11,033
Average 127 10,709
Standard deviation 3 887
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Static central compression of encapsulation system 
Central compression results for the encapsulation systems in dry and 
wet conditions are shown in Figure 3.7A and B, respectively. In Table 3.2 
the maximum compression forces in the two conditions are reported. 
Failure occurred in 30% cases in the circular connection region between 
the mesh and the ring and in 70% cases in the central mesh region, in the 
contact area between punch and mesh. It was observed that the wet 
specimens failed at a lower load in comparison with the dry specimens, 
along with a higher data scatter. No permanent deformations were 
observed in failed specimens, thus suggesting a brittle failure, in good 
agreement with the dogbone specimen testing results. No fragments were 
observed. 
 
Figure 3.7: Static central compression curves for the encapsulation system 
in dry (A) and wet (B) conditions. 
 
Table 3.2: maximum loads [N] for static capsule central compression 
 
Sample NICHEDry
NICHE
Wet
NICHE + Skin
Dry
NICHE + Skin
Wet
1 7.6 4.6 20.5 21.9
2 8.7 12.3 23.8 19.2
3 8.2 4.4 19.3 17.2
4 8.7 5.2 16.6 16.3
Average 8.5 6.6 20.0 18.6
Standard deviation 0.2 3.3 2.6 2.1
Average 
displacement (mm) 1.2 1.1 2.5 2.3
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Static central compression of encapsulation system with 
the tissue layer 
Encapsulation systems were tested ex-vivo for central compression, 
enveloped in a subcutaneous tissue. Results (Figure 3.8, Table 3.2) 
showed that these samples were able to endure higher values of 
maximum force.  
This can be justified with lower local pressure on the mesh due to load 
distribution obtained by means of the intervening tissue.  While no 
differences were observed in maximum force applied, failure for dry 
samples occurred at approximately 20% higher displacement as 
compared to wet samples. The higher displacement measured with the 
interpose dermal tissue in comparison to the capsule alone are ascribed to 
the displacement of the tissue itself under compression as shown in 
Section 3.5 below.  Not significant permanent deformations were observed 
in failed specimens, thus suggesting a brittle failure, according to dogbone 
specimens testing results. No fragments were observed.  
 
Figure 3.8: Static central compression curves for the encapsulation system, 
with tissue layer, in dry (A) and wet (B) conditions. 
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Static compression of encapsulation system enveloped in 
tissue layer and with infiltrated tissue. 
 
To support viability and function of encapsulated cells and avoid 
hypoxia immediately after transplantation subcutaneously inserted NICHE 
are prevascularized to allow for tissue penetration and vessel formation 
within the device, prior to cell loading. Histological sections of NICHE 
retrieved on week 4 post subcutaneous implantation in Yucatan minipigs 
showed high levels of vascularization inside the device (Figure 3.9A,B). 
Further, high density of collagen Type I and II (Figure 3.9C) validated the 
presence of ingrown tissue. While the subcutaneous environment is 
typically poorly vascularized, our results showed that NICHE 
supplemented with PRP hydrogel was able to induce vascularization in 
and around the NICHE. Importantly, the results of the compression test 
showed that the ingrown tissue substantially contributes to the 
redistribution of stresses in the NICHE. In fact, the structure was able to 
withstand higher loads and deformations without failure (Figure 3.9D).  
These results are highly relevant as they indicate that during its intended 
deployment, both NICHE and ingrown tissue contribute to maintain 
mechanical stability and adequate support to encapsulated cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: H&E images of vascularized NICHE retrieved from Yucatan 
minipigs after 4 weeks subcutaneous implantation (A, scale bar 500 µm), 40x 
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magnification of vascularized tissue within the device (B, scale bar 50 µm, black 
arrows show blood vessels); Picrosirius staining showing presence of collagen 
fibers: yellow, orange and reddish color within the NICHE (C, scale bar 500 µm). 
(D) Static central compression curves for NICHEs retrieved from subcutaneous 
implantation. 
 
Chicken dermal tissue compression tests 
Results from the tissue compression tests are shown in Figure 3.10. 
The material stress-strain behavior was modeled based on the Ogden 
hyperelastic behavior equation, and the results from our study 
demonstrated a similar material behavior to the data found in literature 
[294]. The Ogden curve calibration parameters, µ=0.007 and α=1.85, were 
obtained from experimental curves.  
 
 
 
 
 
 
 
 
 
 
Figure 3.10: Tissue compression test curves. 
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Encapsulation system fatigue on central compression  
Hysteresis cycles from the fatigue testing with dry and wet 
encapsulation systems are reported in Figure 3.11A and B. No samples 
survived the test. It was noticed that the damage increased gradually and 
cyclic strain accumulation was observed by gradual displacement of 
hysteresis cycles. This strain accumulation phenomenon (ratcheting) is 
well known for metallic materials [300] as well as polymeric materials 
[301,302]. It indicates that irreversible changes (damages) were taking 
place in the test specimens. Higher cyclic accumulation was observed in 
wet cell encapsulation systems. This phenomenon is probably due to the 
water adsorption in polymer material, which weakens the bonds between 
the molecules thus promoting deformation. Higher deformation achieved 
with the same number of cycles means that wet encapsulation systems, in 
a subcutaneous environment, can sustain higher deformations before 
failure. The increments of area of the cycles in the figure point to a 
progressive damage from the initial cycles (cycle 100) to later cycles 
(cycle 4000), which are more evident in wet specimens. Hysteresis area is 
another damage indicator [303,304]. Higher hysteresis area means higher 
dissipated energy, more damage and irreversible strain. Failure occurred 
in the mesh region, in the contact area between punch and mesh, for all 
specimens. Not permanent deformations were observed in failed 
specimens, thus suggesting a brittle failure, according to dogbone 
specimens testing results. 
 
Figure 3.11: hysteresis cycles for dry (a) and wet (b) specimens during 
fatigue testing for cycle 100, 500, 2000 and 4000. 
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Encapsulation system creep tests 
The instant stiffness curves from the creep tests with the dry and wet 
encapsulation systems at various load conditions are reported in Figure 
3.12. Of the various load conditions tested, the dry specimen at 3 N failed 
during the first creep phase, while the specimen at 2 N abruptly failed 
during the second creep phase. Wet samples at 3N also failed within 800 
sec but showing substantially larger displacements. By comparing the 2 N 
test results for dry and wet conditions, wet specimens showed shorter 
lives and higher displacements than dry specimens with the exception of 
one wet specimen for which failure occurred after the 3rd creep phase at 
approximately 5000 sec. A lower stiffness in subcutaneous conditions 
corresponds also to lower creep life. For creep loads higher than 2 N, 
device life dramatically shortens. Failure occurs in the mesh, which points 
to a brittle behavior of the mesh structure. Failure occurred in the circular 
connection region between the mesh and the ring for some specimens 
and in the central region for others. Neither fragments nor permanent 
deformations were observed in failed specimens, thus suggesting a brittle 
failure.  
Figure 3.12: instant stiffness curves for dry (A) and wet (B) encapsulation 
system. 
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Encapsulation system monotonic bending tests 
The bending force-displacement results in dry and wet conditions are 
plotted in Figure 3.13A and B respectively and the results summarized in 
Table 3.3 below. It was observed that, while the stiffness of dry and wet 
specimens remains the same, dry specimens were able to withstand a 
higher maximum load (38 N) before failure. It was also observed that the 
failure occurred in the mesh part of the devices. Not permanent 
deformations were observed in failed specimens, thus suggesting a brittle 
failure. No fragments were observed. 
 
Figure 3.13: bending force-displacement curves for cell encapsulation 
systems in dry (A) and wet (B) conditions 
 
Table 3.3: bending testing results of cell encapsulation system 
 
NICHE Dry conditions               Max load (N) Stiffness (N/mm)
1 17.1 26.3
2 18.3 31.6
3 19.0 31.9
Average 18.1 29.9
Standard deviation 0.96 3.15
NICHE Wet conditions Max load (N) Stiffness (N/mm)
1 44.5 35.2
2 31.3 27.8
3 40.1 29.0
Average 38.6 30.6    
Standard deviation 6.72 3.97
 91 
FEM Results 
In Figure 3.14A and B, the simulation results of the tensile testing on 
dogbone specimens are presented in dry and wet conditions, respectively. 
The stresses in the central part of the specimen, corresponding to the 
experimental tensile load to failure (N) were 129 MPa and 132 MPa 
respectively. The corresponding experimental failure stresses were 118±9 
MPa and 127±3 MPa. The mismatch between experimental and numerical 
failure stress is lower than 10% and that may be due to the fact that dry 
and wet constitutive material models were defined on average 
experimental data.  
Figure 14 shows the numerical-experimental comparison in terms of 
monotonic testing curves; the results from dry specimens are shown in 
Figure 3.15A while those from wet specimen in Figure 3.15B. Both graphs 
display the curves for all specimens obtained from experimental tests 
(continuous line) and the same results in relation to the numerical 
simulation (dot line). The numerical strain in the central cross section was 
calculated by the software. Experimental and numerical simulation curves 
for uniaxial testing show a good agreement both in the linear and 
nonlinear fields. The hypotheses of isotropic and homogeneous 
constitutive models are shown to be effective in the simulation of the 
uniaxial behavior on AM base material. The maximum difference between 
numerical and experimental data is lower than 10%, thus indicating a 
reliable behaviour of the constitutive model. 
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Figure 3.14: Simulated stress distribution of tensile testing simulation on 
dogbone specimens: dry (A) and wet (B) material 
 
Figure 3.15: Comparison between experimental and numerical results: 
monotonic testing curves on dry specimens (A) and wet specimens (B) 
 
The comparison between experimental and numerical curves related 
to the tissue compression tests are shown in Figure 3.16. Ogden 
parameters used for this model are: P=0.007 and D=1.85 and were 
obtained from experimental testing data fitting. The maximum difference 
between numerical and experimental data is lower than 5%, indicating that 
the Ogden model well fits the experimental results.  
 
 93 
 
Figure 3.16: Comparison between experimental and numerical compression 
results of chicken dermal tissue 
 
Results from the cell encapsulation system central compression 
simulations are presented in Figure 3.17 and Table 3.4. Figure 3.17 shows 
the calculated stress distribution on encapsulation systems for central 
compression static tests. 
 
 
Figure 3.17: Stress distribution on encapsulation system due to compression 
static tests: simulations without tissue layer (up) and with tissue layer (down), for 
dry material (left) and wet material (right) respectively 
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It was observed that in wet conditions, for the same stress (127.5 
MPa), the displacement values obtained for the encapsulation system, 
with or without the tissue, were different. The displacement values were 
about two times with the tissue, compared to that of device alone (1.12 
mm). These displacements correspond to average failure load (last 
column in Table 3.4).  
 
Table 3.4: Values of simulated displacements, stresses and contact area for 
different simulation conditions 
 
This means that the skin layer allows a redistribution of the load, a 
better strain distribution and a decrease in the local stress with tissue 
layer. To obtain the same stress value, a higher deformation is needed if 
the tissue layer is interposed between the puncher and the encapsulation 
device. Similar results and displacement trends were observed in dry 
conditions, with and without the tissue, for a similar stress (124 MPa). A 
symmetrical distribution of the stress was also noticed, with most stressed 
areas located at the center and near the peripheral rim. They also 
corresponded to failure points on sample testing. According to 
experimental results, the stress calculated on cell encapsulation systems 
corresponding to failure load in dry and wet conditions is in the failure 
stress range obtained from uniaxial experimental testing on AM base 
material specimens. While experimental wet base material failure stress 
was 124 MPa, the corresponding simulated stress at failure in cell 
encapsulation systems was 127.5 MPa. Matching simulations with 
experimental results, for dry cell encapsulation systems, experimental 
Model
Max 
displacement 
(mm)
Max 
stress 
(Mpa)
Contact 
area 
(mm2)
Experimental 
Load to 
failure 
(N) 
Dry, no tissue 1.23 124.0 2.42 7.7
Wet, no tissue 1.13 127.5 2.39 5.8
Dry, with tissue 2.50 124.0 56.16 20.0
Wet, with tissue 2.37 127.5 52.16 18.7
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base material failure stress was 118 MPa, and the simulated stress 
corresponding to failure load was 124 MPa. This difference could be 
accounted for the numerical model approximation and the geometric 
reinforcement effects on the component structure. 
The simulated contact area, displacement and stresses are also 
summarized in. For simulation, the contact area dramatically increased for 
devices with tissue layer, in comparison with those without the tissue. This 
result is in agreement with the decrement of maximum normal stress in 
case of subcutaneous tests simulations. The interposition of a high 
compliant layer redistributes local loads and allows a more favorable 
stress distribution. The comparison with experimental results provides two 
other conclusions: the first one is that the Von Mises equivalent stress well 
adapts for the estimation of stress in the presented loading condition for 
the cell encapsulation systems and the second is that the homogeneous 
isotropic constitutive model adopted for the simulation of complex stress 
distribution in the presented AM component well adapts for the description 
of the behavior of the cell encapsulation system. 
Actually, the meshes can be represented as a sequence of beams 
connected in orthogonal directions and the stress shows one preferential 
direction (axial). The stress calculated using solid elements also for the 
mesh part of the cell encapsulation system follows this result and the 
equivalent stress is then almost coincident with uniaxial stress. 
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3.5. Discussion and Conclusions  
In this chapter, we have demonstrated the development and proof of 
concept testing of the 3D printed NICHE. The NICHE can serve as a 
platform technology for the subcutaneous encapsulation of transplanted 
cells. Specifically, we adopted 3D printing to generate the NICHE with 
channel dimensions suitable for vasculature penetration while avoiding cell 
leakage.  
 
3D printing technologies have been increasingly explored for clinical 
applications as it allows for the design and fabrication of complex 3D 
structures simulating body structures and organs, which can be patient 
specific [58,59]. Combining advanced imaging techniques, such as 
magnetic resonance imaging and computer tomography, computer-aided 
design software and 3D printing, is possible to develop customized, 
complex structures in a timely and cost-effective manner, as compared to 
traditional manufacturing processes. In the context of our cell 
macroencapsulation NICHE, 3D additive manufacturing allows for 
straightforward scalability and customization. Different device shapes and 
sizes can be generated depending on the anatomical features of the 
implantation site and the volume of cells required to be encapsulated. 
 
Our choice of printable material (polylactic acid) was motivated by 
PLA’s biocompatibility and adequate mechanical properties previously 
reported in the literature [60,61]. Importantly, PLA shows slow degradation 
kinetics: our results in accelerated degradation condition show that 
mechanical properties are potentially preserved for years, prior to any 
substantially noticeable weakening of the structure. However, in some 
instances, after cell engraftment and the formation of a subcutaneous 
organ-like structure, NICHE could degrade without affecting the function of 
the established system. In other cases, maintaining a bioinert structure 
could be beneficial. This is the case for diabetes, whereby 
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supplementation or replacement of cells may be required to adjust to the 
needs of patients and to address the systematic loss of viability that cells 
endure after transplantation over the years. In these cases, other bioinert 
materials could be used such as polyether ether ketone (PEEK) and 
polytetrafluoroethylene (PTFE), among others, which have been 
demonstrated in other cell delivery applications. 
 
To further demonstrate the long-term application of the NICHE 
technology, we performed combining experimental testing and numerical 
simulations. Various numerical and experimental methods have been used 
in the literature to study the mechanical properties and fracture behavior of 
a wide range of materials and applications [305]. In several studies, 
stress-strain curves obtained by experimental testing were successfully 
adopted as constitutive model curve for numerical simulation obtaining 
good correlation with experimental results even in presence of voids and 
defects derived from manufacturing. In this context, material constitutive 
models can take into account the defects implicitly [306,307]. Alternatively, 
homogeneous material models can be used which macroscopically 
describe the global material behavior inclusive of defects [308,309]. In this 
study, we opted for the latter approach demonstrating its validity for a 
complex 3D-printed structure such as the NICHE.  
The experimental mechanical testing was initiated with the calibration 
on the constitutive material model to be used in numerical FE analysis. 
Numerical simulation of the tensile testing on specimen validated the 
numerical model in case of uniaxial loading. In addition, a numerical FE 
structural model of the cell encapsulation system was implemented and 
results compared to the experimental results. Component simulation of 
central compression matched well with experimental results, thus allowing 
for validation of biaxial loading numerical modeling, both in dry and wet 
conditions. 
As opposed to other rigid materials and subcutaneous implants 
developed for controlled drug delivery [162,164,310] in the case of the 
NICHE deformations are required for the system to conform to the 
surrounding tissues and avoid unwanted stress points that could damage 
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and ulcerate the tissues over time. Mechanical testing demonstrated that 
no device fragments were produced both in dry and wet conditions and no 
permanent deformations were developed indicating an elastic behavior of 
printed PLA. In the majority of the tested NICHEs, failure took place in the 
area where the load was applied and, in some cases, where the mesh is 
connected to the annular part of the capsule. In this location, the 
calculated stresses were lower than demonstrated failure stresses and 
these failures maybe expected from the presence of imperfections in 3D 
printed material. The test conditions with empty NICHE devices and 
central compression were chosen to simulate a worst-case scenario in 
terms of mechanical loading. In an in vivo scenario, the encapsulation 
devices is rapidly filled with blood vessels and tissue ingrowth. This 
engraftment process progressively takes place within approximately 3 
weeks post device implantation. During this phase NICHE is mostly empty. 
Once the NICHE is fully engrafted, external forces and stresses from 
surrounding tissue are more uniformly distributed over the device 
structure. The results of compression testing of NICHEs retrieved from 
subcutaneous implantation in a porcine model, clearly demonstrated the 
combined effect of implant and tissue in withstanding the applied stresses 
to a substantially larger extent as compared to empty devices.  
By comparing structural FEM simulations for the most critical 
mechanical conditions (empty capsule) while adopting homogeneous 
isotropic material properties derived from experimental testing of 3D 
printed dogbones, good agreement was found with the experimental 
results. While published data indicates that the subcutaneous loading of 
devices [292] could reach higher values than those obtained by 
experimental testing on cell encapsulation systems, the current results are 
encouraging. Importantly, NICHEs retrieved from the pig study were intact 
and did not display any deformation or signs of failure. Results obtained 
from wet specimen testing, which is more indicative of physiological 
conditions, show higher load to failure and displacement to failure values 
than dry specimen in monotonic, creep and fatigue testing conditions. 
Furthermore, the presence of a biological tissue layer, simulating the 
subcutaneous application, increased the load to failure and displacement 
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to failure values of monotonic tested specimens, probably due to the 
resulting stress distribution, as reported in similar conditions [308]. The 
FEM analysis, corroborated by experimental results, validates the stress 
distribution in cell encapsulation systems, justifying the differences in load 
to failure and displacement to failure results. Further in vivo studies using 
animal models with comparable subcutaneous conditions to humans are 
required for validation before clinical translation of the system. However, 
these encouraging preliminary data show the promise of the 3D printed 
NICHE for long term clinical subcutaneous implantation and 
transplantation of therapeutic cells. Additionally, the finite element model 
adopting constitutive mechanical properties experimentally obtained for 
3D-printed PLA showed to be able to predict with fidelity the experimental 
mechanical test results for the NICHE. This FEM approach demonstrates 
a promising tool for the design and optimization of a wide spectrum of 
polymeric devices for implantable applications.  
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Chapter 4 
Development and in vitro 
testing of human mesenchymal 
stem cells differentiated into 
islet-like insulin producing 
aggregates (ILIPAs) for 
diabetes treatment 
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1. Introduction 
The current standard of care for Type 1 diabetes patients involves daily 
monitoring of blood glucose levels and the continuous injection of insulin, 
and, for patients with Type 2 diabetes, oral or injected therapeutics [311]. 
Both treatments have their respective side effects including ketosis and 
hypoglycemic coma.  
Pancreas and islet transplants have shown success at re-establishing 
glucose control and reversing diabetic complications, but their routine 
clinical application is still inadequate, primarily due to the limited supply 
of cadaveric organs and loss of graft function over time due to immune 
rejection, lack of neovascularization, and loss of physiological 
architecture. Patients transplanted with cadaveric human islets can 
become insulin independent for about 5 years, but limited quantity and 
quality of donor islets make it an unrealistic cure [22]. 
Being the islet demand way larger than the number of pancreata available, 
several labs are working on the development of engineered insulin 
releasing β-cells that can potentially replace the need of pancreas donors.  
The ideal therapy would restore insulin independency using 
autologous β-cells [312]. Since pluripotent stem cells were discovered, 
several have been the tentative to use these cells for disease treatment 
and drug screening.  
In this chapter, first is presented the production and characterization 
of islet like insulin producing aggregates (ILIPAs) from stem cells 
collected from human bone marrow (BM-MSCs) as potential substitute of 
human pancreatic islets. Successively, is accessed the viability and 
insulin secretion of encapsulating ILIPAs in the NICHE devices, in vitro. 
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2. Materials and methods 
Human pancreatic islets isolation and purification 
Human pancreata (n=5) were obtained from heart-beating donors 
deceased by brain death with informed consent for transplant or research 
use from relatives of the donors. Human islets were isolated from 
cadaver donors using an adaptation of the automated method described 
by Ricordi et al.[313] 
 
Islet cell culture 
Aliquots from human islet isolations were then cultured in Memphis 
Serum-Free Medium (M-SFM) further supplemented with 10 U/mL 
heparin and 10 mM Niacin as described previously. Islet culture media 
was changed at day 1 post isolation and thereafter weekly for all islet 
preparations during the culture period. Islet tissue was cultured for 1-3 
days prior to experimentation, to allow for sterility and viability testing. 
These islets were used as positive controls for BM-MSCs derived ILIPAs. 
 
Isolation, expansion, and differentiation of BM-MSCs 
Bone marrow samples (n=5) were recovered from leftover tissue in 
used bone marrow collection bag sets, properly consented for research 
utilization. Isolation, expansion, and differentiation of BM-MSCs was 
performed according to the procedures outlined by Gabr et al. [314]  
 
Characterization of isolated MSCs by flow cytometry 
For flow cytometric analysis, the MSCs at passage three were 
trypsinized, centrifuged at 300 g for 8 minutes, and resuspended in PBS 
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at a concentration of 1×106 cells/ml. 100 μl aliquots were labeled for 30 
mins with antibodies against CD14, CD45 (FITC) or CD73, CD34 
phycoerythrin (PE) (Becton-Dickinson, USA), or CD105 PE or CD90 
(FITC) (Becton-Dickinson, USA), washed with 1ml of stain buffer (BD-
Pharmingen, USA) and resuspended in 500 μl of stain buffer. The 
labeled cells were analyzed using an argon ion laser with a wavelength 
of 488 nm (FACS Calibur, Becton-Dickinson, USA). A total of 10,000 
events were obtained and analyzed with the DIVA software program 
(Becton-Dickinson, USA). Control staining with appropriate isotype- 
matched monoclonal antibodies was included. 
 
Differentiation of the MSCs to ILIPAs 
After passage three, MSCs with appropriate CD profiles were seeded 
at a density of 1×105 cells/ml in serum-free, high glucose (450 mg/dL) D-
MEM (25 mmol/L) containing 0.5 mmol/L β-mercaptoethanol (Sigma) and 
incubated for 2 days. The medium was replaced with serum-free, 
glucose-rich medium containing 1% nonessential amino acids (Sigma), 
20 ng/ml basic fibroblast growth factor (Sigma), 20 ng/ml epidermal 
growth factor (Sigma), 2% B27 supplement (Gibco BRL, Life 
Technologies, UK) and 2 mmol/L L-glutamine (Sigma).  The preparations 
were cultured for 8-10 days. Finally, the cells were cultured for an 
additional 8-10 days in serum free, high glucose D-MEM containing 10 
ng/ml betacellulin (Sigma), 10 ng/ml activin-A (Sigma), 2% B27 
supplement and 10 mmol/L nicotinamide (Sigma). 
 
Immunolabelling 
Immunohistochemistry was performed using primary antibodies 
against insulin (AB6995, Abcam, Cambridge, MA), and glucagon 
(AB92517, Abcam). For nanogold immunostaining, the ILIPAs were fixed 
in 2% formalin and 0.5% glutaraldehyde (EM grade from Ted Pella) in 
PBS overnight at 4°C. After washing 3 x 15 min with PBS containing 
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0.05% Tween 20 (Bio-Rad Laboratories, Hercules, CA, USA), ILIPAs 
were blocked for 6 hours in casein blocking buffer (BioRad) with 0.05% 
Tween 20 at room temperature. Subsequently samples were incubated 
with mouse monoclonal anti-c-peptide (1H8) antibody (Abcam, ab8297) 
at 1:50 dilution in blocking buffer, overnight at 4°C. The next day, 
samples were washed for several hours with PBS- 0.05% Tween 20 and 
incubated overnight at 4°C with anti-mouse antibody conjugated with 1.4 
nm gold (Nanoprobes, Yaphank, NY, USA) diluted at 1:50 with blocking 
buffer. The next day, samples were washed 3 x 15 min with PBS-0.05% 
Tween 20, post-fixed for 20 min in 1% glutaraldehyde in PBS-0.05% 
Tween 20, washed 3 x 15 min in water, silver enhanced and either 
photographed as a whole mount or processed for electron microscopy 
without the osmium tetraoxide treatment, as described previously. 
Whole-mount immunostained ILIPAs were contrasted with 0.5% uranyl 
acetate only (without osmium tetraoxide) and embedded in Epon. Thin 
(70-100 nm) sections were examined and photographed in JEOL 1200 
transmission electron microscope. 
 
Microarray analysis 
RNA was extracted using the Trizol Hybrid RNA Method and RNA 
quality was assessed on the Agilent Bioanalyzer RNA Amplification using 
the Ambion WT Expression Kit (Affymetrix). Fragmentation/Terminal 
labeling Hybridization to the Affy 1.1ST Human Plate on the GeneTitan. 
 
Gene expression by RT-PCR 
Total RNA (totRNA) was extracted in accordance with the 
manufacturer’s instructions. Variable amounts of total RNA input were 
reverse transcribed using the iScript cDNA Synthesis kit (Bio-Rad), the 
amount defined by the respective samples concentration (from 5 – 1000 
ng total RNA input). 
TaqMan® (Life Technologies) analysis was performed on the Roche 
LightCycler 480 II Instrument with LightCycler® 480 Probes Master mix 
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(Roche). See supplementary table 2 for list of TaqMan® primers/probes 
analyzed. For more representative normalization, a cDNA master mix 
(cDNA, 2X Probes master mix, PCR-grade water) was prepared for each 
cDNA sample to which either query or normalizing TaqMan 
primers/probe were subsequently added. This procedure allows the 
query and normalizing primers/probe to interrogate the same cDNA 
master mix preparation, resulting in more accurate normalization. 
Normalized Cp values (Critical point; Cpquery - geometrix-mean (CpPPIA, 
Cp18S) were analyzed. In addition, relative quantitative RT-PCR (qPCR) 
gene expression for differentiated islet like pancreatic cells were 
analyzed against human islets served as a positive control and acinar 
and undifferentiated MSCs as a negative control. 
 
NICHE surface patterning and modification 
After fabrication as described in chapter 3, NICHE surface 
modification was performed using various agents as described below, to 
obtain suitable external charge and hydrophilicity for supporting cell 
growth and viability. All of the PLA NICHE were immersed in a 5 M NaOH 
(Macron Chemicals, PA, USA) solution in Millipore water for 4 hours 
under mild agitation, then rinsed, and dried at room temperature. A 
NICHE custom holder has been fabricated for running two 60-second 
cycles of Argon plasma (Ar) or Oxygen plasma (O2) etching (30 Watt, 150 
mTorr) (March plasma etcher, Nordson, Ohio, USA). 
Five NICHEs were placed in a petri dish filled with a poly-L-lysine 
solution 0.01%, 150,000-300,000 MW (PLL, Sigma Aldrich), incubated for 
5 minutes, and air dried at room temperature. A second group of five 
NICHEs were placed in a petri dish filled with endothelial cell attachment 
factor (ECAF, Sigma Aldrich, sterile-filtered liquid), followed by a ten-
minute incubation, and drying at room temperature, as per manufacturer’s 
instructions. 
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Cell viability in surface modified NICHE in vitro 
For the in vitro cell viability study, flat PLA membranes (n=7) were 
printed (20 mm diameter, 1 mm thickness), treated with NaOH, Argon 
plasma, PLL, and ECAF (n=6 per each group), assembled into 6-well 
polystyrene cell culture inserts (Becton Dickinson, USA), and filled with 
1.5x105 human umbilical vein endothelial cells (HUVEC) in a volume of 1 
ml of complete Endothelial Cell Basal Medium (EBM, Lonza, USA). All 
samples were incubated at 37 °C and 5% CO2 for 7 days with a change 
of media at regular time intervals (2, 4, and 7 days). To assess viability, 
cells were rinsed with PBS buffer, trypsinized (Trypsin/EDTA solution), 
and quantified using Trypan blue solution. 
 
Assessment of insulin secretion and content in vitro 
Standard aliquots of 50 islets equivalent (IEQ) or 100 IEQ of ILIPAs 
were incubated for 60 minutes with low glucose (60 mg/dL, basal), 
followed by 60 minutes of high glucose (300 mg/dL, stimulated). 
Following high glucose incubation, islets were harvested and insulin was 
extracted in an ethanol–acid solution (165 mM HCl in 75% ethanol). The 
islets were then analyzed for insulin content using a specific ELISA assay 
(ALPCO Diagnostics, Windham, NH). The low glucose media used was 
standard alpha MEM supplemented with 5% Platelet Lysate (PL). The 
high glucose stimulation media was high glucose D-MEM (450 mg/dL 
glucose) supplemented with 5% PL. 
 
ILIPAs insulin secretion in NICHE 
In order to assess the long-term viability of ILIPAs when housed in the 
NICHE devices, we loaded multiple NGs (10 per group) with 
approximately 2,000 ILIPA constructs.  The ILIPAs were loaded in a 
platelet lysate (PL) gel into the NICHE.  Briefly, NICHEs were placed in 
the wells of a sterile 12-well suspension type plate (Sarstedt).  ILIPAs 
were centrifuged and media was removed.  The ILIPAs were mixed with 
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PL at a concentration that would allow for approximately 2,000 ILIPAs to 
be loaded in a volume of 200 uL (10,000 ILIPAs/mL).  Three NICHE 
treatment types were tested in this evaluation.  NICHEs without surface 
modification (untreated), NGs surface modified with Argon plasma, and 
NICHEs surface modified with Oxygen plasma.  Once the PL-ILIPAs were 
loaded into the wells, 50 uL of Thrombin (2,000 units/mL, King Pharma, 
Bristol, TN) was mixed with the solution.  The plates were placed in a 
37°C, 5% CO2 incubator for 60 minutes to allow the gel to completely 
form. 
Once gelation was accomplished, the NICHEs were transferred into 
new microplates and 3 mL of alpha MEM with 5% PL was added to the 
wells.  The media was replaced every 3-4 days for the next month.  The 
NGs were tested weekly for insulin release using a perifusion type 
evaluation. 
On days 7, 14, 21, and 28, the media was collected from the NICHE 
wells and saved for insulin analysis.  The media was replaced with fresh 
media that represented the low glucose portion of the testing (100 
mg/dL).  The plates were incubated for 30 minute intervals, and the media 
was harvested for insulin analysis every thirty minutes for up to six hours.  
The media was changed to high glucose media at 90 minutes and 
remained so until the final incubation of the day.  At this time, the media 
was replaced with low glucose media and the plates were returned to the 
incubator overnight.  The following morning, media was collected and 
replaced with high glucose media again, with incubation extending up to 
another 3-4 hours. 
 
Statistical analysis 
Results are expressed as mean and standard deviation for at least 
three replicates. One-way nonparametric analysis of variance followed by 
the Tukey post-hoc test was assessed to verify statistical significance; p < 
0.05 was considered statistically significant. Statistical analysis was 
performed using Prism 5 software (GraphPad Software Inc., San Diego, 
CA, USA). 
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3. Results 
Morphological and phenotypical characterization of the 
cultured MSCs 
During the MSC differentiation into ILIPA phase, cells gathered 
gradually in groups with the formation of three dimensional aggregates. 
At the end of the differentiation protocol, cells formed clusters with 
spheroidal morphology (Figure 4.1). A difference in the rate of growth or 
differentiation was observed between different donors (data not showed). 
At the end of differentiation, immunofluorescent labeling and electron 
microscopy demonstrated c-peptide positive staining in the differentiated 
ILIPAs. 
Furthermore, using immunohistochemistry we show that 
differentiated ILIPAs contain α-cells that are positively stained for 
glucagon and β-cells positively stained for insulin (Figure 4.2). 
 
 
Figure 4.1: Morphological changes of bone marrow derived cells (MSCs) 
differentiated into functional islet-like structures (ILIPAs). (a) Bone marrow cells, 
(b) purified MSC, (c) undifferentiated MSCs, at the end of the expansion phase, 
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and (d) contrast phase microscopy showing aggregation of differentiating MSCs 
into insulin-producing ILIPA. 
 
Figure 4.2: Differentiated ILIPAs (b) are similar in size to human islets (a). 
ILIPA EM photomicrograph (d) stained with gold nanoparticles labeled with 
antibodies to C-peptide (grey arrows) at the cisternae of rough endoplasmic 
reticulum (c). 
 
Gene expression profile of human pancreatic islets and 
ILIPAs 
Human islets (n=5) and ILIPAs (n=5) were analyzed for gene profile 
using high density Affymetrix U133A Gene Chips (analyzed by Gene 
Spring software). Genes that met the criteria for statistically significant 
differential expression (p ≤ 0.01) at false discovery rate of 2%, were 
identified by the Welch t-test. This list was further refined by omitting 
those genes whose fold-difference of expression was less than two. 
Using Ingenuity Pathways Analysis software, we identified differential of 
gene expression in islets that play a role in insulin synthesis and 
secretion as well as glucose metabolism (Supplementary table 1 and 
Figure 4.3). While there was no difference in the insulin expression 
between islets and ILIPAs, islets had high relative levels of genes that 
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promote insulin production and secretion, such genes included ABCC8, 
PDX1, RFX6 PCSK1, SLC2A2, FOXA2, and SST. 
 
Figure 4.3: Glucose metabolism disorder network generated using Ingenuity 
Pathways Analysis software comparing human islets to ILIPAs. Upregulated 
genes are shown in red and downregulated genes in green. Genes that are 
important to glucose metabolism such as ABCC8, RFX6, and SLC2A2 are 
expressed much higher in the islets with fold changes of 79, 138, and 21, 
respectively. 
 
 
RT-PCR of differentiated ILIPAs 
Islet gene expression profile varies in different donors. To determine 
the variation in gene expression profile of different ILIPA preparations, 
we examined five differentiated ILIPA preparations and compared them 
to an average of five human islet preparations as a positive control and to 
undifferentiated MSCs and acinar cells as a negative control. We tested 
for genes that are crucial for insulin secretion and glucose metabolism 
and results expressed by previous gene expression array, such as 
Insulin, SST, ABCC8, SC2A2, PDX1, FOXA2, RFX6, and PSCK1. As 
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shown in figure 4, there is a wide variation between different ILIPA 
preparations, where two out of five have similar expression levels as the 
islets (Figure 4.4). 
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Figure 4.4: Real time PCR of islet’s key transcription factors expression of 
acinar cells, undifferentiated MSC, and differentiated ILIPAs from 5 different 
donors, normalized to 5 different isolated human islets. The results are 
expressed as the fold change difference of islets to ILIPAs. 
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NICHE surface treatment and endothelial cell culture 
Different surface treatments were tested to augment PLA NICHE 
hydrophilicity. All of the tested surface modifications reduce water contact 
angle on the polymer surface in the first week after treatment. The effect 
was higher when the NICHEs were treated with a combination of Ar 
plasma and ECAF (p<0.001), but this group lost the hydrophilic change in 
almost one week, becoming comparable to the other treated groups. All 
of the groups treated with Ar plasma maintained the surface 
characteristics, as shown by low contact angle at 1 month from the 
surface treatment (p<0.01), but only the combination with PLL and ECAF 
maintained the effectiveness at day 40 (p<0.05). 
Figure 4.5: Comparison of hydrophilicity achieved by various surface 
modification techniques, as measured by water contact angle on day 1 
(a=control, b=PLL, c=ECAF) and their stability over 40 days. 
 
Cell proliferation and viability were tested in surface modified NGs 
using human umbilical vein endothelial cells (HUVECs). HUVECs were 
grown on NICHEs treated with PLL and Ar. Plasma treatment showed a 
slower growth compared to all the other surface treatments (p<0.05). All 
groups cultured in surface treated NICHEs showed a mean viability 
higher than 90%, and dimension comparable to control, with minor 
differences between the control and untreated NGs (16.81 μm vs. 15.54 
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μm, p<0.05). All cells cultured inside the NGs grew slower than the 
control group cultured in classical polystyrene well (p<0.001). 
Figure 4.6: Effect of different polylactic acid surface modification techniques 
on HUVEC viability (a), growth (b), and dimension (c). * p < 0.05, ** p<0.001 
 
 
Insulin secretion by ILIPAs in NICHE 
A month long ILIPA culture was conducted in polymeric NGs with 
different surface treatments to understand long-term viability and insulin 
secretion in response to glucose stimuli. 
ILIPAs showed an ability to produce steady levels of insulin 
throughout the testing process. The insulin accumulated in the testing 
media in a consistent manner showing spikes in insulin production and 
accumulation at time 0 (following weekend incubation) as well as 
following overnight incubation during the testing. These spikes seem 
constant during the entire duration of study, with a statistically non-
significant reduction trend during week 4 in all groups. There were no 
differences in both basal insulin secretion or response to high glucose in 
argon or oxygen treated NICHEs. ILIPAs showed no significant difference 
in overall performance over the testing period when different types of 
surface treatments were compared and insulin release tracking was 
consistent for each NICHE cohort (Figure 4.7). 
When comparing ILIPAs in the NG-PL to free ILIPAs tested in the 
same manner, we see a rapid drop in insulin levels for the free ILIPAs 
compared to those in the NICHE devices, presumably due to retention of 
insulin within the PL gel matrix (Figure 4.7A). 
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Figure 4.7: Effect of NICHE and surface modifications on ILIPAs’ insulin 
secretions after glucose stimulation during the 1st week of culturing (a) and over 
a 4-week experiment (b). The overnight peaks are marked by red arrows. 
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4. Conclusion 
Over the last few decades, islet and stem cell transplantation has 
been explored as a promising method to achieve strict control of blood 
glucose and as a potential cure for diabetes. Two key problems for these 
cell therapies are the lack of adequate islets or islet-like tissue and the 
need to use immunosuppressants. Here is presented the generation of 
human mesenchymal stem cells (MSCs). Since MSCs comprise only 
0.001% to 0.01% of bone marrow mononuclear cells, in vitro expansion 
of these cells is necessary to obtain sufficient cell numbers for clinical 
use.  Following the expansion phase, cells were driven to differentiate 
into islet-like insulin-producing aggregates (ILIPAs) that express 
pancreatic islet genes and secrete insulin. The premise of stem cell 
therapy for diabetes is the production of autogenous differentiated cells 
that mimic pancreatic islets and β-cells as a source of insulin for blood 
glucose homeostasis. Our data show that despite the success in creating 
ILIPAs that are capable of insulin and C-peptide production, there was a 
variation among cultures from different donors in key transcriptional 
factor expression such as PDX1, a factor responsible for the 
development of the pancreas in humans as well as maintaining insulin 
gene expression and β-cell survival. Down regulation in the expression of 
PDX1 could lead to β-cell failure and subsequently type 2 diabetes. 
RFX6 was another transcription factor upregulated in ILIPAs, commonly 
responsible for the regulation of insulin gene expression and secretion, 
and is thought to be involved in islet cell differentiation.  
ILIPAs expressed SLC2A2, a gene that produces GLUT2, the 
specific glucose transporter in β-cells, responsible for glucose 
homeostasis by enabling transport across cell membranes, tuning insulin 
secretion. PCSK1, Proprotein convertase subtilisin kexin type 1 (PCSK1) 
belongs to the subtilisin-like proprotein convertase family that process 
latent precursor proteins, such as proinsulin, into their biologically active 
products. and ABCC8 a gene included ATP-binding cassette, sub-family 
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C (CFTR/MRP), member 8, which functions as a modulator of ATP-
sensitive potassium channels and insulin release. Donor variability is a 
major concern. Our laboratory found that not all donor cells differentiate 
at the expected time frame; indeed, some took a longer time to reach the 
desired phase. Therefore, testing ILIPA preparation with RT-PCR for key 
genes required for healthy islet function could be essential for possible 
future clinical studies. RNA-seq could be a valid method to further 
characterize ILIPA gene expression and their biological characteristics, 
which will require larger quantity of cells.  
3D NICHEs, after performing Plasma surface treatment, were 
adopted to encapsulate ILIPAs in order to evaluate cell viability and 
insulin release. 
Plasma surface treatment, followed by surface functionalization with 
cationic groups have shown to greatly enhance biomimetic properties of 
PLA and the consequent affinity for the cells. Prior work with endothelial 
cells on oxygen plasma treated PLA scaffolds has shown increased cell 
proliferation over 4–6 days and increased angiogenesis in vivo at 12 days. 
This characteristic could be very useful for potential clinical application, 
permitting a better vascularization of PLA implanted devices used as cell 
reservoirs. 
Xia et al. [315] showed rapid endothelialization of plasma treated PLA 
with functionalized –COOH groups to link gelatin or chitosan, while Zhu et 
al. showed similar results through aminolyzed PLA. A possible advantage 
of polymeric PLA implants is the local lactate release after degradation, 
which seems to improve angiogenesis and cutaneous wound healing in 
different mouse strains.  
ILIPAs, either free or in NGs, did not show a measurable acute 
response to high glucose as a secretogogue, likely due to the lack of 
insulin storage granules in the ILIPA construct. However, all groups 
demonstrated very consistent low-level insulin production throughout the 
testing period and as such, may prove clinically useful as a replacement 
source of basal levels of insulin. All tissues tested resulted in a basal 
insulin level of 0.012-0.072 μU insulin per ILIPA (data not shown). An 
interesting observation was that free ILIPAs showed a quicker reduction in 
 117 
insulin release than those housed in NICHEs, presumably due to insulin 
accumulation in the PL gel matrix in the latter.  Also, ILIPA overnight 
incubation in NICHEs produced higher insulin spikes.  
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Chapter 5 
NICHE validation In Vivo for 
insulin and testosterone 
release 
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5.1 3D printed vascularized device 
for subcutaneous transplantation of 
human islets  
 
1. Introduction 
 
In this chapter is presented the validation of NICHE as encapsulation 
system for subcutaneous engraftment of human pancreatic islets in an 
immunocompromised mouse model. After 3D printing, the devices were 
treated with Argon plasma and growth factor enriched platelet gel in order 
to improve polymer biocompatibility and enhance vessel formation within 
the NICHE. After achieving an optimal level of vascularization, human 
pancreatic islets were transplanted. As demonstrated by the detection of 
human insulin over the 22-weeks of the experiment, the device resulted to 
have protected the encapsulated islets from acute hypoxia and kept them 
functional. Moreover, the adaptability of the NICHE for long term 
applications was demonstrated by refilling some of the experimental groups 
via transcutaneous injection of additional islets. 
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2. Materials & Methods 
NICHE devices suitable for rodent studies to hold up to 5,000 islets 
were printed as previously described in chapter 3. After fabrication, NICHE 
surfaces were treated with Argon and Oxygen plasma (March plasma 
etcher, Nordson). The power (30W) and gas flow (150mTorr) were kept 
constant, while changing the exposure time (30, 90, 120 and 150 
seconds). The structure of the device was evaluated at different 
magnification by scanning electron microscopy (SEM) (Nova NanoSEM, 
FEI) for channel quality and size (Fig. 1c-d). Hydrophilicity was evaluated 
by measuring the water contact angle, as described previously in Chapter 
4 and surface nanopattering and roughness were evaluated by atomic-
force microscopy set in tapping mode (Fig. 1e-f, BioScope Catalyst, 
Bruker Instruments, Texas). 
The function of the encapsulation devices was evaluated in nude mice 
(Nu/Nu, female, 8-10-week-old), after receiving approval by the 
Institutional Animal Care and Use Committee of Houston Methodist 
Research Institute. The devices were sterilized with 70% ethanol and UV 
before performing all the surface modification treatment with oxygen or 
argon plasma in a sterile environment (clean room of the Houston 
Methodist Research Institute). Thereafter, devices were filled with a 
platelet-lysate solution (ZenBio), under aseptic conditions and incubated 
overnight at 37 °C in a cell incubator to form the gel, with the addition of 
bovine thrombin (BioPharm Laboratories, LLC). The ready to be implanted 
devices were then packaged and transferred to the animal facility and the 
package opened in a sterile environment just before the implantation.  
Surface treated and sterilized devices, loaded with platelet-lysate matrix 
(PLM) enriched with VEGF at two different concentrations (0.5 and 5 
µg/ml), were implanted subcutaneously in the mice dorsum (n=12 per 
group). At 1, 2, and 4 weeks post implantation, 4 mice per group were 
euthanized and the graft explanted for histological assessment of 
vascularization and innervation. The implant and surrounding tissues were 
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harvested, and processed for histopathology evaluation of tissue response 
to the implanted device with hematoxylin and eosin (H&E). This staining 
was used to analyze tissue morphology and to evaluate the presence of 
immune cells, vessels infiltration, and fibrotic response at the tissue-device 
interface.  CD31 antibody (Abcam, ab28364) was used for 
immunohistochemistry (IHC) analysis and a pan-axonal antibody 
(Cambridge Bioscience, SMI-312R-100) with immunofluorescence (IF) to 
assess device vascularization and innervation respectively. CD31 
expressing cells were counted separately in 10 high-power fields. (HPFs).  
A second experiment was performed in nude mice (n=5 per group) to 
evaluate insulin release from human islets transplanted into a 
prevascularized device. Human pancreatic islets (2,000 IEQ per mice) 
were injected subcutaneously with a 22 G needle into the encapsulation 
system 4 weeks after device implantation or were inserted under the 
kidney capsule (positive control). Human insulin (ultra-sensitive human 
insulin ELISA kit, Alpco) and blood glucose (OneTouch® Glucometer, 
Johnson and Johnson) levels were assessed weekly and body weight was 
monitored throughout the experiment. Intra peritoneal glucose tolerance 
test (IPGTT) was performed weekly to stimulate insulin secretion from the 
transplanted islets. Blood was collected using retro-orbital method, under 
topical anaesthesia and aseptic techniques. A subsequent test was 
performed on the same animal cohort to demonstrate the subcutaneous 
refillability of the implant. Twelve weeks after the first injection, additional 
human islets (2,000 IEQ per mice) were injected trancutaneously in all 
groups where the insulin production was lower than 0.125 µIU/ml. 
Statistical analysis was performed using Student’s two tailed paired t-
test. Results are presented as mean and standard error of the mean 
(SEM). A value of p<0.05 was considered statistically significant. 
GraphPad Software, Inc. was used for the analysis. 
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3. Results 
Transplantation of cells on porous biomaterials has emerged as a 
promising strategy for long-term function facilitating rapid tissue ingrowth, 
vascularization and innervation providing oxygen, nutrition, and waste 
removal [147]. Recognizing such needs for an islet and cell encapsulation 
system, we are working on new strategies to deliver cells subcutaneously 
[35–37]. The architecture of the proposed device is designed to maintain 
pancreatic islets close to blood vessels, but separated from each other to 
mimic the physiological architecture in the pancreas and avoid cell 
crowding. 
To increase the biointegration of the NICHE, we decided to use 
PLA, which is a widely adopted polymer in biomedical devices, 
biocompatible, and presents good elasticity and mechanical strength 
suitable for subcutaneous implantation as previously described in Chapter 
3 and 5. Due to the chiral nature of lactic acid, PLA is hydrophobic with 
low cell adhesion properties. Surface treatment with plasma improves the 
low surface free energy of different materials and offers a solvent-free 
technique capable of changing the wettability, surface roughness and 
surface chemistry of polymers, enhancing cell proliferation and viability 
[315,316]. Plasma activation also increases PLA’s surface free energy 
forming a broad variety of functional groups on the surface, including polar 
groups, which drastically change wettability and have a positive effect on 
material–cell interactions. Previous work from our group demonstrated that 
plasma treatment substantially increased the hydrophilicity of the surface 
and reduced the contact angle, which remained stable over 30 days in 
phosphate buffered saline (PBS) [36]. Here we looked at the effect of 
plasma exposure time on surface patterning and roughness and compared 
Oxygen and Argon treatments. Since UV light sterilization methods 
showed to increase polymer wettability without affecting morphology and 
mechanical properties, we decide to evaluate the effect of the surface 
modification only at the end of plasma treatment.  As shown in Fig. 5.1E, 
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both treatments increased surface roughness, reaching a maximum value, 
after which the roughness diminished with continued exposure, possibly 
due to eventual etching of the crystalline regions. It was also noticed that 
the Oxygen treatment cause deeper patterns (4.63 nm with Argon and 
26.45 nm with Oxygen, p<0.01, Fig. 1F), which has been demonstrated to 
be beneficial for cell attachment and proliferation. For this reason, a 120 
seconds Oxygen treatment was selected for the following experiments 
[317] . 
 
 
Figure 5.1. Mouse prototype of the 3D-printed NICHE (A) and rendering of 
the structure (B) that includes insulin reservoirs (IR) and microchannels ( CH). 
Magnification of the microchannels under SEM (C) and (D). PLA superficial 
roughness measurements after Argon and Oxygen plasma treatments, changing 
time of application (0, 30, 90, 120, and 150 seconds) (E). AFM pictures of PLA 
surface treated with Oxygen plasma after 0, 90 and 120 seconds (F). Average 
and SEM are represented. ** p<0.01. 
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We then investigated the in vivo vascularization and innervation of 
Oxygen treated devices after subcutaneous implantation in nude mice. 
Nude mice were selected for these studies with the novel encapsulation 
device as they show an inflammatory response to a foreign body, but allow 
for transplantation with human islets without the need for 
immunosuppression. It has been broadly demonstrated that 
vascularization of the graft is the key for successful engraftment of islet 
transplants [288,289]. Prevascularization could mitigate the issue of acute 
hypoxia which was shown to result in islet apoptosis and graft failure. To 
stimulate neovascularization and to support the islet viability and function 
for a period of time after transplantation we tested devices loaded with 
biological gels with different VEGF concentrations. An acute inflammatory 
response to the foreign body was present in the first week after device 
implantation, mainly in the VEGF groups, and subsided with time, leaving 
a rim of vascularized connective tissue around the device at week 4 (Fig. 
2). Indeed, the neutrophils, which are considered to have an impact on the 
development of the inflammatory response leading to the formation of the 
fibrotic capsule, were almost absent from the second week (Fig. 5.2 A-I). 
The red arrows in Fig. 5.2 indicate the protrusion of the surrounding 
subcutaneous tissue into the devices. Tissue samples were taken from the 
side of the device closer to the skin, representing the subcutaneous 
environment. We noticed a positive trend between VEGF concentration 
and the number of vessels stained by CD31 (Fig. 5.2J-M), but there was 
no statistically significant difference between the groups after 1 week, 
probably for the limited number of animals per group. After 4 weeks, we 
noticed calcification in the VEGF 5 μg/ml sample as evident by the dark 
spots in high density close to the tissue-implant interface (Fig. 2I, black 
arrow). It has been already shown that VEGF is involved in the 
calcification process of cartilage and at similar concentration it was tested 
to induce bone response to implanted craniofacial implants. It was 
observed that in 4 weeks the subcutaneous tissue and the inside of the 
device were also vascularized with lower concentration of VEGF (Fig. 
5.2N-O). Based on these results, 0.5 μg/ml VEGF was selected for further 
studies.  
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Finally, we also found nerve bundles in the proximity of the device (Fig. 
5.2P-Q). These may have reached the device and the transplanted islets. 
However, further long-term studies are necessary to prove and quantify 
islet innervation, considering the slower rate of growth of nerves compared 
to vessels. 
After proving the device vascularization, we performed a second 
experiment injecting human islet into a prevascularized device previously 
loaded with the VEGF rich matrix. By the time of the islet injection the gel 
was already degraded, releasing growth factors (Fig. 5.2N).  
Figure 5.2. H&E of the tissue surrounding the device at 4x. Tissue response 
at the device-subcutaneous tissue interface is shown (red arrow, A-I). Different 
concentrations of VEGF were tested and device retrieved after 1, 2, and 4 weeks 
from the implantation. Diffuse spots of calcification (black arrows) were present at 
week 4 with the highest VEGF concentration (I). CD31 staining of tissue (J-L). 
Scale bar is 50 μm. Average and SEM of the CD31 count for high power field 
(M). Representative optical microscope visualization of the tissue collected from 
the device reservoir (VEGF 0.5 Pg/ml group), showing the presence of mature 
vessels (N-O) Dotted lines represent device-subcutaneous tissue interface and 
the black arrows follow the path of a vessel through the polymeric scaffold. 
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Neurofilament staining (SMI312-R, in green) indicates the proximity of 
subcutaneous nerve bundles to the encapsulation device (P-Q).  
 
We observed detectable levels of human insulin from week 4, but at 
lower levels compared to the positive control (p<0.001). As described in 
various islet encapsulation models, there is a lag time for adequate 
function until the transplanted islets are vascularized [15,288]. The 
prevascularization of the device appeared to have helped encapsulated 
islets to overcome the initial post implant injury, but it takes longer for the 
transplanted cells to develop mature vasculature and be functional. The 
lower insulin level detected after IPGTT in the device group as compared 
to the kidney capsule control could be ascribed to a non-complete 
vascularization of islets in the device. Although prevascularized, it is 
expected that islets will need to fully connect to the vasculature post 
transplantation. The duration of this process is compatible with the 2 
weeks timeframe observed in Fig. 5.3 for an increase in insulin secretion 
in the device group. As the platelet lysate matrix is expected to be 
resorbed within few days from device implantation, we do not expect that 
islets were affected in their function by residual PLM. A second load of 
islets (2,000 IEQ) into vascularized devices increased the insulin levels 
(~10 µIU/ml) to values that were comparable to the kidney capsule 
transplantation (Fig. 5.3a, p>0.05). The total number of islets loaded was 
4,000 IEQ per device, less than the theoretical maximal loadable volume 
according to the three-dimensional structure of device and the presence of 
a vascularized environment. Nevertheless, it was not possible to estimate 
exact volume of vessels and tissue present in the device at the time of the 
second islet loading, and this could have an effect on the distribution and 
the packing density of the islets in the device. Further studies are required 
to understand the optimal timing and the amount of islets needed to obtain 
a valid insulin secretion after multiple loading of islets. Achieving this could 
help adapting the insulin output to patient physiology and clinical need. 
Additionally, the devices were well tolerated and animals showed 
comparable basal glucose level (Fig. 5.3b) and weight (Fig. 5.3c), 
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demonstrating that the presence of additional islets is not associated with 
hypoglycemia. 
 
Figure 5.3. Insulin release from kidney capsule (black) and encapsulation 
device (red) after glucose stimulation (A). On week 12 all the animal with insulin 
level below 0.125 uU/ml where treated by refilling the implant with additional 
2000 IEQ (red arrow). Basal blood glucose levels (B) and body weight (C). 
Average and SEM are represented. * p<0.05; *** p<0.001. 
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4. Conclusion 
In this study, we showed that the subcutaneous implantation of a 3D 
printed and functionalized NICHE generates adequate and prompt 
vascularization of the graft. Vascularization was enhanced by the ability to 
dispense pro-angiogenic factors, such as VEGF, which is also known to 
increase islet viability and function [318]. In addition, the device could 
protect the graft, while the islets are being vascularized, from initial 
transplant site stressors and support their long-term survival. The 
transcutaneous refillability of the device offers opportunities for cell 
supplementation, without surgical retrieval and re-implantation, to 
accommodate for changing physiological needs. This will be of significant 
advantage in the case of the growing children with diabetes. Moreover, the 
reservoir structure permits the potential retrievability of the graft, which is 
important for stem cell derived engineered cells, undergoing malignant or 
other unwanted transformations. A current limitation of this device is the 
lack of immunoprotection of the transplanted cells. The priority of this work 
was to prove the vascularization and function of the device without 
compounding with the risk of immune rejection. For this reason, we used 
an immunodeficient animal model.  A different device design can 
incorporate a strategy for local delivery of immunomodulators, which will 
expand its use in immunocompetent diabetic animals [319]. Further 
studies in diabetic animal models are required to evaluate the full potential 
of this versatile encapsulation device for diabetes cell therapy. 
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5.2 Transcutaneously refillable, 3D-
printed biopolymeric encapsulation 
system for the transplantation of 
endocrine cells. 
 
1. Introduction: 
 
The NICHE is designed to be a technological platform for the 
encapsulation of a large range of cell lines. The encapsulation of human 
pancreatic islets or ILIPAs for diabetes treatment has been the first field of 
application. However, several other endocrine disorders can benefit from 
this solution, among them male hypogonadism is a disorder that affects 
more than 34% of men between 45-54 years old [320,321]. Nowadays, 
male hormone replacement therapy (testosterone replacement therapy) 
via oral, nasal or injection are the only treatment options available. 
However, Testosterone therapy carries various risks, including also heart 
attack [322].  
Therefore, there is the need to develop novel alternative treatment 
solutions in order to restore the testosterone levels. Recent developments 
in the production of Leydig cells derived from bone marrow, adipose 
tissue, umbilical cord, and the testes have shown promise for future 
therapy for primary hypogonadism. However, as described in the case of 
islet transplantation, there is the need of an encapsulation system in order 
to support long-term graft viability and functionality. 
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In this chapter is presented the vascularization and testosterone 
release of Leydig cells encapsulated in 3D printed NICHEs In Vivo.  
First, is described the modification of NICHE with a platelet-rich 
plasma (PRP) based hydrogel and coating designed to promote rapid 
biointegration of the device after implantation.  
Second, is investigated the device compatibility in vitro and with the 
CAM assay using human pancreatic islets and mouse Leydig cells as 
representatives of endocrine cells.  
Finally, NICHE is implanted subcutaneously in a castrated Rag1 -/- 
mouse model, assessing vascularization, engraftment with Leydig cells, 
function in terms of testosterone secretion, and device retrievability. 
 
NICHE was designed to be used according to the protocol shown in figure 
5.4.  
 
 
Figure 5.4: Deployment protocol for the NICHE. (A) Subcutaneous 
implantation and local release of growth factors to stimulate angiogenesis. (B) 
NICHE vascularization with vessel penetration inside the NICHE reservoir across 
microchannels. (C) Once the vascularization is completed, cells are 
transcutaneously inserted via injection. (D) Subcutaneous implantation allows for 
the complete retrieval of NICHE and transplanted cells if needed.  
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2. Materials and Methods 
Device coating 
After fabrication as described in Chapter 3, NICHEs were sterilized 
using 70% ethanol and UV in a sterile environment (clean room of the 
Houston Methodist Research Institute). Thereafter, the surfaces of devices 
were treated with a polyvinylpyrrolidone (PVP)-based platelet rich plasma 
(PRP, ZenBio, Inc., Durham, NC, USA) or platelet lysate (PL, ZenBio, Inc., 
Durham, NC, USA). Six (6) devices of each type of coating (PVP only, 
PVP + PRP and PVP + PL) were prepared. PLA devices were then 
immersed in 70% ethanol (Fisher Scientific, Hampton, NH, USA) for 4 h 
under mild agitation, rinsed, dried at room temperature. Three devices 
were coated with PVP solution (Sigma-Aldrich, St. Louis, MO, US) 
incubated for 5 min, and air-dried at room temperature (RT). The PLA 
devices were coated with one of three solutions of PVP, PVP + PRP, and 
PVP + PL, and allowed to dry at RT overnight (n=3 devices per group). 
Once coated with solutions, the PLA devices were placed on 
Polydimethylsiloxane (PDMS) templates containing micro sized vertical 
posts. The PDMS templates were fabricated via photo- and soft 
lithography as previously described. To evaluate the degradation kinetics 
and release of proteins and growth factors from the coating, all samples 
were individually immersed in 750 µl of 1X PBS for 7 days under gentle 
agitation at 37°C. Protein release in the sink solution was measured at day 
1, 2, 3, 5 and 7 via a µBCA protein assay kit (Thermo Fisher Scientific Inc., 
USA). SEM micrographs were also collected to directly image coating 
degradation over time.  
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Hydrogel preparation 
Growth factor rich hydrogels were prepared by crosslinking alginate-
PRP/PL solutions with calcium chloride. 300 µl of 1.2% alginate/PRP or PL 
solution was added to the wells of a 24-well plate, stirred for 10 min at 
room temperature followed by addition of 80 µl of 15% 1M calcium 
chloride in 1X PBS (CaCl2; Fisher Chemical, Hampton, NH, USA). Alginate 
solutions were prepared by mixing alginic acid sodium salt (Sigma-Aldrich, 
St. Louis, MO, USA) with either 1.2% w/v PRP (ZenBio, Inc., Durham, NC, 
USA) or PL (ZenBio, Inc., Durham, NC, USA) and stirred overnight at 
37°C. The alginate/PRP or PL solution was agitated on a shaker at 400 
rpm for 10 mins at 37°C to ensure homogeneous cross-linking.  
 
Hydrogel in vitro degradation, in vitro 
PRP/PL hydrogels (n=6 per group) were weighted and placed in the 
wells of a 12-well plate 1 ml 1X PBS and incubated at 37°C. Hydrogel 
samples were weighed on day 1, 2, 3, 5, 7, 10, and 13, to evaluate the gel 
stability and degradation. Quantification of protein release from the 
hydrogels were performed by collecting 500 µl of the supernatant and was 
analyzed using micro-BCA assay (Micro BCA™ Protein Assay Kit, Thermo 
Fisher Scientific Inc., USA). The removed supernatant was replaced with 
500 µl of fresh 1X PBS. 
 
Isolation of human pancreatic islets and culture 
Pancreata were procured from heart beating cadaveric multi-organ 
donors perfused in situ by aortic flushing with cold preservation solution, 
placed in a container of cold preservation solution and packed in wet ice. 
Upon arrival at Methodist Hospital Islet Center the pancreata were 
digested using a modification of the islet isolation procedure described by 
Ricordi et al. After isolation islets were suspended and cultured in 
Memphis serum free media (M-SFM at 24°C, 5% CO2 prior to use. 
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Pancreatic islet viability on hydrogel 
1 ml PRP hydrogels (n=4 per time point) were prepared, as described 
previously, in 24-well plates. 200 islet equivalents (IEQ) in M-SFM were 
seeded per well over PRP hydrogel. Islets seeded directly in M-SFM in the 
24-well plate were treated as control.  On days 3, 7, 14 and 28, islet 
viability was tested by the Dye exclusion technique using fluorescein 
diacetate (FDA, Sigma Chemical Co.) and propidium iodide (PI, (Sigma 
Chemical Co) and images were captured by fluorescence microscopy 
(TiEclipse, Nikon instruments, Inc.). The islets were microscopically 
evaluated and measured for FDA (bright green fluorescence) and PI 
(red/orange fluorescence) dye uptake. Islets with greater than 25% PI dye 
uptake were scored as non-viable. At least 50 islets were assessed per 
well.  
 
Glucose-stimulated insulin release from pancreatic islets 
on hydrogel 
200 IEQ were seeded on 24-well plates with PRP gel in 24-well plates, 
as in the viability assay. On days 3, 7, 14 and 28, insulin secretion in 
response to a secretogogue was evaluated by a sequential static 
incubation method. The insulin content (IC) was determined after 
extraction of islets with acid ethanol. For the static incubation, islets were 
washed twice in low glucose media to remove M-SFM.  The islets were 
then incubated for one hour in low glucose media (60 mg/dl) at 37°C / 5% 
CO2.  After removal of pre-incubation media, an additional aliquot of low 
glucose media was added to the wells.  Following 1-hour incubation, the 
supernatant was collected for insulin analysis by ELISA (ALPCO 
Diagnostics, Windham, NH, USA). The centrifuge tube was rinsed with 
high glucose media (300 mg/dl) to recover any islets that may have been 
removed during media collection. The recovered islets were transferred to 
a microwell plate and incubated for one hour (37°C / 5% CO2). The media 
was again collected for insulin analysis. An acid/alcohol solution was used 
to collect all of the remaining islets in each well. After vortexing, the islets 
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were frozen at -20°C overnight. The following day, after vortexing the 
supernatant was collected for IC measurement by ELISA [low glucose, 
high glucose and insulin content].  
 
Leydig cell WST-1 proliferation assay and testosterone 
release ELISA analysis 
The proliferative behavior of Leydig cells on PRP hydrogels was 
analyzed via WST-1 Cell Proliferation Assay (Sigma Aldrich, St. Louis, MO, 
USA) over a period of 28 days. 1000 Leydig cells were seeded per well in 1 
ml media (day 0) on top of PRP hydrogel in a 24-well plate. 24 h after 
stimulating cells with 6 mIU/200 μl horse human chorionic Gonadotropin 
(hCG; Sigma-Aldrich, Missouri, USA), WST-1 reagent was added. After 2-
hour incubation at 37°C, an area scan absorbance measurement was 
performed at 450 nm and 690 nm using the Synergy H4 Hybrid Multi-Mode 
Microplate Reader (Biotek Instruments Inc., Winooski, VT, USA). Using the 
area scan measurement, the absorbance readings at 9 areas in each well 
were used to calculate the mean absorbance per well. Triplicates of each 
condition were performed. A graph was plotted with OD690 reference values 
subtracted from OD450 values and normalized to absorbance on day 0. The 
procedure was repeated on days 1, 5, 9, 13, 21 and 28. Using the same 
culture conditions of the Leydig cell proliferation assay, on days 2, 6, 10, 
14, 22 and 28, the entire 1 ml of supernatant was collected (and replaced 
by fresh culture media), which was used to quantify testosterone release 
via ELISA (ENZO Life Sciences, New York, USA).   
 
Chorioallantoic membrane assay  
Fertilized chicken eggs were purchased from Charles River (Norwich, 
Connecticut, USA). The chick chorioallantoic membrane (CAM) assay was 
performed as described previously. On embryonic day 7, PRP hydrogel 
alone or PRP hydrogel + PRP coated NICHE was placed on top of the 
CAM (n=20) with a silicone ring around the gel to demarcate its location. 
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The CAM, hydrogel or NICHE-hydrogel (n=6) were harvested on days 1,3, 
and 5 post cells seeding and analyzed via optical microscope to evaluate 
the degree of vascularization, followed by histological analysis via H&E 
staining after Optimal Cutting Temperature (OCT) cryoembedding.  
 
In vivo bioluminescence imaging 
1 x 106 luciferase-overexpressing Lewis lung carcinoma (LLC) cells 
were suspended in 30 µl 1X PBS and 20 µl Matrigel (Corning, Tewksbury, 
MA, USA) were grafted on the CAM with or without PRP hydrogel within a 
silicone ring. As a negative control, we cultured 1 x 106 LLC cells on PRP 
hydrogel with 100 µl media supplementation, compared to cells in media 
only and PRP only. Bioluminescence imaging was performed in a Caliper 
in vivo imaging system (IVIS) Spectrum (PerkinElmer, Inc., Waltham, 
Massachusetts, USA) on day 3 after cell seeding. Exposure time was 1 
second and 5 minutes after adding 100 µl D-luciferin (15 mg/ml). The 
region of interest (ROI) was quantified by the Lumina software 
(PerkinElmer, Waltham, MA, USA) and data was plotted with Prism 
(Graphpad Software, Inc., La Jolla, California, USA).  
 
In vivo NICHE assessment 
Sterilized 3D printed NICHEs containing 300 µl PRP hydrogel 
supplemented with 0.5 µg/ml of VEGF were implanted in the dorsum of ten 
castrated Rag1-/- male mice, after collecting blood samples for baseline 
testosterone measurements. 4 weeks after implantation, 2 mice were 
euthanized to evaluate the vascularization within the NICHE, and devices 
with surrounding tissue were harvested for histological evaluation. On 
week 4, 6 x 106 Leydig cells were transplanted via transcutaneous 
injection through the loading port of the NICHE in the 6 remaining mice. 
On week 10, NICHEs were retrieved and mice were euthanized on week 
12. Blood was sampled weekly (50 μl) 4 hours after subcutaneous hCG 
injection to stimulate testosterone production from day 0 till week 12. 
Testosterone level was measured via ELISA (ENZO Life Sciences, 
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Farmingdale, New York, USA).  
 
 
Histological analysis 
NICHEs collected from the mice were fixed in 10% formalin overnight, 
transferred to 10% sucrose solution for 2 days and then stored in 1% 
sucrose solution. NICHEs were then embedded in OCT and stored in -
20°C. 4 hrs. before cryo-sectioning, samples were transferred to -80°C. 
Samples were sectioned at 7 µm thickness and stained via H&E, CD31 
(ab28364, Abcam, Cambridge, UK) and HSD3B (ab65156, Abcam, 
Cambridge, UK). Vasculature formation within the NICHE was assessed 
on week 4 by quantification of CD31 staining intensity. Presence of 
functional Leydig cells was determined by HSD3B staining. Rabbit anti-
mouse FITC conjugated antibodies (ab6717, Abcam) were used as 
secondary antibody for immunofluorescence staining. 
 
Statistical analysis  
Results are expressed as mean ± SEM. All statistical analyses were 
performed using GraphPad Prism 7 software (GraphPad Software Inc., 
San Diego, CA, USA). Student t-tests or one-way ANOVA were performed 
to determine the significant difference between groups. P values of less 
than 0.05 were considered statistically significant, whereby symbols 
indicating statistical significance are as follow: n.s., not significant, * 
P≤0.05, ** P≤0.01, *** P≤0.001, **** P≤0.0001. 
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3. Results 
NICHE coating characterization and degradation 
To promote neovascularization and rapid bio-integration of the device 
upon implantation using growth factor release, 3D printed NICHEs were 
coated with a solution of polyvinylpyrrolidone (PVP) containing either 
platelet-rich plasma (PRP) or platelet lysate (PL). PVP is a water-soluble 
biocompatible polymer widely used in biomedical applications as a binding 
and solubilizing agent. PRP and PL contain growth factors that stimulate 
vasculature formation and innervation [323]. SEM analysis of the treated 
NICHE demonstrated a uniform, smooth surface coating (Fig. 5.5A) with a 
thickness of approximately 30 µm (Fig. 4B). The coating was patterned 
with monodispersed pores of average size of 45-50 µm in regular arrays 
(Fig. 5.5A, C). The outer surface of the coated device was imprinted with 
the circular posts on the PDMS template to enhance the coating efficiency. 
In addition, patterned micro-chambers on the surface formed a uniform 
non-porous layer which improved the release kinetics of growth factor. To 
evaluate coating degradation over time, we analyzed samples in PBS at 
37°C via SEM and measured protein release from PRP or PL coated 
NICHEs. SEM analysis showed near complete degradation of both 
coatings by day 5 (Fig. 5.5D, E). Protein quantification showed a burst 
protein release in the first 2 days, reaching 80.7 ± 5.4% for PVP-PRP and 
93.7 ± 4.7% for PVP-PL, respectively. While PVP-PL reached a complete 
plateau by day 3, a slower release of proteins from the PVP-PRP samples 
extended until day 7 (Fig. 5.5F). Based on the better release kinetics of 
proteins, we selected PVP-PRP as the coating of choice for the following 
analysis in vivo.  
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Figure 5.5: PRP coating of NICHE. (A) Baseline SEM images of NICHE 
coated with PVP-PRP coating, (B) with mean pore size of 47.6 µm and (C) cross 
section of PRP coating. (D,E) Day 7 SEM images of the degraded coating. (F) In 
vitro protein cumulative release from coating over 7 days. 
 
 
Hydrogel degradation analysis 
With the objective of promoting angiogenesis within the NICHE, we 
tested PRP or PL hydrogels, to be loaded in the device at time of 
implantation. We evaluated the degradation of both hydrogel formulations 
in PBS at 37°C in terms of mass changes (Fig. 5.6A) and growth factor 
release capability (Fig. 5.6B). Mass loss profiles demonstrated a quicker 
degradation of PL hydrogel with an 80% weight reduction in the first 5 
days of testing as compared to 20% for PRP hydrogel. While by day 9 PL 
was almost completely degraded (90% weight loss), and PRP hydrogel 
retained 50% of its initial weight. By day 13, both hydrogels were 
completely degraded. 
Protein release from the PRP hydrogel was sustained over 11 days in 
a constant manner (Fig. 5.6B). In contrast, PL hydrogel presented a linear 
protein release for 5 days, corresponding to 80% mass loss (Fig. 5.6A), 
and reached a plateau thereafter. In light of slower degradation and 
sustained protein release, PRP hydrogel was selected as the most 
 139 
suitable constituent in the NICHE to support vascularization and 
engraftment.  
Figure 5.6: PRP and PL hydrogel in vitro stability. PRP and PL hydrogel (A) 
weight change and (B) protein release over 13 days 
 
 
Cell viability and hormone secretion in PRP hydrogel  
In the intended in vivo deployment of NICHE, PRP hydrogel is 
expected to completely degrade by 2-3 weeks post-implantation, after 
which cells are transplanted into the device for encapsulation [35]. To 
ensure cytocompatibility of hydrogel degradation by-products or in the 
event of residual hydrogel by the time of cell transplantation, we performed 
a 14-day experiment to test viability and function of two representative 
endocrine cell types – murine Leydig cells and human pancreatic islets, as 
an additional relevant endocrine cell that could be of potential applicability. 
Results demonstrate that Leydig cells on PRP hydrogels have similar 
viability (Fig. 5.7A) and testosterone release (Fig. 5.7B) as compared to 
cells with media (control). Consistent with literature reports, we observed 
cluster formation of Leydig cells in PRP hydrogel by day 4. In the case of 
human islets, over the course of 14 days, we observed comparable 
viability of islets cultured in media and PRP hydrogel via dye exclusion 
using fluorescein diacetate and propidium iodide analysis (Fig. 5.7C,D). 
While quantitative assessment of insulin secretion via ELISA showed that 
islets cultured in PRP hydrogel exhibited an upward trend  of insulin 
release throughout the 14 days as opposed to islets cultured in media only 
(Fig. 5.7E), there was no statistically significant difference between the two 
  140 
groups. Overall, these results demonstrate that both islets and Leydig cells 
remained viable and functional activity was maintained in PRP hydrogel. 
 Figure 5.7: Leydig cell and human pancreatic islet culture. (A) Leydig cell 
viability on PRP hydrogel and (B) testosterone release over 14 days. (C) 
Fluorescein diacetate and propidium iodide analysis of human islets in PRP and 
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control over 14 days (Scale bar represents 100 µm). (D) Islet death ration 
between PRP hydrogel and control group with (E) insulin release level.  
 
Vascularization of PRP hydrogel 
For initial assessment of the ability of PRP hydrogel to stimulate 
vascularization in vivo, we used a chick CAM model, which is an 
established, rapid, and cost effective assay to visualize and evaluate 
angiogenesis [324]. After placing PRP hydrogel samples onto the CAM 
(Fig. 5.8A), we monitored them for signs of vascularization using optical 
microscopy. Hydrogels appeared stable in morphology on day 1 and 3, on 
day 5, and clear signs of incorporation within the CAM were observed (Fig. 
5.8B,C), suggestive of CAM vasculature infiltration into the gel (Fig. 5.8C). 
Hydrogel samples retrieved from the CAM on day 1, 3, and 5 confirmed 
the observation in vivo, with clear presence of vasculature penetration into 
the gel across the CAM (Fig. 5.8C). Next, to determine if PRP hydrogel 
could stimulate vasculature penetration through the NICHE’s 
microchannels into the gel, PVP-PRP-coated NICHE containing PRP 
hydrogel within were overlaid onto the CAM (Fig. 5.8D). We observed 
signs of angiogenesis by day 3, with progressive vasculature formation by 
day 5 surrounding the PLA microchannels (Fig. 5.8D). Histological 
analysis of the explanted device showed endothelial cell infiltration into the 
hydrogel (Fig. 5.8E). Additional histological analysis of cross sections of 
the retrieved samples confirmed direct vessel connection of hydrogel with 
the CAM (Fig. 5.8F). To further validate our findings, we established an in 
vivo cell viability test on CAM. Luciferase-expressing Lewis lung 
carcinoma (LLC) cells were seeded either directly onto the CAM (positive 
control), or placed onto a layer of PRP hydrogel laid onto the CAM (Fig. 
5.8G). Bioluminescence imaging analysis showed that both groups of cells 
were viable after 3 days on the CAM, while cells in PRP without CAM were 
not viable. This demonstrated that PRP hydrogel was rapidly vascularized 
providing support to the LLC cells to a similar extent to cells directly in 
contact with the CAM. In the negative control, cell seeded on PRP 
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hydrogel (Fig. 5.8G) in cell culture plates demonstrate loss of viability in 
absence of vascular tissue supplying cells with oxygenation and nutrients. 
Figure 5.8: PRP hydrogel vascularization on CAM. (A) PRP hydrogel at day 
1 and (B) day 5 (scale bar represents 4 mm). Optical microscopy images of (C) 
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harvested PRP and of (D) NICHEs on day 1, 3 and 5 (scale bar represents 4 
mm). H&E images of (E) PRP hydrogel at 20x and (F) cross section showing 
intersection between PRP and CAM indicated by the dotted line (scale bar 
represents 200 µm). (G) IVIS analysis of PRP only on CAM, LLC cells only 
cultured on CAM, LLC cells + PRP hydrogel on CAM and LLC cells on PRP 
hydrogel in a well of a 24-well cell culture plate. 
 
In vivo validation of NICHE 
To investigate the function of our encapsulation system in vivo, we 
subcutaneously implanted sterile NICHEs filled with PRP-VEGF hydrogel 
in castrated Rag1-/- mice (n=10). VEGF was used as an additional 
stimulant for vessel formation. Rag1-/- mice were used because despite 
being immunocompromised, they maintain intact innate immunity and 
foreign body response, which is ideal for assessing the biocompatibility of 
the NICHE. NICHEs were implanted free of cells to achieve a pre-
vascularized bed for the cell transplant. To establish the suitable time for 
Leydig cell transplantation, we harvested the devices from 2 mice each on 
weeks 2 and 4, to visualize and assess tissue growth and vascularization 
within the NICHE. At week 2, retrieved samples exclusively showed 
presence of hydrogel and low tissue and vasculature formation was 
observed. Therefore, histological images were difficult to obtain. In 
contrast, histological sections obtained from NICHEs retrieved on week 4 
and stained with H&E and CD31 showed high levels of vascularization 
(Fig. 5.9A-F). While the subcutaneous environment is typically poorly 
vascularized, our data showed that VEGF-supplemented PRP hydrogel 
was able to induce vascularization in and around the NICHE. 
Immunofluorescent analysis of CD31 in histological sections from NICHEs 
implanted for 4 weeks (Fig. 8D) and week 14 (Fig. 5.9E,F) showed 
progressive vasculature network formation within the devices over time. 
Importantly, we did not observe immune infiltration, suggesting the 
biocompatibility of the NICHE. Picro siruis staining of tissues within the 
device further confirmed vascularized environment, with collagen 
formation inside of the NICHE (Fig. 5.9G-I). 
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Figure 5.9: Vascularized tissue formation within the NICHE. (A) H&E staining 
of internal tissue retrieved on week 4 showing vessels penetration at 4x, (B,C) 
magnified cross section of vessels containing red blood cells at 20x. (D-F) CD31 
(green) staining of blood vessels within the NICHE with DAPI counterstain 
(nuclei). (G-I) Picro sirius staining showing collagen I and II formation of blood 
vessels and surrounding tissues. 
 
Upon determining that the implanted devices were vascularized within 
4 weeks, we transplanted testosterone-secreting Leydig cells into the 
NICHE devices via transcutaneous injection through the NICHE loading 
port. Normal function of encapsulated Leydig cells over the 7-week 
transplantation was evaluated by weekly blood samples to measure 
testosterone levels using ELISA. ELISA analysis confirmed little to no 
testosterone up to 4 weeks prior to cell transplantation in the castrated 
mice. Throughout the 7 weeks of transplantation, testosterone levels 
ranged from 1.5 ng/ml to 2.2 ng/ml (Fig. 5.10A). Our results are 
comparable to physiological testosterone levels of non-castrated mice, 
which are around 1.2-1.5 ng/ml. Upon NICHE implantation, mouse total 
body weight stabilized and upon NICHE retrieval, increased to up to 28 g 
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(Fig. 5.10B). 7 weeks after cell transplantation, evaluation of the tissue 
within the device showed extensive vasculature formation (Fig. 5.10C-E). 
Further, immunohistochemical staining of HSD3b (a marker for Leydig 
cells), confirmed presence of cells within the vascularized tissue in the 
NICHE (Fig. 5.10F-H). Overall, this study demonstrated the capability of 
the NICHE to provide a pre-vascularized and physiological like 
environment conducive for the preservation of viability and functionality of 
encapsulated cells.  
 
Figure 5.10: Leydig cell transplantation in NICHE. (A) serum testosterone 
levels and (B) body weight of castrated mice before device implantation, after cell 
transplantation and device retrieval. (C-E) H&E staining of vascularized tissue 
and (F-H) HSD3b staining within NICHE on week 14. (Scale bar represents 200 
µm). 
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4. Discussion 
Here we demonstrated that our PVP-PRP coating strategy provides a first 
line approach for stimulating rapid biointegration and vascularization of the 
structure. The flexibility of this coating technology permits for modification 
of thickness and porosity, and consequently control of degradation rate 
and growth factor release to tailor to different clinical needs. The same 
applies for the PRP-hydrogel matrix incorporated inside the NICHE. As 
demonstrated with the CAM assay and the rodent study, we were able to 
achieve a high level of vasculature density within the NICHE triggered by 
device coating and PRP-VEGF- combination hydrogel. In certain 
instances, as in the case of pancreatic islets transplantation, graft 
innervation to replicate the structure of islets in the pancreas would be 
beneficial [325,326]. For this, the growth factor and hydrogel cocktail in 
coating and hydrogel can be engineered to deliver local gradients of nerve 
growth factor (NGF) and glial cell line-derived neurotrophic factor (GDNF). 
Additionally, PRP hydrogels could contain perfluorocarbons to support 
oxygenation of cells to avoid acute hypoxia immediately post 
transplantation [327].    
For the transplantation site, we chose the subcutaneous environment 
as it provides flexibility for the implantation of devices of various size and 
dimensions, has an adequate vascular network, and is easily accessible 
through minimally invasive surgical techniques. Several other sites, 
including the peritoneal cavity, have been investigated because of the 
higher density of blood vessels, and the capacity to accommodate large 
transplant volumes. However, invasive surgery procedures are required 
for graft insertion, retrieval, and refilling. 
 
In the above mentioned in vivo study, at week 4, we were able to 
successfully execute transcutaneous cell loading in the pre-vascularized 
NICHE, using an external guide. No significant challenges were 
experienced during loading. Additional transcutaneous cell loading could 
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be performed for cell supplementation at need. Pediatric diabetic patients 
represent a clear example of individuals for whom the ability of 
replenishing and supplementing cells could present a clear advantage to 
address the changing physiological needs in terms of hormone secretion 
[328,329]. Post-transplant hypoxia and loss of cell function were not 
observed as cells became functional soon after transplantation, achieving 
plasma testosterone levels of approximately 1.3 ng/ml, which are in line 
with physiological levels for intact Rag1-/- mice [330]. Notably, 
substantially increased testosterone levels (2.3 ng/ml) were measured 5 
weeks after cell transplantation. This increase suggests that Leydig cells 
required this timeframe to colonize the NICHE and form larger clusters as 
observed by immunohistochemical analysis. There was low level 
mononuclear cell (MNL) infiltration into areas within the NICHE device and 
no neutrophils in regions surrounding the device.  
Biocompatibility of the adopted material and absence of adverse reaction 
to the transplanted cells were further demonstrated with the lack of fibrotic 
tissue surrounding the NICHE and no overgrowth of the surrounding tissue 
within the implant. These aspects are of additional advantage allowing for 
further refilling of the implant with additional cell dosage. However, if some 
tissues need to be removed to refill the NICHE with fresh cells, 
transcutaneous injection of clinically-approved dosage of collagenase may 
be used, a technique already adopted for treatment of several clinical 
conditions [331]. A limit of our model is the absence of a valid adaptive 
immune response in Rag 1-/-, which have limited a potential role of 
lymphocytes on the device biointegration. On the other side, this is still a 
good model to test foreign body response [332]. Further experiments are 
needed to prove a similar behavior of the implant in different animal 
models, but implants of similar materials were well-tolerated in other work 
from our group.  
12 weeks after NICHE implantation, we demonstrated the ability to retrieve 
the implant via an endoscopic subcutaneous surgery. The procedure was 
well tolerated by the animals, which healed within 3 days post NICHE 
removal. The ability of retrieving transplanted cells is of particular 
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importance for treatments adopting stem cell-derived transplants, for 
which the long term fate is still uncertain and there is a risk for teratoma or 
cancerous tissue formation [211]. As expected, testosterone levels 
decreased substantially after device retrieval. However, as testosterone 
did not completely revert to basal level we cannot preclude the possibility 
of minor cell injection outside the device that could have occurred during 
cell loading. To optimize the loading protocol for future testing we are 
considering to change the positioning of the ports to the periphery of the 
NICHE. This modification would allow us to transplant cells via needles 
presenting multiple openings. In this way, cells would be simultaneously 
injected in different regions of the NICHE, reducing the volume released 
from each opening and consequently, the hydrostatic pressure on cells at 
injection.  
Several encapsulation systems have been developed for cell 
transplantation. Among them, PEC-EncapTM of Viacyte, MAILPAN® of 
Defymed, βAir of Beta-O2 Technologies and others have reached advance 
pre-clinical testing and clinical trials. A large percentage of these 
approaches rely on semipermeable polymeric membrane to act as a 
physical barrier to prevent immune rejection of the transplant in allo- and 
xeno transplantations. The major challenge of this approach is the limited 
supply of oxygen and nutrients to the transplanted cells due to the physical 
separation from the surrounding vasculature [333].  
In contrast, our approach is fully focused on achieving proper 
vascularization of cells. In the context of autologous transplantation, the 
NICHE allows for direct contact of the transplanted cells with vascular 
network resulting in an adequate supplementation of oxygen and nutrients. 
In the case of allo- or xeno- transplantation, the NICHE can be modified to 
provide local delivery of immune suppressants. We are currently working 
on the second generation of NICHE, which implements a nanofluidic drug 
delivery system for sustained release of immunosuppressants in situ 
[162,164]. This novel approach could allow non-autologous cell 
transplantation while avoiding systemic administration of 
immunosuppressant drugs and related adverse effects. 
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Chapter 5 
 
Summary and future prospective 
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In this thesis, the development and validation of the NICHE as a novel 
macroencapsulation system for autologous cell transplantation was 
detailed.   
 
First the potential of adopting 3D printing technology to manufacture and 
customize the structure of the NICHE was demonstrated. As discussed in 
chapter 3, 3D printing allows for the design and fabrication of complex 
structures mimicking body structures and organs, which can be rapidly 
and inexpensively generated to be patient specific. Moreover, 3D additive 
manufacturing allows for straightforward scalability and customization of 
devices in terms of shape and size depending on the anatomical features 
of the implantation site and the volume of cells required to be 
encapsulated. These properties offer substantial advantages with respect 
to traditional manufacturing processes. In this work PLA was adopted, 
which showed to be biocompatible and suitable for long term applications 
in terms of polymeric degradation rate and mechanical properties.   
 
Second, NICHE vascularization and engraftment was achieved 
subcutaneously using two immune compromised murine models. This 
investigation was of crucial importance as obtaining proper engraftment is 
determinant for the successful transplantation of cells and supporting their 
viability and function long-term. It was shown that transplanted cells were 
able to thrive thanks to a direct access to blood vessels and supply of 
oxygen and nutrients.  
 
Third, two cells line (human pancreatic islets and Leydig cells) were used, 
to validate the NICHE capability to release insulin (up to 10 µIU/ml) and 
testosterone (up to 2.2 ng/ml), respectively. It is important to note that the 
presented NICHE was designed for the encapsulation of autologous cells 
only. In fact, it allows for the direct contact of the transplanted cells with 
blood vessels and did not provide any immunoisolating mean to protect 
cells from rejection.   
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The results achieved provide substantial evidence of the potential of the 
NICHE to promote the formation of an ideal environment for the 
transplanted cells, able to support their viability and functionality for long-
term applications.  
 
To enable heterologous cell transplantations, Grattoni’s team is working 
on the development of an advanced version (NICHE-2) that includes a 
reservoir to house transplanted cells in a fully prevascularized 
environment (as presented in this thesis), and a drug reservoir for the 
constant and sustained release of immunosuppressive drugs in situ 
through a nanofluidic silicon membrane. Figures 5.11 A and B 
schematically show the differences between the two NICHE architectures. 
Both systems include microwells that promote a homogeneous distribution 
of cells in the device while avoiding clustering. Further, they prevent loss 
and dispersion of transplanted cells while allowing blood vessel 
penetration into the device, transcutaneous cell loading, easy retrieval, 
and addition or replenishment of cells at need.  
 
In the case of NICHE-2, sustained drug release through a nanofluidic 
membrane, which is under investigation for the controlled release of 
immunosuppressants. The objective is to abrogate graft rejection by 
achieving effective concentration of immunosuppressants locally, while 
minimizing systemic drug exposure and associated adverse effects. 
Importantly, the system allows for transcutaneous drug replenishment 
once the drug reservoir is depleted. This allows for extending the 
immunosuppressive regimens for years without requiring surgical 
substitution of the implant. Notably, the membrane could be used for the 
local sustained delivery of immune suppression in cocktail with growth 
factors and nutrients to provide additional support to the transplanted cells.  
 
In light of the promising results, the NICHE exemplifies a clinically 
translatable strategy for preserving viability and function of transplanted 
cells. This technological platform may offer exciting potential for clinical 
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adoption in relevant medical areas of diabetes, hypogonadism, 
hypothyroidism, cancer, and neurological diseases, among others. 
 
Figure 5.11 (A) NICHE-1 encapsulation system consists of a reservoir that 
houses autologous insulin producing cells in a prevascularized environment. (B) 
Schematic of NICHE-2 composed by a fully vascularized cell reservoir for 
heterologous cells and a drug reservoir for the constant and sustained release of 
immunosuppressive drugs in situ through a nanofluidic silicon membrane. 
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